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THESIS ABSTRACT 
Mood pathophysiology and the pleiotropic role that dopamine plays in 
depressed and manic mood states is an active area of scientific investigation. Recent 
advancements in neuromodulatory techniques are helping to elucidate the role of 
mesolimbic dopamine in mood regulation. Development of small devices for direct 
application of neuromodulatory stimulation in rodent models provides neuroscience 
researchers with tools to directly control specific brain circuits for understanding the 
neural mechanisms mediating mood.  
Multiple lines of evidence suggest that dopamine dysregulation is a key feature 
of affective mood disorder pathophysiology. This thesis presents an investigation into 
this relationship in a rodent model of antidepressant resistance via chronic deep brain 
stimulation (DBS) of the mesolimbic dopamine system. A miniature low-power DBS 
device is designed and developed to carry out this investigation. In the rodent model, 
chronic adrenocorticotropic hormone (ACTH) treatment elicits a state of tricyclic 
antidepressant resistance (ADR) via daily injections of ACTH (100 µg/mL/day; 14 
days). Bilateral electrode implantation was performed at the nucleus accumbens (NAc) 
core, and some animals received DBS for 7 days. NAc DBS reduced forced swim test 
(FST) immobility and increased homecage psychomotor activity counts, 
demonstrating antidepressant-like effects. NAc DBS also reversed ACTH-induced 
i
elevation in sucrose consumption. These effects were only partially observed in sham 
animals, indicating that direct modulation of the NAc region, within the mesolimbic 
dopamine system, plays an important role in regulating these mood-related behaviors. 
Extending these findings, and to better understand the role of dopamine in 
NAc DBS response, dopamine neurotransmission was facilitated via selective 
reuptake inhibition of the dopamine transporter (DAT). Specifically, the 
antidepressant and psychomotor effects of NAc DBS, with and without DAT 
inhibition [GBR12909 (GBR); 16 mg/kg] were quantified. This dose has previously 
been used to induce a mania-like phenotype in rodents, and hence we were interested 
to see if this might be present in ADR animals and to determine the impact of NAc 
DBS on this phenotype. Additionally, phosphorylated mTOR, and S6K protein levels, 
which are markers of type 2 dopamine receptor (D2R) activation and mediators of the 
antidepressant response, were measured along with D2R in the NAc and infralimbic 
cortex (IL). ADR + GBR animals demonstrated acute hypo-activity (open field test) 
and chronic hyperactivity (24-hour homecage monitoring) in this study. Additionally, 
the antidepressant response of NAc DBS may be characterized by increased activated 
mTOR ratio and lowered D2R in IL. The specific role of dopamine receptors (DRs) 
in the antidepressant efficacy of mesocorticolimbic DBS was then investigated. The 
antipsychotic drug risperidone (1mg/kg) inhibits type 1 and type 2 DRs and was 
utilized in conjunction with DBS and served to predominate hypo-locomotor 
induction in rats. However, a DBS-risperidone interaction effect was also observed 
ii
through differential stress-induced psychomotor activation in Risperidone + 
DBS/sham groups. Taken together, these studies suggest that dopamine 
neurotransmission and subsequent activation of DRs may play a critical role in DBS 
efficacy but may also produce an unpredictable response in stressful conditions. 
Concurrent with investigation of the mechanism of action of DBS, this 
research aimed to improve upon currently available DBS technologies for preclinical 
rodent studies. In this regard, a new iteration of our standard DBS device was 
developed with improvements on component and circuitry design. This extended the 
device’s capacity for continuous stimulation from 7 days to over 22 days, using a 
single coin battery. This will have important implications for rodent studies of DBS 
mechanisms for mood, which are progressive in nature and occurring over the course 
of several weeks to months, and will allow us to avoid the need for frequent battery 
replacement during the experiment. This device was validated in bench and behavioral 
tests. For the latter, the device was utilized to apply continuous NAc DBS in a rat that 
demonstrated enhanced psychomotor activation (homecage monitoring) and 
anxiolytic behavior (elevated zero maze) due to stimulation. Anxiolytic effects were 
not observed in sham controls. Finally, an implementation of resistance monitoring is 
added to our DBS microdevice. This additional functionality provides continuous 
measurement of resistance at the electrode-tissue interface, which has important 
implications for understanding the neurobiological mechanisms of DBS. Herein, the 
thesis presents the first systematic demonstration of a steady increase in resistance of 
iii
the NAc tissue-electrode interface after the commencement of DBS, congruent with 
reported glial activation.  
The studies presented in this thesis contribute towards our growing knowledge 
of mood disorders by coupling neuromodulation technologies with animal models. 
Together, these research findings demonstrate that neuromodulation of dopaminergic 
systems contributes to the antidepressant-like effects of DBS in ADR animals. 
Mechanistic studies of DBS action at the cellular, network, and behavioral level 
require translationally valid animal models, with chronic continuous DBS. Therefore, 
future development of these technologies, animal models and behavioral procedures 
for translational preclinical rodent studies will be important for progressing the 
clinical application of this promising technology for mood disorders. 
iv
THESIS STRUCTURAL OVERVIEW 
 The works presented in this thesis are structured into a 3 main segments. These 
segments are entirely composed of articles that have been previously published or 
manuscripts that have been prepared for journal submission. Each of the chapters 
represent original works that have been authored by myself or works that I have put 
significant contributions towards. 
 The first thesis segment, titled “Thesis Introductory Review” (Chapters 1 and 2), 
provides important background material to readers on the current understanding of 
mood disorders pathophysiologies, particularly in bipolar disorder and depression. It 
contains two unpublished review manuscripts that discuss the maladaptive changes 
that occur in the body and the brain with disease progression. These are investigated 
at several different scales, including (from micro to macro): molecular, chemical, 
cellular, circuitry- and network-wide, regional, structural, whole-body, and behavioral 
scales. Therefore, these reviews offer readers a systems levels perspective on affective 
disorders and further explores how these systems are exploited for treatment relief, be 
it through pharmaceutical intervention or neurostimulatory approaches. Ultimately, 
this segment offers readers a sufficient introduction for the doctrines that guide the 
preclinical research studies in this thesis. 
 The second thesis segment, titled “Preclinical Experiments” (Chapters 4 through 
8) contains the primary research that was performed for this thesis. Each of these 
manuscripts utilized preclinical animal models and neurostimulation to study mood 
disorders and therapeutics. The experiments were methodologically designed and 
executed as per approved protocol. The translational findings are discussed in terms 
of behavioral and neurophysiological adaptations, as well as their implications towards 
clinical applications. This segment is preceded by a linking methodology overview 
(Chapter 3) that guided these studies’ research methods, and is proceeded by a linking 
v
research summary discussion (Chapter 9) of these studies that provides additional 
translational implications, study limitations, and future directions. 
 The third, and final, thesis segment, titled “Neural-Interface Engineering” 
(Chapters 9 through 13) contains manuscripts based on engineering principles and 
biomedical device development. It demonstrates our fabrication of a novel portable 
optogenetic microdevice and its subsequent benchtop validation for future use in 
preclinical behavioral studies (Chapter 10). It also contains reviews that have been 
published or have been accepted for publication and are in press (Chapters 11 
through 13). These reviews explore the recent technologies that are recently being 
incorporated into neural-interface systems, especially for the neurostimulation 
techniques deep brain stimulation and optogenetics. In general, this segment provides 
exciting information on the future directions of preclinical translational research and 
neurostimulation technologies, which, when coupled together, generate incredible 
scientific findings on the brain and neuropsychiatric diseases. 
vi
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CHAPTER 1 
A Systems Biology Approach to the Neuroprogression of Bipolar 
Disorder 
Introduction 
A shift is emerging in the way we diagnose, treat and study the etiology and 
emergent pathophysiology of bipolar disorder. This is driven, in part, by the push for 
personalized treatment approaches targeted towards the unique interplay of biological 
systems affecting each individual, and their respective stage of disease progression 
(Kendler, 2005). The integrated systems biology approach is the study of complex 
interactions within biological systems. This approach considers both the independent 
and interactive outcomes of various dysregulated networks, from neural to metabolic 
to cell signaling. A systems biology and staging approach may assist to move beyond 
our current limitations in our understanding and capacity to treat bipolar disorder. 
Our current clinical tool box is limited, with the majority of available antidepressants 
and mood stabilizers discovered by serendipity over 50 years ago (Berton and Nestler, 
2006).  
In the United States alone, estimates report that 11.5 million Americans suffer 
from debilitating mental illness, on which the country spends roughly $150 billion 
annually on medical interventions such as drugs, behavioral therapy and 
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hospitalizations (Rampell, 2013). Lost earnings for affected individuals tally roughly 
$193 billion annually in the US alone, with each individual income reduced by $16,604 
per year on average when compared with those without such conditions (Insel, 2008). 
Additionally, the capacity of our health and community support systems is often 
inadequate to meet the needs of those suffering acute and chronic episodes of 
depression, mania or psychosis. Taken together, the cumulative sum of mental health 
issues costs the U.S. economy roughly half a trillion dollars per year in total. The CDC 
National Vital Statistics Reports of 2009 confirms that more deaths are caused from 
people with behavioral health issues than from HIV, traffic accidents, and breast 
cancer combined (Kochanek, Xu et al., 2011).  
 The focus of this review is to explore the potential of a systems biology 
approach to individualize medical intervention and management for bipolar disorder. 
Not only can the identification of genetic factors that greatly affect the individual’s 
vulnerability or resilience to disease be identified, the molecular mediators through 
which these are impacted, including chronic immune activation, oxidative stress, and 
metabolic stress, can also be targeted. Accumulation of these mediators can result 
from chronic stress and/or a dysfunctional hypothalamic-pituitary-adrenal (HPA)-
axis, poor diet and exercise, obesity, hormone dysfunction etc. Ultimately, this 
provides the capacity to assess the deleterious accumulation of allostatic load on the 
brain and body as its associated physiologic “wear and tear,” which has the potential 
to impact disease progression and treatment response. Identifying the patient’s stage 
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of disease progression is also imperative when forming personalized treatment 
regimens to combat the symptoms and support recovery. This review specifically 
applies the allostatic load model to evaluate the neuroprogression of bipolar disorder, 
and takes an emphasis on the integrated systems and personalized medicine approach 
to classify its effects. 
 
Behavioral Symptoms 
Bipolar disorder is an affective disorder that causes patients to experience 
episodes of depression (low mood, loss of pleasure, reduced energy) and episodes of 
mania or hypomania (elation, increased energy, less need for sleep) (Phillips and 
Kupfer, 2013). Four main subtypes exist (American Psychiatric Assoication, 2000). 
Bipolar disorder Type I patients are those affected by depressive episodes who have 
also had at least one full-blown manic episode. Type II patients, on the other hand, 
may have only experienced hypomanic symptoms, but they are primarily characterized 
by several episodes of depression. Cyclothymic disorder patients have had several 
mood cycling events between hypomania and mild depression, but do not meet the 
criteria for a full depressive episode. Finally, unspecified bipolar disorder is when 
patients experience mild intensity of depression and hypomania rapid mood cycling 
(Phillips and Kupfer, 2013).  
Bipolar patients can be misdiagnosed with unipolar depression (Hirschfeld, 
Lewis et al., 2003) if the depressive mood state dominates, or if the mania episode 
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does not emerge early. This occurs because depressive symptoms are much more 
prevalent than manic symptoms in most forms of the disease (Phillips and Kupfer, 
2013). Type I and Type II bipolar patients experience manic or hypomanic symptoms 
1% and 9% of the time respectively (Judd, Schettler et al., 2003). Prescribing a strong 
antidepressant regimen to bipolar patients can inadvertently cause full-blown mania or 
rapid cycling symptoms to emerge (Ghaemi, Boiman et al., 2000). 
As stress and other influences build allostatic load, levels of molecular factors 
that modulate neuroprogression differ throughout the body. Both the body and the 
brain receive insults from neuroprogression of the disease and are gradually 
degenerated through later stages (Berk, Kapczinski et al., 2011). Early detection and 
intervention of any mood disorder is essential to slowing progression. About half of 
all lifetime mental health disorders start by age 14, and three-quarters are reported to 
initiate by age 25 (Kessler, Berglund et al., 2005). As a result, many cases go 
unreported and are only treated at later stages of the disease. Failure to differentiate 
between mood disorder subtypes provides another source of confound in disease 
characterization. A systems approach that incorporates a combination of genetic, 
molecular, structural, and physiological biomarkers will be critical to this endeavor. 
Genetic Mechanisms 
Within families, innate heritability of bipolar disorder is strong with estimates 
being around 70% (Ghaemi, Boiman et al., 2000; Sullivan, Kendler et al., 2003) and 
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some studies claiming prevalence as high as 85-89% (McGuffin, Rijsdijk et al., 2003). 
However, the disease concordance within monozygotic twins is still far from 100% 
(Cardno and Gottesman, 2000; Craddock and Jones, 1999), indicating that 
environmental stressors are providing kindling for the disease as shown in Figure 1. 
Many biological and cognitive factors have been demonstrated to cause epigenetic 
modification of DNA such as neurogenesis (Ma, Marchetto et al., 2010), brain 
development and maturation (Pidsley, Dempster et al., 2009), learning and memory 
(Lubin, Roth et al., 2008), substance abuse (Renthal and Nestler, 2009), 
neurodegeneration (Migliore and Coppedè, 2009), and disrupted circadian rhythms 
(Nakahata, Grimaldi et al., 2007). Likewise, many genetic variations have been 
associated with promoting small effects towards the emergence of this complex 
disease state (Purcell, Wray et al., 2009). One such gene implicated in both bipolar 
disorder and schizophrenia is ZNF804A (Riley, Thiselton et al., 2009). Among twins 
with discordant phenotypes of bipolar disorder, several different sites of 
hypomethylation were found at gene loci unique to the affected individual, and among 
all affected individuals unique to the disease (Dempster, Pidsley et al., 2011). Within 
combined bipolar disorder and schizophrenia data, the most significant 
hypomethylation site was at the promoter of ST6GALNAC1. Although this particular 
site is an important duplication site in schizophrenia (Xu, Roos et al., 2008), its 
redundant occurrence highlights the notion that multiple mood and psychotic 
disorders express similar biomarkers despite being phenotypically diverse. Common 
6
genetic and biomarker identification between different mood disorders may provide 
similar treatment targets for disorders with overlapping biomarker data (Berk, 
Kapczinski et al., 2011).  
 
 
Figure 1 – Progressive kindling is represented as different types of fuels to burn a 
fire. Prodromal kindling originating through genetic factors function as small sticks to 
start a fire. Adding larger and more influential forms of fuel precipitate acute forms of 
the disease, as represented by a fire with medium firewood. A chronic form of the 
disease is fully evident through the accumulation of deleterious kindling, represented 
by large firewood in a heavy fire. This figure demonstrates how chronic forms of the 
disease can only manifest from progressively milder stages of the disease, just as a 
small fire would not be hot enough to burn large firewood. 
 
Molecular Mechanisms 
Stress, Inflammation and Immune Activation 
The inflammatory system releases endogenous molecules that have been 
associated with the deleterious effects of allostatic load. This stress response is the 
crucial first step to allostatic load buildup, and primary mediators include 
glucocorticoid and catecholamine release through the stimulation of the HPA-axis 
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and the sympathetic-adrenal-medullary axis respectively (Glaser and Kiecolt-Glaser, 
2005). The brain’s evaluation and subsequent execution of action for these perceived 
threats is performed by the hypothalamic, amygdaloid, and prefrontal cortical 
regulation pathways (Herman, Ostrander et al., 2005). This overall gating of emotional 
valence dictates the amount of glucocorticoid released. Correct release reflects an 
optimized response to the body. However, too much glucocorticoid release can have 
atrophic effects on neuronal cells, while too little can cause impairment by an 
inadequate response to the stress, both of which increase allostatic load (Mateo, 2008). 
This relationship follows a bi-phasic inverted “U” shape as shown in Figure 2; 
adequate release of glucocorticoids promotes positive neuronal branching and survival 
while also enhancing emotional memory, whereas hyperactivity and hypo-activity have 
no balancing effect on the stressor, and cause detrimental effects (Grande, Magalhães 
et al., 2012). 
Adequate glucocorticoid release during the stress response is also implicated in 
the anti-inflammatory action that combats endogenous inflammatory molecules in the 
body (Marx, 1995). However, during allostatic overload when this response is 
exaggerated, the increased glucocorticoid concentration instead signals a release of 
pro-inflammatory mediators by the body’s immune system, including interleukin-1β 
(IL-1β) and tumor necrosis factor-α (TNF-α) (MacPherson, Dinkel et al., 2005). The 
exact mechanisms by which glucocorticoids affect this release are not known and 
require further research. IL-1β and TNF-α activate nuclear factor κB (NF κB), which 
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subsequently promotes the synthesis and release of pro-inflammatory cytokines (Berk, 
Kapczinski et al., 2011). Increases in cytokine activity have been implicated in kindling 
effects via destabilizing the brain’s threshold to stress in such a way that further 
genetic and environmental influences can precipitate bipolar disorder episodes 
(Drexhage, Knijff et al., 2010), such as depression and mania (Wadee, Kuschke et al., 
2002). Bipolar disorder is being established as a pro-inflammatory state condition 
(Goldstein, Kemp et al., 2009), where the transcriptome of these individuals favors 
the production of elevated cytokine levels through genetic and epigenetic 
modifications. Immune dysfunction can also lead to a pro-inflammatory state through 
dysregulation of the phagocyte mononuclear system (Drexhage, Knijff et al., 2010). 
The compensatory effects of anti-inflammatory cytokines are thus overwhelmed by 
the heightened expression of pro-inflammatory cytokines, resulting in a state of 
chronic inflammation (Kim, Jung et al., 2007).  
The pro-inflammatory transcriptome of bipolar patients is not entirely the 
result of genetic heritability but is instead largely influenced by shared environmental 
factors. Studies between monozygotic twins demonstrated a similarly high correlation 
of pro-inflammatory gene expression as that between dizygotic twins (Padmos, Van 
Baal et al., 2009). This demonstrates how shared environmental factors, and not just 
genetic heritability, predispose individuals to a pro-inflammatory state. This is 
consistent with the notion that the pro-inflammatory response in bipolar disorder is a 
secondary outcome that occurs subsequent to a dysregulated stress response 
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(Brietzke, Kapczinski et al., 2011). Distinctions exist in the progression of bipolar 
disorder in relation to the allostatic mediators being expressed. Early versus late stage 
bipolar patients are noticeably different in their express of various molecular 
mediators (eg. inflammatory cytokines, neurotrophins, and oxidative stress molecules), 
and a relationship between each of these biomarkers to severity of disease can give an 
indication of what treatment options are feasible (Berk, Conus et al., 2010). 
Characterizing the disease progression into stages that are based on expression levels 
of these molecular mediators can provide significant benefits for clinical diagnosis, 
ensuring patients have treatment options specific to their disease staging. Studies have 
demonstrated stage-related changes throughout disease progression. For example, 
while pro-inflammatory cytokines IL-6 and TNF-α are elevated in both early and late 
stages of the disorder, anti-inflammatory cytokine IL-10 is increased only in the early 
stages (Kauer-Sant'Anna, Kapczinski et al., 2009). Characterizing these changes and 
their correlation with disease severity will help establish a clinical staging paradigm 
and determine appropriate therapeutic action. 
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Figure 2 – The limbic system’s feed-forward response during low stress exposure 
(left) and repeated stress exposure (right). Stress-induced neurotoxicity accumulates 
within limbic areas of the brain during repeated stress conditions to initiate a 
continuous feed-forward loop. When subsequent stressors are experienced, there is 
higher likelihood of a detrimental glucocorticoid response occurring from too low or 
too high output, which in turn further feeds toxicity into the feed-forward 
mechanisms. Furthermore, the pro-inflammatory transcriptome upregulates 
detrimental cytokine transcription and downregulates anti-inflammatory agents, 
leading to disease progression. 
 
Neurotrophins 
 Molecular neurotrophic factors found in both serum and cerebral spinal fluid 
vary greatly between early and late stage bipolar disorder. A wide variety of these 
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neurotrophins undergo modulations in the brain, but certain neurotrophins such as 
brain-derived neurotrophic factor (BDNF) can cross the blood-brain-barrier at high 
capacity (Grande, Fries et al., 2010) and are measureable in serum. Therefore, BDNF 
is a strong candidate biomarker for staging of early and late bipolar disorder. BDNF is 
expressed in higher amounts during early stages of the disease, but is dramatically 
lowered in concentration at late stages (Grande, Fries et al., 2010). Although basal 
fluctuations are common during early stages of the disease, this drop in BDNF 
concentration provides evidence that late stages of the disease are associated with 
maladaptive changes in the brain. Changes in the levels of these biomarkers through 
disease progression are unique to the particular molecule and do not all follow the 
same trajectory (Brietzke, Kapczinski et al., 2011). Instead, their concentrations 
change at different stages of disease, and therefore, further research into each 
molecule’s unique profile can give valuable insight into the effects of the disease on 
the body (Kapczinski, Dal-Pizzol et al., 2011). For example, even though BDNF 
levels begin to fall only at late stages of bipolar disorder, some cytokine and 
inflammatory activity is instead increased during later stages (Grande, Fries et al., 
2010). The combination of these trajectories can be clinically utilized to identify an 
individual’s profile of disease staging.  
 BDNF also changes in plasma concentration during changes in episodic mood 
states. Shifts between euthymic state and depression or euthymic state and mania 
show dramatic changes in plasma BDNF concentration and is detectable in serum; 
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specifically, BDNF expression levels decrease during manic and depressive episodes, 
and recover in euthymia or during treatment for acute mania (Fernandes, Gama et al., 
2011). These changes in BDNF levels have been shown to persist even in patients 
who are either continually medicated or nonmedicated for bipolar disorder (Cunha, 
Frey et al., 2006; de Oliveira, Ceresér et al., 2009). Since BDNF levels decrease during 
episodes regardless of the presence of medication intervention, it can be concluded 
that BDNF changes occur as a result of disease progression and not because of the 
medications themselves. 
 
Oxidative Stress 
Cerebral metabolic analyses in patients with bipolar disorder have 
demonstrated a polarity in energy regulation between mood states (Strakowski, 
Delbello et al., 2004). Episodes of depression cause brain energy generation to 
decrease, whereas episodes of mania cause brain energy generation to increase 
(Baxter, Phelps et al., 1985). Much of this energy regulation is controlled by the 
cellular energy derived from mitochondrial output. Mitochondria are able to convert 
carbon-based fuel into ATP through aerobic and nonaerobic processes. The electron 
transport chain (ETC) chaperones electrons through complexes of oxidative 
gradients, where the electron jumps from higher to lower oxidative states to release 
the stored energy needed to produce ATP (Williams, Van Remmen et al., 1998). 
During these jumps the electron has the potential to escape, causing an electron 
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charge imbalance and forming an unintended superoxide anion (O2-), which can 
damage molecules in its vicinity, and thus leads to oxidative stress (Williams, Van 
Remmen et al., 1998).  
Bipolar patients express abnormal alterations in their production of 
mitochondrial complexes, such as complex 1 in prefrontal cortex (PFC) cells (Tang 
and Wang, 2014). Complex 1 is an important first-reducing step in the ETC. Along 
with production of low-functioning complexes, evidence also show a reduction in 
expression of the mitochondrial complex subunits, particularly in complex 1, in 
patients with bipolar disorder (Konradi, Eaton et al., 2004). This leads to a greater 
probability of radicalized electrons jumping to unintended molecules in their vicinity. 
The result is the production of reactive oxygen species (ROS), which act as molecular 
mediators of allostatic load. As shown in Figure 3, ROS result in deleterious effects by 
causing mitochondrial and cellular damage through DNA oxidation breakage, lipid-
membrane peroxidation, and protein carbonylation/nitration (Berk, Kapczinski et al., 
2011). This is particularly evident in bipolar disorder and schizophrenia patients, but 
not in control subjects (Wang, Shao et al., 2009). Lipid peroxidation in cells of the 
anterior cingulate cortex (ACC) can have major consequences on the interpretation of 
stressful scenarios. Brain regions connected to the ACC, such as the PFC, amygdala, 
and ventral striatum, function together to generate an appropriate stress response 
(Allman, Hakeem et al., 2001). Damage to these regions through allostatic mediators 
gives clear indication as to how this inadequate response may occur (McEwen, 1998). 
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Acute episodic mood fluctuations as well as chronic disease progression 
modulate the amount of synaptic neurotransmission occurring in different regions of 
the brain (Berk, Kapczinski et al., 2011). Dopamine and glutamate have a direct effect 
on the level of oxidative stress in the cell when present at high concentrations, which 
happens during acute episodes in bipolar disorder (Berk, Kapczinski et al., 2011). 
Substantial release of these neurotransmitters floods the synaptic space to higher 
levels than the threshold of enzymatic clearance systems, with damaging results to 
cells. Dopamine goes through auto-oxidation in the presence of Fe2+, and forms by-
products of hydroxyl ions (-OH), which are of the most reactive free radicals 
(Halliwell, 1992). Glutamate on the other hand can promote calcium ion (Ca2+) influx 
into neurons, and subsequently elevated concentrations activate nitric oxide synthase 
(NOS), forming the powerful oxidant peroxynitrite (ONOO-) (Lafon-Cazal, Culcasi et 
al., 1993). It is important to note that ROS provide regulatory functioning as cell 
signals to beneficially indicate an imbalance in proper cellular functions (Sauer, 
Wartenberg et al., 2001). When scavengers that protect the cell from oxidative stress 
are outnumbered by ROS, the ROS accumulation promotes cellular apoptosis. 
Although this process continuously occurs in healthy individuals, accelerated ROS 
production leads to further neuronal degeneration that outweighs neurogenesis 
(Koopman, Nijtmans et al., 2010). Thus, this has a net atrophic effect and results in 
further progression of the disease. 
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Modulations in dopaminergic activity is implicated in episodic bipolar disorder, 
where low levels correspond to a depressive state and high levels correspond to a 
manic state (Berk, Dodd et al., 2007). During transmission, synaptic dopamine is 
removed through various clearance mechanisms, a prominent one being presynaptic 
reuptake through membrane-bound dopamine transporters (DAT) (Gainetdinov, 
Jones et al., 1998). Through repeated exposure of dopamine transmission in patients 
with bipolar disorder, this constant reuptake causes an elevated influx of cytosolic 
dopamine, giving dopamine the potential to form ROS byproducts such as hydrogen 
peroxide (H2O2) and 6-OHDA within the cell (Berman and Hastings, 1999; 
Thannickal and Fanburg, 2000). Auto-oxidation of H2O2 forms highly oxidative 
hydroxide ions (OH-) that further cause damage to the cell.  
One example of cellular damage occurs when ROS indiscriminately attacking 
mitochondrial and nuclear DNA when in their immediate vicinity (Reiter, 2001). In 
this situation, poly-ADP-ribosome polymerase (PARP)-mediated repair of DNA 
strand breakage results in the formation of homocysteine, a neurotoxic amino acid 
that aggregates in the cell and causes it to undergo apoptosis (Ho, Ortiz et al., 2002). 
A second method of oxidative damage results in lipid peroxidation. ROS produce 
fatty acid chains with peroxide functional groups by stealing electrons from 
membrane lipids. This can be detected in lipid peroxidation of the ACC in patients 
with bipolar disorder (Wang, Shao et al., 2009). The result is instability in the 
hydrophobic region of the lipid bilayer, modulating the fluidity of the affected cell or 
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organelle relative to its environment. This has been implicated in cell death and thus 
leads to neurodegeneration (Mahadik, Evans et al., 2001). A third example of 
oxidative damage targets amino acid residues on proteins to form aggregates. These 
reactions can produce peptide bond breakage or formation of highly reactive 
functional groups, such as semialdehydes on amino acids lysine, arginine, and proline 
(Dalle‐Donne, Aldini et al., 2006). The resultant reactive functional groups create 
conformational misfolding through bonding interactions with other functional groups 
of the protein. Often the misfolded protein will simply be ubiquinized and degraded 
through the proteasome. However, some conformational changes are minor and allow 
the protein to mimic its natural functioning state to bypass degradation mechanisms. 
Nonfunctional proteins can combine to form protein aggregates with 
neurodegenerative properties (Beal, 2002). 
Neurotransmission of glutamate is also found to be abnormal during 
symptomatic episodes in bipolar patients (Öngür, Jensen et al., 2008; Yüksel and 
Öngür, 2010). Magnetic resonance spectroscopy studies specifically show elevated 
levels of glutamate in medial PFC during episodes of depression (Frye, Watzl et al., 
2007), and elevated levels of glutamine in ACC and parieto-occipital cortex during 
mania (Öngür, Jensen et al., 2008). Glutamate is associated with allostatic role through 
N-methyl-D-aspartate (NMDA) receptor activation, which opens the ion channel to 
allow the influx of Ca2+ ions. When increasing the amount of glutamate molecules are 
present to bind to NMDA receptor subunit-2 (NR2), there is a higher probability of 
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NMDA receptor channels conformed in their open configuration (Jahr, 1992; 
McEwen, 2000). The resulting heightened Ca2+ influx has excitotoxic effects on 
neuronal cells. Ca2+ ions are normally crucial to many cellular signal transduction 
pathways, and are sensitive to a plethora of stimuli while still being able to elicit a 
response in many different cellular activities (Barnham, Masters et al., 2004). This 
produces nitric oxide (NO) molecules through NOS activation, which are highly 
reactive to oxide ions to produce peroxynitrite (Lafon-Cazal, Culcasi et al., 1993). 
Peroxynitrite causes nitrosative damaging effects similar to ROS. They also form 
protein aggregates through the nitration of tyrosine residues. This forms nitrotyrosine, 
a residue that mimics phosphotyrosine due to its similar structure (Mallozzi, Di Stasi 
et al., 2001). However, the presence of nitrotyrosine at the protein’s phosphorylation 
domain irreversibly blocks its ability to be phosphorylated, therefor making the 
protein a nonfunctional aggregate (Torreilles, Salman-Tabcheh et al., 1999). 
Accumulation of these aggregates, as well as other forms of oxidative damage, results 
in cellular degeneration and contributes to the regional changes associated with 
disease. Continuous damage to neurons at the cellular level cumulative account for 
macroscopic damage in neural circuitry, and these effects are detectable when imaging 
pathophysiologcal neurotransmission, neurostructural morphology, and 
connectomics. 
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Figure 3 – Sources of reactive oxygen/nitrogen species (ROS/RNS) and the cellular 
damage they cause to promote neurodegeneration. The right side illustrates a cell with 
high allostatic load whereas the left side illustrates a healthy cell for comparison. A: 
Glutamate-induced calcium ions and dopamine react separately to form ROS/RNS. 
B: The process also occurs through mitochondrial dysfunction within the electron 
transport chain. C: ROS/RNS scavengers are outnumbered in a cell already 
expressing high allostatic load, leading ROS/RNS to cause deleterious damage. D: 
Nuclear DNA is attacked and undergoes breakage. The repair mechanisms to fix 
these breakages release homocysteine byproducts that aggregate in the cell and 
promote apoptosis. E: ROS/RNS attack protein residues and leave the proteins 
nonfunctional, yet mask these maladaptive proteins from proteasomes, which leads to 
aggregating in the cell and promotes cell death. F: Membrane lipid peroxidation 
occurs in the presence of ROS/RNS and leads to damage that alters cell fluidity and 
subsequently leads to cell death.  
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Neural Circuitry 
Neurotransmission 
Modification of neurotransmission plays a central role in how the brain is 
maladapted in a disease state. Mood disorders that feature dysfunctional circuits have 
profound effects on an individual’s behavior and perspective (Brambilla, Perez et al., 
2003; Drevets, 2000). Dopamine in particular is important in modulating mood 
related behaviors. Increased levels of synaptic dopamine neurotransmission lead to a 
heightened state of mania (Johnson, Edge et al., 2012; Young, Goey et al., 2010; 
Young, van Enkhuizen et al., 2011). This is in line with the use of classical 
psychostimulants, such as amphetamines, which increase the dopaminergic output in 
the brain and induce mania-like behaviors (Young, Goey et al., 2010). In contrast, type 
2 dopamine receptor antagonists reduce the mania symptoms in patients and are 
clinically used as antipsychotic medication (Berk and Dodd, 2005; Chengappa, Suppes 
et al., 2004; Frey, Martins et al., 2006; Malhi, Berk et al., 2005). Dopamine is quickly 
removed from the synapse through reabsorption and metabolism, utilizing available 
DAT and monoamine oxidase (MAO) enzymes respectively (Elsworth and Roth, 
1997). Normal MAO metabolism of dopamine produces H2O2 and 
dihydroxyphenylacetic acid (DOPAC). At elevated concentrations, the leftover 
dopamine undergoes a third process of non-enzymatic hydroxylation, which leads to 
the formation of 6-hydroxydopamine (6-OHDA) (Graham, Tiffany et al., 1978). 6-
OHDA readily auto-oxidizes into H2O2, superoxide radicals, and hydroxyl radicals 
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(Cohen and Heikkila, 1974). The production of free radicals from these ROS causes a 
heavy oxidative stress on the environment. If left uncontrolled, oxidative stress 
accumulates and result in mitochondrial dysfunction (Berman and Hastings, 1999), 
and therefore contributes to neurodegeneration. For example, 6-OHDA also forms 
into p-quinone, an activator of the caspase-8 pathway that leads to apoptosis (Stokes, 
Hastings et al., 1999). As multiple neurons in a region develop these pro-apoptotic 
signaling pathways, large-scale atrophy may be observed. 
Similarly glutamate, while being an important neurotransmitter for excitatory 
information transfer and cellular energy balance, is also a powerful neurotoxin that is 
capable of causing neuronal atrophy in the central nervous system when extracellular 
concentrations are sufficiently high (Rothman and Olney, 1986). Glutamate plays a 
central role in mediating calcium influx through activation of NMDA receptors (Jahr, 
1992). This occurs through the binding of glutamate with NR2. High levels of 
glutamate allows for greater calcium ion influx (Laube, Hirai et al., 1997), and results 
in increased NO production (Garthwaite, 1991). NO levels increase the chance of 
nitrosative damage and lead to a higher allostatic load associated with oxidative stress, 
resulting in neural degeneration (Berk, Kapczinski et al., 2011). This is evident in ACC 
layer II cortical interneurons in postmortem brain studies of bipolar patients that 
produce γ-aminobutyric acid (GABA) messenger-RNA (mRNA). A neuronal density 
reduction of 35% was found in ACC for these GABA neurons, and a reduction of 
60% was found in GABA neurons that coexpress NR2A, even though the amount of 
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NR2A production level was not affected in the remaining NR2A-expressing neurons 
(Woo, Walsh et al., 2004). The activity of these GABA neurons is mediated by 
glutamate pyramidal cells, and therefore the high release of glutamate from these 
neurons in bipolar patients leads to the postsynaptic atrophy associated with GABA-
neuron density decrease, as seen in Figure 4.  
Studying dysfunction of the ACC for bipolar disorder is important because of 
its large-scale neural networks with the limbic system, the dorsolateral prefrontal 
regions, and the motor and premotor cortex, all of which are involved in a wide range 
of functions such as affective regulation, selective attention, motivation, executive 
control, and orchestration of motor programming (Woo, Walsh et al., 2004). The 
ACC involvement in these regions includes error detection and conflict monitoring 
(Carter, Braver et al., 1998), and therefore, structural and functional alterations in 
ACC are commonly found in bipolar patients (Bouras, Kövari et al., 2001; Wang, 
Kalmar et al., 2009). Furthermore, NRS2A is an important mediator for activation of 
the GABA cells through Ca2+ influx depolarization. Knockout mice that do not 
express this subunit demonstrated increased striatal dopamine release (Miyamoto, 
Yamada et al., 2001), a disinhibitory effect of GABA-neuron activity suppression. 
Such animals displayed mania-like hyperlocomotion that was attenuated through 
antipsychotic treatment and resembled the depleted GABA-neuron activity in ACC of 
bipolar patients. Future studies aiming to regulate this glutamate-GABA-dopamine 
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loop may have vital implications in managing the manic effects associated with bipolar 
disorder symptoms. 
 
Figure 4 – A: Glutamatergic inputs from local ACC pyramidal neurons or other 
limbic and reward centers transmit elevated concentrations of glutamate to ACC 
GABAergic neurons in brains of patients suffering acute to chronic stages of bipolar 
disorder. This elevated glutamate increases influx of cytosolic calcium ions, which 
promotes the formation of RNS through NOS. The resulting allostatic load degrades 
the ACC GABAergic neurons, which weakens the overall inhibitory output to the 
dopaminergic medial forebrain bundle (mfb). Disinhibition of mfb increases its 
activity. B: Dopamine production and synaptic reabsorption from increased mfb 
activity produces heavy allostatic load associated with RNS, as well as promoting 
apoptotic signaling. The subsequent degeneration of mfb neurons results in a 
dysregulated dopamine response by reward, memory, and limbic regions. Some of 
these connections are fed into the ACC, thus promoting feedforward degradation. 
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Functional Imaging 
Imaging studies of mood disorders illustrate a progressively changing brain 
affected by neurodegeneration associated with allostatic load. Apoptotic signaling, 
inflammation, oxidative stress, and neurotransmitter modulation are among the insults 
to the brain that promote changes in structural morphology (Frey, Andreazza et al., 
2013; McEwen, 2003). These structural alterations are detectable in late-stage bipolar 
disorder but rarely produce noticeable changes during the early stages of the disease 
(Vieta, Reinares et al., 2011). Even after the first major episodic attack, the structural 
alterations are negligibly small and thus undetectable by imaging methods (Berk, 
Hallam et al., 2010). Wear-and-tear accumulated through continuous episodes of 
allostatic overload is detectable however, and contributes to the gradual yet significant 
changes in the brain following repeated stress. With subsequent symptomatic 
episodes, these changes become increasingly visible. In unipolar depression, the 
hippocampus does not display a reduction in size until after 2 years of disease 
exposure and only after more than one significant episode (McKinnon, Yucel et al., 
2009; Sheline, Gado et al., 2003). Videbech and Ravnkilde (2004) found a direct 
correlation in hippocampal volume reduction influenced independently by frequency 
of episodes and time since disease onset. Other brain regions such as amygdala, 
orbitofrontal cortex, ACC, pituitary, and basal ganglia have altered structural 
morphology related to depression (Moylan, Maes et al., 2012). Functional imaging 
methods, such as positron emission tomography (PET) and single-photon emission 
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computed tomography (SPECT), also demonstrate neural abnormalities. They have 
been found to identify patients with depression and discriminate between subtypes of 
depression by scanning region-specific functional changes (Baxter, Schwartz et al., 
1989; Bench, Friston et al., 1992). For example, in patients suffering preexisting basal 
ganglia disorders, there is resting state paralimbic hypometabolism observed in these 
patients who also have depressive symptoms when compared to those patients with 
no depressive symptoms (Ketter, George et al., 1996). Another brain area implicated 
in depression is the frontal lobe, as it appears to have the most robust and consistent 
decrease in function (Mayberg, 2003).  
Many bipolar patients are often misdiagnosed with unipolar depression due to 
behavioral and phenotypic similarity (Bowden, 2001). By scanning brain regions that 
discriminate between these diseases through magnetic resonance imaging (MRI), 
clinicians can diagnose the individual based on powerful imaging data. To heighten 
the biological discrimination between bipolar and unipolar depression, the effects of 
mania on the brain are also imperative to analyze (Bowden, 2001). A significant 
structural brain change that is distinct in bipolar patients but not in unipolar depressed 
patients is ventricular enlargement, which does not occur until at least one episode of 
mania (Strakowski, DelBello et al., 2002). Other changes that contribute to bipolar 
disorder include a progressive loss of gray matter (Lyoo, Sung et al., 2006) and 
cerebellar vermal V3 reduction (DelBello, Strakowski et al., 1999). Although most 
structural changes occur well after onset and become distinct after episodic attacks, 
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some changes are apparent during earlier stages of the disease. Fornito et al. (2009) 
(Fornito, Yücel et al., 2009) demonstrated that patients at a high risk for bipolar 
disorder, but who have yet to have a first manic episode, have increased thickness in 
the right subcallosal limbic ACC. A progressive volumetric reduction in many brain 
regions can thus be detected throughout chronicity of the disease (Berk, Hallam et al., 
2007). In contrast, some regions such as the amygdala and hippocampus already 
display a reduction in size during early stages (Blumberg, Kaufman et al., 2003) and 
provide valuable early detection points. Functional changes are also present in patients 
suffering bipolar disorder observed through a reduction in dorsolateral PFC activation 
and increased amygdala activation (Yurgelun‐Todd, Gruber et al., 2000). Many 
morphological changes that occur in unipolar depressed patients are similar to those 
of bipolar depressed patients (Strakowski, Adler et al., 2002), while many 
schizophrenic morphological changes are similar to those of manic episodic changes 
(Rimol, Hartberg et al., 2010). Therefore, individual changes in brain regions can give 
confounding diagnoses unless it is compiled and compared with several other 
important regional alterations. These morphological changes offer important insight 
in the staging of a mood disorder, especially in terms of connective strengths between 
regions. Some studies have determined ways to discriminate diseases based on 
connection weights (Calhoun, Maciejewski et al., 2008), offering a new source of 
information that can be of great importance when understanding a disease and 
characterizing its staging. 
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Connectomics 
 As bipolar disorder progresses there is continuous modulation of the synaptic 
strength of individual neurons (Quiroz, Gray et al., 2008). This occurs through long-
term potentiation and long-term depression (Moser, Krobert et al., 1998). When 
regional growth or atrophy associated with disease effects several neuronal clusters, 
the result can be a modulation in connective strengths between entire brain regions. 
Interregional and intraregional synaptic strength changes can be tracked using voxel-
based neuroimaging methods such as functional MRI (fMRI) and diffusion weighted 
imaging (DWI) (Fornito and Bullmore, 2012). Most imaging methods that study 
connectivity modulations focus on white matter abnormalities in the brain. Since 
white matter represents areas dense with axonal fibers, the changing weights of these 
tracks during disease progression demonstrate modulatory connectivity between 
specific brain regions, or between the two hemispheres themselves. The largest white 
matter connection is the corpus callosum. Bipolar patients demonstrate abnormalities 
in this connecting tract seen through DWI, resulting in altered interhemispheric 
connectivity, an important marker for identifying this disease (Bellani, Yeh et al., 
2009). Other white matter connectivity tracks reported to be abnormal in bipolar 
disorder include the PFC to limbic system tracks, as well as the internal capsule to 
superior longitudinal fasciculus tracks (Benedetti, Yeh et al., 2011; Heng, Song et al., 
2010). 
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 There is also an important relationship in the modulation of connectivity 
strengths that are caused by specific genetic variants associated with mood disorders 
(Heinz, Braus et al., 2004). It has been implicated that the expression of certain genes 
can alter synaptic transmission through genetic mutations, resulting in pathological 
expression such as through reduced transcriptional efficiency of normal variants of 
the gene (Heils, Teufel et al., 1996) or expression of altered forms of genes and 
proteins resulting in disease progression (Sabol, Hu et al., 1998). Ultimately, these 
changes modulate the transmission of information between neurons. The result of 
this is postsynaptic signal transduction that is modulated through Hebbian plasticity, 
which affects connectivity strengths between regions. For example, fronto-limbic 
connectivity is modulated in humans associated with negative emotionality and mood 
disorders, such as when the SLC6A4 gene (a serotonin transport gene) is transcribed 
in its shorter variant (Clarke, Flint et al., 2010; Munafò, Freimer et al., 2009). This 
causes an increase in amygdala and medial PFC functional connectivity (Heinz, Braus 
et al., 2004) (Phillips, Drevets et al., 2003) and has drastic effects on emotional 
regulation. There is also a reduction in functional connectivity between amygdala and 
pre- and sub-genual ACC, which is implicated in depressive symptoms (Pezawas, 
Meyer-Lindenberg et al., 2005). Other changes include fronto-temporal connectivity 
modulations that are the result of genetic variations associated with the disease. For 
example, the rs1344706 polymorphism of ZNF804A gene alters proper functionality 
of zinc finger domains in this protein, which are normally implicated in 
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oligodendrocyte regulation and neuronal development (Chung, Lee et al., 2010; Riley, 
Thiselton et al., 2009). The rs1344706 polymorphism has been associated to be a 
genome-wide significant risk factor for bipolar disorder (Steinberg, Mors et al., 2010) 
and is the most strongly associated genetic marker for the disease (Williams, Norton 
et al., 2010). This variant has been shown to result in reduced connectivity in the 
dorsolateral PFC with other PFC regions while increasing connectivity between PFC 
and hippocampal regions in patients suffering psychosis (Esslinger, Walter et al., 
2009). The allele is also specifically associated with emotional perception alterations in 
bipolar disorder, caused by increasing the functional connectivity within fronto-limbic 
circuits (Fornito and Bullmore, 2012). Globally across the whole brain, bipolar 
disorder patient have been illustrated through a graph theory-based brain network 
analysis to have a greater characteristic path length (which impedes and slows down 
information transfer), a lowered clustering coefficient (less locally interconnected 
clusters), and a reduced global information transfer efficiency (Leow, Ajilore et al., 
2013). Studying these changes throughout disease progression may help to identify 
functional modulations that occur throughout disease neuroprogression that may be 
detectable before structural modifications occur, therefore providing higher efficacy in 
early detection methods. 
 The total cumulative information taken from changes in neurotransmission, 
functional imaging, and connectomics could help identify useful information 
regarding disease progression and staging. The alterations seen in bipolar disorder are 
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listed in Table 1, however many more are being discovered. By characterizing discreet 
levels of staging based on progressive imaging information and biomarker data, a 
specific treatment option could be developed for the affected patient. This 
methodology can help establish a personalized treatment plan specific for the patient’s 
staging of the disease. A clinical staging paradigm must contain robust, scientifically 
validated biomarker expression levels and imaging information characteristics 
particular to its staging level. This would help establish empirical methods to treat 
conditions that have been conventionally diagnosed solely through behavioral 
observations and surveys. Using a staging paradigm could shift therapeutic targeting 
towards actual modifications in the body and brain associated with the disease. This 
model could then be further extended towards all degenerative psychiatric conditions. 
Once a clinical staging model is established for bipolar disorder and other 
neurological diseases through clinical and preclinical studies, a greater number of 
patients will receive treatment options based on an integrative systems approach and 
personalized medicine approach, fundamentally benefiting the patients and our 
healthcare system.  
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Table 1 – A summary table of changes in bipolar brain regions based on size, function, 
and connection strength. Changes labeled “altered” represent studies that notice some 
modulation but not enough evidence for systematic changes in one direction 
Brain region Size  Depression/ 
mania/bipolar 
 
Reference 
hippocampus reduced depression/bipolar (Videbech and Ravnkilde, 2004), 
(Sheline, Gado et al., 2003) / 
(Blumberg, Kaufman et al., 2003) 
amygdala altered depression/bipolar (Moylan, Maes et al., 2012) / 
(Blumberg, Kaufman et al., 2003) 
orbitofrontal cortex altered depression (Moylan, Maes et al., 2012) 
anterior cingulate 
cortex 
altered depression (Moylan, Maes et al., 2012) 
pituitary altered depression (Moylan, Maes et al., 2012) 
basal ganglia altered depression (Moylan, Maes et al., 2012) 
ventrical increased bipolar (Strakowski, DelBello et al., 2002) 
gray matter reduced bipolar (Lyoo, Sung et al., 2006) 
cerebellar V3 reduced bipolar (DelBello, Strakowski et al., 1999) 
subcallosal limbic ACC increased bipolar (Fornito, Yücel et al., 2009) 
 Function    
paralimbic reduced depression (Ketter, George et al., 1996) 
frontal lobe reduced depression (Mayberg, 2003) 
orbitofrontal cortex reduced bipolar (Yurgelun‐Todd, Gruber et al., 2000) 
amygdala increased bipolar (Yurgelun‐Todd, Gruber et al., 2000) 
 Connection   
interhemisphere 
(corpus callosum) 
altered bipolar (Bellani, Yeh et al., 2009) 
PFC-limbic altered bipolar (Heng, Song et al., 2010) 
internal capsule-
superior longitudinal 
fasciculus track 
altered bipolar (Benedetti, Yeh et al., 2011) 
amygdala-mPFC increased bipolar (Heinz, Braus et al., 2004), (Phillips, 
Drevets et al., 2003) 
amygdala-pre/sub-
genual ACC 
reduced depression (Pezawas, Meyer-Lindenberg et al., 
2005) 
dorsolateral PFC-PFC reduced mania (Esslinger, Walter et al., 2009) 
PFC-hippocampus increased mania (Esslinger, Walter et al., 2009) 
frontal-limbic increased bipolar (Fornito and Bullmore, 2012) 
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 Conclusion 
 To successfully characterize how the integration of molecular mechanisms and 
imaging fluctuations relates to mood disorder vulnerability, staging, and progression, it 
is important to recognize what these fluctuations represent in the body and how they 
relate to the systems involved. For example, decreased BDNF in the hippocampus 
have different implications than decreased BDNF detected in serum, and the same 
can be said about ROS production, cytokine activity, and insulin. Neurotransmitter 
dysregulation, particularly for dopamine, and functional modulations in the brain also 
occur due to factors related and nonrelated to the disease. Therefore, the integration 
of this data, combined with phenotypic behaviors and genetic dispositions all factor 
into an integrated systems level of disease understanding. Establishing an empirical 
diagnoses chart for disease staging criteria, based on cumulated biomarker activity 
levels, is within reach as further research highlights the importance of proper disease 
characterization. Because of the complexity in bipolar disorder neurogenesis and 
progression, there are few methods of describing this disease model. The allostatic 
load and overload hypothesis gives us good indication of the neuroprogressive 
mediators that promote the severity of this disease throughout life. An integration of 
this data is the next step towards eradicating the growing epidemic of mental 
disorders worldwide. 
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CHAPTER 2 
Dopamine Dysregulation and Neuroplasticity Deficiencies in 
Treatment Resistant Depression 
  
The role of dopamine (DA) in modulating mood valence is well established 
(Brown and Gershon, 1993; Dunlop and Nemeroff, 2007; Krishnan and Nestler, 
2008). After decades of investigations into the pathophysiology of neuropsychiatric 
disorders, which has included both clinical studies and animal models, researchers 
have elucidated many of the intricate mechanisms, part of which involve the brain’s 
dopaminergic (DAergic) systems. DAergic systems regulate a variety of complex 
intrinsic behaviors relevant to mood disorder pathophysiology, including motivation, 
reward salience, arousal, motor programming, and cognitive control. Respective to 
these, disruption of DAergic systems can lead to debilitating neuropathologies 
including anhedonia (Wise, 2008), addiction (Koob, 1992), sexual dysfunction (Melis 
and Argiolas, 1995), Parkinson’s disease (Lotharius and Brundin, 2002), and attention-
deficit (hyperactivity) disorder (Cook Jr, Stein et al., 1995).  
 DA, like other central nervous system monoamines, including norepinephrine 
and serotonin, functions as a neuromodulator where activity can influence divergent 
populations of neurons and their responses to other incoming stimuli. This is in 
contrast to classical neurotransmitter function, including glutamate and gamma-
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aminobutyric acid (GABA), which directly affect the membrane potential of a single 
postsynaptic neuron. A growing body of evidence indicates that DA dysregulation 
plays a critical role in mood disorder pathophysiology. This review integrates current 
knowledge of DAergic systems and their contribution to synaptic plasticity and 
treatment response in depression. As well, it highlights mechanisms and timecourse of 
effective interventions for treatment resistant depression (TRD), including deep brain 
stimulation (DBS) and rapid-acting antidepressants such as ketamine. 
 
DA Dysregulation in Mood Disorders 
 The monoamine hypothesis states that the pathophysiology of depression is 
based on the depletion of serotonin, DA, and norepinephrine (Delgado, 2000). While 
major antidepressant therapeutics primarily target imbalances in the monoamines 
serotonin and norepinephrine (Hindmarch, 2002; Hirschfeld, 2000), all classes of 
antidepressants are shown to increase DA levels in prefrontal cortex (PFC) (Lavergne 
and Jay, 2010). What’s more, dysregulation of the mesocorticolimbic DAergic system 
is critically implicated in depression and bipolar disorder pathophysiology (Berk, 
Dodd et al., 2007; Ordway, Klimek et al., 2002; Willner, 1997). Diminished and 
elevated DA activity in the mesoaccumbal circuit has been linked to manifestation of 
clinical depression (Dunlop and Nemeroff, 2007) and mania (Swerdlow and Koob, 
1987) symptoms, respectively. The synaptic clearance of elicited DA, which is 
mediated by DA transporter (DAT), is also expressed in altered functionality (Meyer, 
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Krüger et al., 2001) and concentration (Laasonen-Balk, Kuikka et al., 1999; Rao, 
Kellom et al., 2012) in mood disorders. Likewise, lowered DA activity in depression 
leads to compensatory up-regulation of DA receptors and results in potentiated DA 
signal transduction (Dunlop and Nemeroff, 2007). Patients suffering from depression 
therefore experience greater behavioral and rewarding effects from DA-releasing 
psychostimulants (Tremblay, Naranjo et al., 2002; Tremblay, Naranjo et al., 2005)]. 
Pharmaceutical antidepressants that target DAergic activity are effective in 
treating depression (Berk, Dodd et al., 2007; Tremblay, Naranjo et al., 2005). Similar 
to psychostimulants, non-DAergic antidepressants are shown to increase DA release 
due to secondary DAergic effects that potentiate reward behaviors related to DA 
activity (D'Aquila, Collu et al., 2000; Tanda, Carboni et al., 1994; Willner, 1997). Yet, 
for the majority of antidepressants, depressed patients are at minimal risk for 
developing addiction to their treatment (Haddad, 1999). Patients are at risk however 
towards developing treatment resistance to medication. About 30% of patients who 
are majorly depressed will develop TRD (Warden, Rush et al., 2007), which is 
characterized by failure in clinical response to antidepressant treatments at sufficient 
dose and duration (Anderson, Frye et al., 2012). TRD patients also demonstrate 
failures in brain homeostatic mechanisms (Haile, Murrough et al., 2014). This is 
consistent with evidence of diminished neuroplasticity and cellular resistance in 
difficult-to-treat depression (Manji, Quiroz et al., 2003). Neuroplasticity markers, such 
as brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin 
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(mTOR), are correlated with treatment efficacy for fast-acting antidepressants in TRD 
patients (Abdallah, Sanacora et al., 2015; Haile, Murrough et al., 2014). Non-refractory 
depressed patients also demonstrate elevated levels of neuroplasticity markers with 
successful antidepressant treatment (Aydemir, Deveci et al., 2005; Duman, Malberg et 
al., 1999). Therefore, pharmaceutical interventions in TRD patients may have 
diminished antidepressant effects as a result of maladaptive neuroplasticity, resulting 
in (or perhaps from) attenuated DA output and dysregulation of DAergic systems. 
 
DA Modulation of Neuroplasticity and Reward – Critical for Antidepressant 
Response 
Diminished neuroplasticity and disrupted cellular homeostasis are key 
components of depression and the antidepressant response (D'Sa and Duman, 2002). 
Only a subset of patients develops treatment resistance and it is yet unclear what the 
pathways of neurogenesis are or whether this process occurs gradually or all at once 
(Kapczinski, Dias et al., 2009). Predictive measures of treatment resistance and its 
vulnerability lack clinical validity, and clinicians have difficulty coming to a consensus 
for staging criteria (Souery, Amsterdam et al., 1999; Souery, Papakostas et al., 2006). 
Evidence shows that neuroplasticity modulation of the mesocorticolimbic circuit 
occurs continuously in healthy patients and leads to synaptic plasticity long-term 
potentiation (LTP) of ventral tegmental area (VTA) DAergic tracts projecting to the 
nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) regions for rewarding 
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and aversive stimuli respectively (Pignatelli and Bonci, 2015). It is possible that 
repeated and continuous activation of the endogenous stress response, which is a 
major contributor to depression manifestation (Walker, Kim et al., 2014), has 
downstream effects in diminishing neuroplasticity through various pathways. The 
direct causal mechanisms for this effect is unclear. However, blood BDNF expression 
is a good indicator of neuroplasticity and correlated with changes in depression 
(Brunoni, Lopes et al., 2008), and decreased blood BDNF levels are observed in 
depressed patients (Karege, Perret et al., 2002; Lee, Kim et al., 2007).  
It is important to note that, among other factors, DA is proposed to be a direct 
modulator of LTP (Sweatt, 1999). As well, functionality of the DA system in response 
to particular stimuli (rewards and stress) is tightly regulated by LTP mechanisms 
(Pignatelli and Bonci, 2015). LTP of DAergic signaling serves to modulate behavioral 
response to subsequent stress or rewarding stimuli and contributes to learning and 
attunement of incentive-motivation behavioral responses. It has been proposed that 
DA originating from the VTA functions as a reward-prediction error signal and 
generates a value to each stimulus through phasic bursting (Schultz, 2015). This 
induces positive-reinforcement behavioral adaptations in cognitive processing of 
reward perception (desire) and motor function (acquisition) from the NAc shell and 
core respectively (Malenka, Nestler et al., 2009), and is particularly evident in DAergic 
drug-reinforcement studies (Ito, Robbins et al., 2004; Sellings and Clarke, 2003). 
When the reward is unexpected or exceeds expectations, a second phasic bursting is 
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elicited and contributes to N-methyl-D-aspartate (NMDA) receptor-dependent LTP 
(Harnett, Bernier et al., 2009). Rewards that meet expectations produce no secondary 
phasic bursting. However, the omission of expected reward drops phasic DA below 
its background level and attenuates LTP. It is likely that consistent omissions of 
expected reward and attenuation of mesoaccumbal phasic DA activity contribute to 
the pathophysiology of depression. This is further exemplified by attenuation of 
reward-seeking behaviors and the manifestation of phenotypic anhedonia in these 
patients (Nestler and Carlezon, 2006). Indeed, DBS of this circuitry has been shown 
to alleviate clinical anhedonia (Schlaepfer, Cohen et al., 2008). 
 
Antidepressant mechanisms of DBS and Modulation of DA 
While the effects of pharmaceutical interventions are hindered in TRD, DBS of 
key mesocorticolimbic structures has demonstrative efficacy for TRD patients 
(Bewernick, Hurlemann et al., 2010; Dougherty, Rezai et al., 2015; Mayberg, Lozano 
et al., 2005; Merkl, Schneider et al., 2013). However, the underlying mechanisms of 
DBS antidepressant actions remain unknown (Dostrovsky and Lozano, 2002; Vitek, 
2002). In general, the DBS electrical pulses produce inhibitory neuronal effects on 
soma that are proximal to the electrode placement (Dostrovsky, Levy et al., 2000; 
Filali, Hutchison et al., 2004). The inhibitory effect is thought to be the result of direct 
somatic inhibition through depolarization blockade, of which these mechanisms 
include sodium channel inactivation (Benazzouz, Piallat et al., 1995; Beurrier, Bioulac 
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et al., 2001; Magarinos-Ascone, Pazo et al., 2002) and potassium current potentiation 
(Shin, Samoilova et al., 2007). In contrast, distal soma are thought to be activated by 
DBS electrical pulses (McIntyre, Grill et al., 2004). Axons and dendrites proximal to 
the area of stimulation experience bidirectional depolarization, which produces 
enhanced frequency and amplitude of action potentials at the distal soma connected 
to these fibers (Anderson, Hu et al., 2004; McIntyre, Savasta et al., 2004; Nowak and 
Bullier, 1998; Vitek, 2002). Therefore, DBS can activate multiple brain regions up- or 
down-stream of the stimulation site, and subsequently promote connectivity through 
Hebbian plasticity. This would explain why multiple distinct and functionally 
heterogeneous mesocorticolimbic DBS targets have been identified for the treatment 
of depression, as a large part of this circuit may be modulated by stimulation of a 
single region. 
In rodents, high-frequency DBS (130 Hz) of the mPFC (Hamani, Diwan et al., 
2010), NAc (Kim, Kang et al., 2014), or lateral habenula (LHb) (Kim, Morath et al., 
2016) produce antidepressant-like effects. As shown in Figure 1, these regions make 
direct and indirect projections to the (VTA) via glutamatergic and GABAergic 
neurons. Studies suggest that DBS of these targets evokes DA release from the VTA 
(Friedman, Lax et al., 2010; Tong, Overton et al., 1996; Yan, Chen et al., 2013), likely 
due to the lowering of GABAergic inhibition that project to VTA DAergic neurons. 
Lowering this threshold would allow excitatory projections from other limbic regions, 
such as lateral hypothalamus, extended amygdala, mPFC, and laterodorsal tegmental 
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nucleus (Russo and Nestler, 2013), to directly activate DAergic neurons, resulting in 
enhanced limbic DA activity. TRD patients who exhibit attenuated DA activity 
(Lambert, Johansson et al., 2000) can therefore restore these DA deficits through 
DBS despite failing pharmaceutical antidepressant response. 
 
Figure 1 – The rodent mesocorticolimbic circuit with antidepressant DBS targets 
(lightning bolts). This simplified illustration of glutamatergic, DAergic, and 
GABAergic connections of key limbic structures demonstrates the ability of DBS to 
singularly block (x) local soma of mPFC (purple), NAc (orange), or LHb (yellow) and 
subsequently produce network-wide DAergic activity increase (+). mPFC DBS blocks 
local glutamatergic neurons that innervate NAc GABAergic neurons. This lowers 
GABAergic output to VTA DAergic neurons. NAc DBS blocks local GABAergic 
neurons from inhibiting VTA DAergic neurons. LHb DBS blocks local glutamatergic 
neurons in rostromedial tegmental nucleus (RMTg), which lowers GABAergic output 
to VTA DAergic neurons. Each of these DBS targets lowers inhibitions of VTA 
DAergic neurons, which can subsequently elevate DAergic activity of VTA targets 
throughout the mesocorticolimbic system. Image modified from Russo and Nestler 
(2013) with permission. 
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Timecourse of Novel Antidepressant Treatments 
Cellular atrophy and diminished neuroplasticity is believed to be induced 
through chronic stress and or inflammatory mechanisms in both in human patients 
and animal models. Importantly, overwhelming and converging data now demonstrate 
that a common mechanism of antidepressant action – across classes – is the 
successful response to oppose and reverse these effects through enhanced 
neuroplasticity (Schlaepfer, Cohen et al., 2008). Depressed patients, in particular, 
express diminished neuroplasticity. This may account for the initial time delay of 10 
days before patients experience only minimal antidepressant effects from the 
norepinephrine reuptake inhibitor reboxetine (Versiani, Amin et al., 2000). In 
contrast, healthy control volunteers demonstrate initial behavioral changes to 
reboxetine in 3 hours (Harmer, Bhagwagar et al., 2003; Wai and Bond, 2003). 
Treatment response to modern antidepressants varies between patients and TRD 
patients fail antidepressant response from several treatment regimens, thereby 
undergoing several weeks or months without symptomatic relief. There currently 
exists a great clinical need for novel antidepressants that provide rapid symptomatic 
relief and produce high remission and treatment response rates, especially for TRD 
patients. 
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Rapid-Acting Antidepressants 
To address these issues, ketamine therapy is being investigated as a potential 
fast-acting antidepressant intervention. Ketamine operates through different 
mechanisms of action than modern antidepressants by directly blocking NMDA 
receptors and thereby inhibiting spontaneous miniature NMDA receptor currents 
(Caddy, Giaroli et al., 2013; Naughton, Clarke et al., 2014). This leads to cellular 
deactivation of kinase eukaryotic elongation factor 2 (eEF2) and subsequently 
produces rapid and transient translation of BDNF, which is thought to mediate the 
rapid therapeutic actions of ketamine. Ketamine also produces sustained activation of 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which 
are frequently co-expressed with NMDA receptors at synapses and together 
synergistically enhance synaptic plasticity through LTP (Machado-Vieira, Salvadore et 
al., 2009; Malinow and Malenka, 2002). Antidepressant response from ketamine 
treatment occurs within hours after initial exposure, with astronomical response rates 
for major depression therapy (Caddy, Giaroli et al., 2013; Rasmussen, Lineberry et al., 
2013) and even in TRD patients (Murrough, Perez et al., 2013; Price, Nock et al., 
2009). Interestingly, TRD patients who responded to ketamine therapy expressed 
elevated plasma BDNF levels compared to non-responders (Haile, Murrough et al., 
2014). TRD who were ketamine responders also demonstrated increased stimulus-
evoked somatosensory cortical responses, a marker of synaptic neuroplasticity 
measured through magnetoencephalographic recordings, compared to non-
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responders (Cornwell, Salvadore et al., 2012). These findings further support the 
mechanistic role of the brain’s neuroplasticity state as a mediator in treatment 
response and demonstrates a reversal of neuroplasticity resiliency in TRD patients 
despite failures to modern antidepressant therapy. However, predicting the 
persistence and magnitude of individual response to ketamine treatment remains 
difficult (Murrough, Iosifescu et al., 2013; Zarate, Singh et al., 2006). Although there 
are some doubts to ketamine becoming a conventionally administered antidepressant 
treatment due to its potential for abuse and side-effects (Aan Het Rot, Zarate et al., 
2012), it does facilitate our understanding of depression therapy and elucidates novel 
therapeutic avenues towards interventions targeting neuroplasticity augmentation. 
While elevated BDNF levels may account for the rapid symptomatic relief of 
ketamine therapy, the mechanisms of long-term antidepressant effects are likely more 
complicated than simple NMDA receptor blockade and AMPA receptor activation. 
Another mechanism by which ketamine enhances neuroplasticity is through mTOR-
mediated synaptogenesis in rodent PFC (Hoeffer and Klann, 2010). mTOR activation 
is observed rapidly (30 minutes) after ketamine infusion, but PFC expression of 
synaptic proteins persists for the duration of ketamine’s therapeutic effect (up to 7 
days) with concurrent behavioral amelioration of anhedonia and anxiety (Li, Lee et al., 
2010; Li, Liu et al., 2011). Additionally, inhibition of the mTOR pathway through 
rapamycin infusion blocks the behavioral and neuroplasticity effects of ketamine, 
implicating mTOR-mediated plasticity as a critical mechanism of ketamine’s long-term 
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therapeutic effects (Li, Liu et al., 2011). A diverse variety of plasticity factors influence 
the activation of mTOR towards translational control and LTP, including NMDA 
receptors, AMPA receptors, BDNF, and DA receptors (Hoeffer and Klann, 2010). 
Modern antidepressants, which generally fall into the mechanistic classes of tricyclics 
or monoamine oxidase inhibitors (and were discovered by serendipity over 50 years 
ago), act as monoamine modulation therapies but only produce about 50% patient 
remission rates (Berton and Nestler, 2006). Furthermore, these antidepressants alter 
mTOR signaling (Park, Lee et al., 2014), likely through their secondary DA activity 
enhancing effects (D'Aquila, Collu et al., 2000; Tanda, Carboni et al., 1994). While this 
pathway may be responsible for inducing antidepressant effects, the mechanisms of 
actions of different monoamine modulation therapies appear to be congruent as their 
efficacy and therapeutic time course are similar (Murrough and Charney, 2012). Not 
all patients respond to each of these treatments and those that do respond usually 
have a 4-12 week time lag before demonstrating therapeutic effect (Rush, Trivedi et 
al., 2006). The need for fast-acting antidepressant therapeutics cannot be understated, 
and targeted mTOR signaling modulations through non-DAergic pathways may be 
critical to developing neuroplasticity-enhancing pharmacotherapies that are safe, 
efficacious, easy to administer, have sustainably high response and remission rates, 
and produce minimal side-effects. 
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Neurostimulation Techniques 
Neurostimulation techniques have also demonstrated therapeutic efficacy for 
TRD with shorter latency than modern antidepressant drugs. Electroconvulsive 
therapy (ECT) produces brief electroconvulsive seizures in the brain and is the 
current gold standard for TRD patients following antidepressant treatment response 
failure. A meta-analysis shows that about 50% of patients with either unipolar or 
bipolar major depression responded to ECT (Dierckx, Heijnen et al., 2012). Greater 
effectiveness for ECT antidepressant therapy was found with bilateral stimulation 
over unilateral stimulation and with higher doses (The UK ECT Review Group, 
2003). The response latency to ECT treatment occurs after roughly 5-7 treatments, or 
about 3 weeks (Nobler, Sackeim et al., 1997; Segman, Gorfine et al., 1995). Consistent 
with antidepressant pharmacotherapies, electroconvulsive seizures produce elevated 
frontal lobe BDNF expression (Allen, Naughton et al., 2015) as well as elevated 
hippocampal expression of cyclic adenosine monophosphate (cAMP) response 
element-binding protein (CREB), which promotes cell survivability, neuronal 
plasticity, and BDNF gene expression (Li, Lee et al., 2010). However, unlike 
antidepressant pharmacotherapies, electroconvulsive seizures do not increase serum 
BDNF (Allen, Naughton et al., 2015) nor does it affect mTOR signaling in rat PFC 
(Li, Lee et al., 2010). This seems to indicate that ECT treatment has neuroplasticity-
promoting effects that are region specific and does not produce globally redundant 
alterations in neuroplasticity marker expression.  
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Despite ECT having one of the most successful response rates for TRD 
patients, there is a potential for some patients to be resistant to this treatment. 
Interestingly, ECT-resistant patients may still benefit from ketamine antidepressant 
therapy (Ibrahim, Diazgranados et al., 2011; Zarate, Singh et al., 2006), however little 
is known about the response to ECT in ketamine non-responders. TRD patients 
typically trial ECT after failing antidepressant regimens, and if found to be 
additionally non-responsive to ECT, are then considered for ketamine therapy if 
available. Ketamine, like ECT, is proconvulsive and may facilitate the actions of ECT 
by improving seizure duration (Krystal, Weiner et al., 2003; McDaniel, Sahota et al., 
2006). Studies that have investigated the treatment efficacy of augmented ECT and 
ketamine co-administration have been mixed, but point to ECT and ketamine 
combined treatment for expediting antidepressant effects compared to ECT alone 
(Goforth and Holsinger, 2007; Okamoto, Nakai et al., 2010). Further studies on 
timing and dose of augmented treatments will be needed to determine clinical viability 
of this therapy. 
 DBS intervention for TRD patients is efficacious at varying timescales 
corresponding to therapeutic relief of different symptoms associated with depression. 
Positive benefits of DBS are experienced at a range of latencies after stimulation is 
initiated, from seconds to minutes for calming effects to days and weeks for elevated 
energy, interest, and mood (Herrington, Cheng et al., 2016). Similarly, varying 
latencies that are associated with relief from different disease-specific symptoms are 
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observed for other neurological and psychiatric conditions, indicating that a multitude 
of mechanisms are being incorporated with DBS therapy (Agnesi, Johnson et al., 
2013). Symptomatic response to DBS at very low duration timescales (seconds to 
minutes) are mediated by rapidly reversibly neuromodulation mechanisms of 
pathophysiological circuitry, while response to intermediate (minutes to hours) and 
chronic (days to weeks) duration timescales are mediated by modulations in synaptic 
plasticity and anatomical remodeling (Herrington, Cheng et al., 2016). Figure 2 
summarizes these timescales for different neurological and psychiatric diseases. 
Additionally, cessation of the stimulation leads to reemergence of symptoms 
following the same latency timelines as symptom amelioration from DBS 
commencement (Agnesi, Johnson et al., 2013). This is consistent with the notion that 
DBS is a reversible therapy, and gives evidence that symptomatic reemergence follows 
similar yet opposite mechanistic neuroprogression. 
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Figure 2 – Latencies to symptom relief after DBS commencement for various 
diseases, with mechanisms of actions shown above. Disease-specific symptoms 
reemergence occurs at similar latency durations after DBS cessation. Image 
reproduced from Herrington, Cheng et al. (2016). Permission for image reproduction 
in thesis not required according to RightsLink. 
 
 Rapid neuromodulatory effects of DBS for TRD occur through elicited VTA 
DA release throughout the mesocorticolimbic network, as discussed in a previous 
section. Longer-term stimulation however produces changes in neuroplasticity of 
postsynaptic cells, including short-term potentiation (~5 minutes) and long-term 
depression and LTP (>30 minutes) (Shen, Zhu et al., 2003). These neuroplasticity 
changes can occur as a result of DBS even at regions distal to the stimulation site 
(Van Hartevelt, Cabral et al., 2014), further exemplified through transcranial magnetic 
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stimulation (Ruge, Tisch et al., 2011), and demonstrates global network level 
neuroanatomical reorganization from neurostimulation (Agnesi, Johnson et al., 2013). 
Postsynaptic neuronal BDNF is also elevated with DBS in regions relevant to 
therapeutic effect (Do-Monte, Rodriguez-Romaguera et al., 2015; Nagappan, Zaitsev 
et al., 2009). Additionally, LTP-inducing high-frequency electrical stimulation of 
neuronal cultures appears to promote the synthesis of mature BDNF from its 
precursor pro-BDNF, which is a negative regulator of neuroplasticity (Nagappan, 
Zaitsev et al., 2009; Waterhouse and Xu, 2009). Therefore, electrical stimulation 
appears to shift neuronal homeostasis towards an elevated neuroplasticity state (Yang, 
Harte-Hargrove et al., 2014). The DBS-induced elevated neuroplasticity state of the 
brain can then manifest into therapeutic progress through a variety of target-
dependent mechanisms (Smith, 2013). These include neurogenesis of new 
hippocampal cells after 6 weeks of stimulation for learning and memory formation in 
rodents (Encinas, Hamani et al., 2011; Stone, Teixeira et al., 2011), cerebral blood 
flow changes after 3 months to critical regions of depression in patients (Mayberg, 
Lozano et al., 2005), and restoration of decreased cortical glucose metabolism and 
functional connectivity after 1 year in Alzheimer’s disease patients (Laxton, Tang‐Wai 
et al., 2010; Smith, Laxton et al., 2012). DBS therapy is an intervention of last resort 
because of its procedural invasiveness and its risks for complications and non-
response. However, the insights presented by DBS research in neuroplasticity further 
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demonstrates the need for plasticity-modulating drugs that mimic these beneficial 
effects. 
Conclusion 
 Mood disorder pathophysiology induces a state of DA dysregulation and 
neuroplasticity deficits. Standard pharmaceutical interventions have addressed the 
former issue through monoaminergic therapy with mixed results. More recent and 
robust interventions such as rapid-acting antidepressants and neurostimulation 
techniques enhance neuroplasticity and are associated with better treatment outcomes. 
The advancement of neurostimulation techniques systems for research 
implementation is therefore one avenue in which exciting experimental research is 
taking place, particularly in rodent models of depression. Animal models of mood 
disorders facilitate the elucidation of novel therapeutics and are therefore critical to 
utilize and develop in translational research settings. Despite the limitations of these 
new therapies, the accumulation of evidence integrated in this review presents 
abundant support towards the need for development of targeted plasticity modulating 
interventions.  
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CHAPTER 3 
Preclinical Methodology 
 
General Scope and Aims 
 This thesis investigates the restorative mechanisms of actions in deep brain 
stimulation (DBS) antidepressant therapy as it relates to dopaminergic and 
inflammatory modulations within the research context and resource availability. 
Mesocorticolimbic dopamine pathways are clinically implicated in affective states, 
specifically in treatment-resistant depression (TRD). DBS of key limbic regions have 
demonstrated therapeutic efficacy in TRD, such as nucleus accumbens (NAc) and 
medial forebrain bundle (mfb) stimulation (Bewernick, Kayser et al., 2012; Schlaepfer, 
Bewernick et al., 2013). The invasive procedure of electrode implantation during DBS 
results in mechanical, inflammatory, and immune activation directly to the site of 
implantation and to associative networks, and further modifies the brain’s response to 
DBS. Our general aim, therefore, is the examine the dopaminergic changes in the 
mesocorticolimbic system as it is affected by behavior, inflammatory/immune 
activation, and dopamine modulating interventions. These mechanisms are 
investigated through the engineering and development of microdevices for small 
animal neurostimulation. The preclinical studies methodology is described in this 
chapter in two main sections: rationale of each method and details of its execution. 
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Theories and Rationale 
Animals 
 Animal models provide a sufficient biological basis for studying biomedical 
phenomena and interventions as they relate to human beings. Many experimentally 
intense procedures that are regarded as controversial in human research can be 
performed in animal models when strict regulatory standards and approvals are met. 
These regulations are to ensure that the specific research project is necessary to 
perform in the animal models, that as little harm or excessive stress will come to the 
animal outside of, and within, the research protocols, that proper training and 
handling standards are met, that the specific animal model is optimal for the 
investigation, and more. The Institutional Animal Care and Use Committee (IACUC) 
has reviewed the protocols with scrutiny and approved every research investigation 
performed within this thesis to meet national regulatory standards (Silverman, Suckow 
et al., 2014). 
 We procure male Wistar rats at 5 weeks after birth for the experiments 
described in this thesis. Male Wistar rats have previously been shown to demonstrate 
vulnerability to anxiogenic treatments as characterized by their response to the 
elevated plus maze and corresponding differential levels of serotonin exhibited in the 
ventral striatum. Importantly, as our experiments aim to develop the relationship 
between depression-like symptoms and dopamine, Wistar rats do not demonstrate 
changes in dopamine as a response to anxiogenic effects (Schwarting, Thiel et al., 
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1998). Therefore, modulations of basal ganglia and limbic regions are not likely to be 
confounded by inherent dopaminergic changes associated with behaviors not 
specifically related to depression when using this rat model. 
 Translational studies presuppose that the results obtained from animal model 
investigations has relevant properties towards higher order animals. In the case for 
rodent studies, the findings are typically translatable towards higher order mammals 
such as swine, non-human primate, and humans. This allows for difficult methods, 
such as invasive procedures or resource-demanding studies, to be investigated with 
high-throughput in parallel. Physical and financial limitations cannot provide the same 
investigational adequacy for larger animals, including humans. In the experiments 
described in this thesis, rodent models particularly rat provide the sufficient model for 
generating the translational properties relevant to the human condition. 
 
Stress Hormone Challenge - Antidepressant Resistance 
 The hypothalamic-pituitary-adrenal (HPA)-axis acts as the 
neuroendocrinological stress response system. During periods of perceived stress, 
hypothalamic production of corticotropin releasing hormone generates systemic 
secretion of adrenocorticotropic hormone (ACTH) by the anterior pituitary gland. 
ACTH travelling through the systemic vasculature is received by the cortex of the 
adrenal glands, which stimulates the secretion of the glucocorticoid cortisol in humans 
(corticosterone in rodents) (Pariante and Lightman, 2008). The resulting 
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glucocorticoid secretion induces negative feedback regulation, inhibiting HPA-axis 
activation at each of the key junctions (Figure 1). 
 We hijack the HPA-axis to exploit the stress-response system’s 
neurodegenerative effects during repeated overactivation. Repeated overactivation of 
the HPA-axis can be achieved in rodents through daily administration via 
intraperitoneal injection of ACTH at 100 µg diluted into 1 mL. In healthy subjects, 
adrenal secretion of glucocorticoids dramatically rises at the onset of waking up and 
peaks in roughly 3 hours, before gradually falling to its lowest point a few hours after 
the onset of sleep (Watts, Tanimura et al., 2004). In our experiments, we administer 
ACTH during this period of minimal corticosterone expression, which is at the 
circadian nadir. This, in effect, blocks beneficial biochemical changes associated with 
neuroregeneration, memory, and neuroplasticity enhancements that occur during low 
points of corticosterone activity, generally associated to be the positive aspects of 
sleep (Backhaus, Junghanns et al., 2006; Balbo, Leproult et al., 2010; Frank, Issa et al., 
2001). It is important to note that these injections do not produce a state of 
hypercortisolemia as the corticosterone levels do not consistently surpass maximal 
diurnal levels but instead remain basally elevated (Walker, Burnett et al., 2013). 
After a minimum of roughly 7 days of treatment, rodents develop a resistance 
to the tricyclic antidepressant drugs imipramine and desipramine (Kitamura, Araki et 
al., 2002; Kitamura, Fujitani et al., 2008; Tokita, Fujita et al., 2012; Walker, Burnett et 
al., 2013) as behaviorally measured through the forced swim test, a primary measure 
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of antidepressant efficacy (Lucki, 1997). After 14 days of ACTH administration, 
prefrontal cortex monoamines serotonin, dopamine, noradrenaline, and adrenaline are 
all significantly altered compared to controls, even though HPA-axis corticosterone 
releasing response to ACTH administration has returned to baseline levels (Walker, 
Burnett et al., 2013). This indicates prolonged neurodegenerative effects of repeated 
HPA-axis activation despite the body’s adaptation to ACTH administration. 
Clinically, HPA-axis hyperactivity has been associated with a poorer treatment 
response to antidepressant drugs (Brouwer, Appelhof et al., 2006). A more recent 
meta-analysis spanning four decades of research further demonstrates HPA-axis 
hyperactivity with depression, as well as an increased risk for diabetes, dementia, 
coronary heart disease, and osteoporosis (Stetler and Miller, 2011).  
The fundamental understanding for why HPA-axis hyperactivation leads to 
antidepressant resistance (ADR) phenotypes remains elusive at best. However, DBS at 
key limbic regions is a therapeutic procedure that seems to reverse the effects of 
ADR. Therefore, understanding the underlying neurobiological adaptations that occur 
with DBS is of great interest towards understanding the cellular processes that 
mediate stress, and for developing personalized treatment options to enhance patient 
response. For this reason, we aim to implement portable DBS devices on freely-
moving rats to bilaterally stimulate continuously using clinically relevant 
neuromodulatory parameters and targets. We further develop the devices and 
technologies to expand this research for more refined neurostimulation. 
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Figure 1 – The HPA-axis when activated during perceived stress. Secretion of each 
hormone involved in this system signals the release of subsequent hormones, 
ultimately resulting in production of glucocorticoids (cortisol in humans, 
corticosterone in rats). Glucocorticoid production has inhibitory feedback effects on 
HPA-axis activation. Image sourced from Vitale, Salvioli et al. (2013) with permission. 
 
Social Isolation - Depression 
 Social isolation paradigms have been demonstrated to induce depression-like 
symptoms in rodents (Brenes, Rodríguez et al., 2008; Lapiz, Fulford et al., 2003; 
Sáenz, Villagra et al., 2006). This is achieved by singly housing the animals during 
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animal vivarium acclimation (~5 weeks after birth) and remaining singly housed for 
the duration of the experiment. Social isolation tended to increase depression-like 
behaviors as characterized by the forced swim test and also reduced norepinephrine in 
the ventral striatum (Brenes, Rodríguez et al., 2008). Other behavioral effects 
associated with rodent social isolation include impairments in learning and memory 
tasks (Larsson, Winblad et al., 2002; Schrijver, Bahr et al., 2002), and behavioral 
despair (Brenes, Rodríguez et al., 2008; Lapiz, Fulford et al., 2003), similar to those 
found in clinical depression. 
 Induced depression-like symptoms through early social isolation, coupled with 
ADR through ACTH-induced HPA-axis activation, formulates our model of 
treatment resistant depression (TRD) in rats. With the TRD model, we have the 
ability to experimentally manipulate the mesocorticolimbic regions of the brain and 
observe the resulting behavioral and neurochemical changes. We can then infer 
translational conclusions based on this data to understand the phenomenology and 
effective treatment methods, such as DBS, for TRD. 
 
Mood Altering Drugs 
 Clinical affective disorders, particularly that of depression and bipolar disorder, 
are diagnosed as episodic phases of altered mood states. Patients experience periods 
of euthymia between symptomatic episodes of depression (and/or mania in bipolar 
disorder). Those suffering recurrent depression exhibit higher deficits in executive 
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function while in euthymic state (Bhardwaj, Wilkinson et al., 2010). The use of 
antidepressants and mood stabilizing drugs attenuates the intensity of these episodes 
and help patients manage their symptoms.  
 Preclinical work with mood altering drugs helps elucidate the molecular and 
network mechanisms that lead to their therapeutic value. Mood altering substances 
often have potent pharmacodynamic effects in the brain by acting as selective cellular 
signaling modulators. These drugs, in combination with preclinical deep brain 
stimulation therapy, can greater deepen our understanding of antidepressant response 
criteria and facilitate the progression towards individualized medicine. 
 
GBR12909 – Dopamine Reuptake Inhibitor 
 GBR12909 is a potent and selective dopamine reuptake inhibitor (DRI) that 
binds to the target site of dopamine transporter (DAT). This drug most effectively 
acts on mesocorticolimbic dopaminergic tracts, specifically at the nucleus accumbens, 
olfactory tubercle, and striatum, and to a lesser extent in medial prefrontal cortex 
(Izenwasser, Werling et al., 1990). The behavioral effects are similar to that of cocaine, 
but GBR12909 has about 50-fold stronger effect. In the ACTH-induced ADR rat 
model, mesocorticolimbic dopamine levels are normally attenuated but demonstrate 
strong evoked release. The combination of GBR12909 with mesocorticolimbic deep 
brain stimulation may have a profound effect in destabilizing the depressed brain and 
precipitating acute mania-like behaviors. 
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Risperidone – Dopamine Receptor Antagonist 
 Risperidone is an atypical antipsychotic medication for schizophrenia and 
bipolar disorder patients. It tightly binds to mesocorticolimbic dopamine receptors for 
an extended period of time due to its long half-life. This has the effect of reducing 
dopaminergic transmission in these regions, leading to lowered movement and 
sleepiness in individuals. Risperidone has the potential to block the antidepressant 
effects of mesocorticolimbic deep brain stimulation and may elucidate some of the 
underlying mechanisms of antidepressant action.  
 
Deep Brain Stimulation Principals 
 DBS remains an effective tool to combat neurodegenerative disorders through 
the invasive procedure of electrically stimulating specific regions of the brain. 
However, the underlying causality for its efficacy is still poorly understood. Prior to 
twenty years ago, treating such disorders relied on global ablation techniques resulting 
in greater damage to the brain and blunt trauma to the skull. Thermal and cryogenic 
lesioning have replaced these medieval tactics to offer greater regional selectivity, 
however these procedures are often irreversible and cannot be modified to the 
patient’s specific needs (Aziz, Peggs et al., 1991; Benazzouz, Gross et al., 1993; 
Bergman, Wichmann et al., 1990). More recently, DBS has been implemented to treat 
various neurological disorders starting with Parkinson’s disease and essential tremors 
in the early 1990’s (Benabid, Pollak et al., 1996; Benabid, Pollak et al., 1991; 
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Perlmutter and Mink, 2006) and progressed towards clinical trials in dystonia (Kumar, 
Dagher et al., 1999; Lozano, Kumar et al., 1997; Sellal, Hirsch et al., 1993), Tourette 
syndrome (Diederich, Kalteis et al., 2005; Houeto, Karachi et al., 2005; Perlmutter and 
Mink, 2006; Temel and Visser‐Vandewalle, 2004; Visser-Vandewalle, Temel et al., 
2003), pharmaceutical-resistant epilepsy (Fisher, Salanova et al., 2010; Kocabicak, 
Temel et al., 2015; TekriwAl and BAlTuch, 2015), neuropathic pain (Franzini, Ferroli 
et al., 2003; Katayama, Yamamoto et al., 2002; Kumar, Toth et al., 1997; Perlmutter 
and Mink, 2006), obsessive-compulsive disorder (Abelson, Curtis et al., 2005; 
Gabriëls, Cosyns et al., 2003), as well as major and treatment resistant depression 
(Dougherty, Rezai et al., 2015; Grubert, Hurlemann et al., 2011; Mayberg, Lozano et 
al., 2005). 
 DBS is performed by sending an electrical impulse from a pulse generator to 
electrodes implanted into specific locations of the brain (Figure 2). The parameters are 
predetermined to the specific location and treatment, and can be modified as 
appropriate on the external pulse generator by the clinician. These parameter 
adjustments include the frequency, pulse duration, and pulse intensity. In our 
experiments, we match these parameters to those typically used in Parkinson’s disease: 
130 Hz frequency, 200 µA current, 90 µs pulse duration. The generated current travels 
to the brain region at the electrode tip and nonspecifically stimulated the neurons. The 
volume of activation can be dependent on many factors. For example, a greater pulse 
intensity can travel further distances before the electrical diffusion becomes deficient. 
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Furthermore, the type of electrode being used can vary the volume of stimulation. 
Monopolar electrodes diffuse the current in all directions from the electrode tip, while 
bipolar electrodes contain two nodes that allow current to pass from one tip to the 
other, creating a current pathway that concentrates the stimulation between the two 
nodes. The experiments described in this thesis utilize bipolar electrodes for spatially 
specific stimulation areas. 
 
 
Figure 2 – An example of a DBS system on a patient. External pulse generators 
deliver specific electrical impulses to the electrode via a connector wire. The pulse 
generator remains external to the body for battery replacement and to modify the 
parameters of the electrical impulse by the clinician. Image sourced from Kern and 
Kumar (2007) with permission. 
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Optogenetics 
  Causal relationships between stimulated neurons and evoked neural response 
can elucidate the behavior of significant mesocorticolimbic pathways relevant to 
affective disorders. In particular, the dopaminergic tracts between the VTA and 
striatum (i.e. caudate, putamen, and nucleus accumbens), through the medial forebrain 
bundle that are responsible for depression phenomenology, can be directly modulated 
with optogenetics (Deisseroth, 2014). This is because optogenetics incorporates a 
refined stimulation technique that selectively modulates neurons of interest. In 
contrast, DBS nonselectively modulates a wide volume of cells due to electrical 
diffusion. Optogenetics utilizes light pulses to stimulate or inhibit genetically modified 
cells that are responsive to photostimulation. Responsivity is achieved through 
transgenesis or transfection (via viral vectors) to induce susceptibility to 
photoactivation by neurons. The result is precision control within cells of interest, as 
the genetic responsivity process can target specific cell types. This is because viral 
vectors can be encoded to only modify certain cell types while remaining inert to 
other cells. 
 Light-sensitive proteins, known as opsins, can be genetically encoded into cells. 
Once expressed, these opsins migrate to the membrane surface and function as ion 
channels when activated by photostimulation. This, in effect, forces the cell to flux 
ions across the cell membrane and alter the membrane potential, resulting in 
depolarization or hyperpolarization of the cell, depending on the opsin type. Several 
84
genetically engineering opsins have been produced to provide incredible versatility in 
the optogenetic technique, but the most typical opsins are the depolarization-
promoting channelrhodopsin-2 from the alga Chlamydomonas reinhardtii and the 
hyperpolarizing-promoting opsin halorhodopsin from the archaeon Natronomonas 
pharaonisi (Price, Nock et al., 2009). These function by gating the cations sodium, 
potassium, and calcium when activated by blue light (~470 nm) and by gating chloride 
anions when activated by yellow light (~580 nm) respectively. Once the neurons 
express these opsins in vivo, stereotactic insertion of a light transmitting system can be 
used to modulate the cellular activity. Tethered optogenetic systems that use high-
energy lasers can be beneficial for delivering sufficient illumination, but fall short on 
portability in animal behavioral experiments. Alternatively, microdevices that 
incorporate light emitting diodes (LEDs) can be beneficial for animal behavior 
experiments, but design of these devices needs to be efficient enough to use a 
portable energy source such as a battery or wireless energy harvesting (Kale, Kouzani 
et al., 2015). 
 
Fast Scan Cyclic Voltammetry Principals 
 The mechanisms of actions in DBS neuromodulation are yet to be fully 
understood, however it has become apparent that release of neurotransmitters is one 
of the primary modes towards therapeutic value (Perlmutter and Mink, 2006). 
Preclinical identification of neurotransmitter release in vivo elucidates some of the 
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underlying mechanisms of therapeutic DBS. However, characterizing these 
transmitter modulations with precise spatial and temporal resolution is technically 
challenging. Microdialysis offers relevant spatial resolution of neurotransmission 
changes but is temporally slow. Conversely, functional magnetic resonance imaging 
offers brain activation information with high temporal resolution while falling short 
on spatial resolution. 
 Fast scan cyclic voltammetry (FSCV) is a unique procedure that offers 
sufficiently high spatiotemporal resolution using an electrode. This electrode is 
inserted into the site of measurement and incorporates a cyclic voltage change to 
oxidize and reduce transient electroactive neurotransmitters, including adenosine, 
serotonin, and dopamine (Van Gompel, Chang et al., 2010). This voltage change 
occurs on a carbon-fiber microelectrode, which sits at the detection point. The 
voltage that is generated by the electrode is chosen specifically to the electroactive 
compound that is being detected. The electric charge then cycles at a rate of about 10 
cycles per second. When cyclic stimulation occurs, the voltage increases and the 
targeted compound oxidizes and releases electrons. When the voltage decreases, the 
compound reduces and absorbs the electrons, returning to its original state. This 
transfer of electrons causes perturbations in current-voltage recordings. Measuring 
this data helps determine the concentration of the electroactive compound. An 
example of this is dopamine. When the voltage increases, dopamine loses 2 electrons 
and oxidizes to the compound DOQ. Upon return to the baseline voltage, DOQ 
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gains 2 electrons and returns to the compound dopamine (Figure 3B). The voltage 
perturbation upon electron transfer is recorded for further analysis. 
 FSCV specifically measures evoked release of neurotransmitters. 
Neurostimulation techniques such as DBS induce this release by stimulating at the 
presynaptic terminals. The produced neurotransmitter efflux is detectable by the 
electrode. The amount of current that is measured is dependent both on the strength 
and frequency of the stimulation. This is due to the fact that an increased stimulation 
releases more target compounds and thus the electrode has greater detection. 
 The Wireless Instantaneous Neurotransmitter Concentration System (WINCS) 
is a portable, battery-operated, wireless device developed at the Mayo Clinic to 
perform FSCV (Figure 3A). The device consists of 1) front-end analog circuit for 
FSCV (i.e. current-to-voltage transducer); 2) Bluetooth transceiver; 3) microprocessor; 
and 4) direct-current battery. It connects directly to the carbon-fiber electrode to 
gather the voltage perturbations generated by the electrochemical compound. WINCS 
then sends these perturbation signals wirelessly via Bluetooth to an external computer 
that analyzes the data. The WINCSware program measures the current picked up by 
the carbon-fiber microelectrode and compares it with the voltage applied to create a 
current versus voltage plot. WINCSware displays this raw voltage graph along with 
the original voltage graph on the same plot (Kimble, Johnson et al., 2009). The 
software subtracts the applied voltage from the raw voltage to determine how the 
current has been changed by the target compound when oxidizing and reducing. The 
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subtracted current versus voltage plot is then displayed for the particular stimulation 
event. 
 A reference electrode is also used to compensate for background noise and 
other sources of confounding deviations. However, typical stimulation artifacts arise 
when stimulating with DBS that can diminish the signal. The Mayo Clinic has 
developed the Mayo Investigational Neuromodulation Control System (MINCS) that 
can perform DBS stimulations and optically connect to WINCS for simultaneous 
FSCV recording. This combination minimizes the stimulation artifacts and also 
couples stimulation and recording on the WINCSware visual interface for convenient 
temporal display. This allows researchers to pinpoint exact start and stop times of 
stimulation and observe evoked neurotransmitter release. 
The voltage applied with the FSCV system in WINCS must be configured 
depending on the neurotransmitter that is being targeted. A simple version of the 
voltage cycle is for dopamine waveform, which starts at -0.4 V and linearly peaks to 
+1.0 V before falling back down to -0.4 V (Bledsoe, Kimble et al., 2009). It takes 100 
ms for each subsequent peak and occurs at a rate of 300 V/s. This waveform 
successfully oxidizes and reduces dopamine and exposes a current perturbation that is 
picked up by WINCS and displayed as a pseudocolor plot (Figure 3D). Another 
electroactive compound that has a similar waveform is adenosine, however the 
waveforms can be very diverse. For example, serotonin detection requires a waveform 
that more resembles an ‘N’ shape.  
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Figure 3 – A) WINCS circuit board. B) Visual of the carbon-fiber electrode and 
tissue interface where dopamine is converted into DOQ and releases 2 electrons, and 
then reversed back to dopamine. C) Example waveform of applied voltage for 
dopamine detection. D) Pseudocolor plot of dopamine and typical subtracted 
voltammogram of dopamine. Image sourced from Koehne, Marsh, et al. (2011) with 
permission. 
 
Behavioral Tests 
Forced Swim Test 
 The Forced swim test (FST) is our primary measure of antidepressant 
treatment efficacy. This test screens for behaviors related to behavioral despair and 
learned helplessness. Rodents are placed in clear cylinders of room temperature water 
where they are forced to swim in the narrow space while being recorded. After an 
initial period of vigorous swimming, the animals switch to a passive coping behaviors 
characterized by an immobile posture. During this period of immobility, animals will 
tend to minimize any movements except those necessary to keep its nose above water 
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(Porsolt, Bertin et al., 1977). The total amount of time that the animal performs this 
immobile behavior during the test is compared. 
 Antidepressants reduce passive immobility times and switch rodent behaviors 
to more active coping, such as swimming, diving, and climbing movements. However, 
ACTH-treated ADR rats are not affected by typical antidepressant therapies and as a 
result produce elevated immobile behaviors than control animals. Alternative 
depression therapies such as atypical antidepressants, DBS, and optogenetics also 
demonstrate strong antidepressant screening validity in this test. Accordingly, the FST 
has high predictive validity, yet limited face validity and low construct validity (Powell, 
Fernandes et al., 2012). 
The switching between active and passive coping is an energy conservation 
mechanism in response to being placed into an inescapable stressful environment. 
Furthermore, unlike most tests used to screen antidepressant treatments, the forced 
swim test can discriminate between types of antidepressant drugs being taken (Lucki, 
1997). This is done by analyzing the type of active coping behavior that is being 
performed, with swimming behaviors characteristic of serotonergic mechanisms and 
climbing behaviors characteristic of noradrenergic mechanisms (Detke, Rickels et al., 
1995). The ability to measure learned helplessness allows us to compare the 
antidepressant qualities of DBS and other therapies.  
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Open Field Test 
The open field test (OFT) is a common behavioral test that measures 
exploratory behaviors as well as anxiety levels and general activity. The test can 
measure both quantitative and qualitative properties of the animal’s mood, such as 
distance travelled, velocity of ambulations, time spent in periphery versus center 
regions, waste accumulation, grooming, and rearing behaviors. Along with measuring 
general emotional and mood behaviors, the OFT can also analyze sedative, toxic, or 
stimulant effects of other treatments (Gould, Dao et al., 2009). Variety and diversity 
of measureable behaviors, along with the ease in performing high-throughput testing 
makes the OFT a champion behavioral test among most animal models.  
The OFT satisfies face and construct validity as a behavioral test for its ability 
to produce stressful anxiogenic situations and measure the produced behaviors that 
are comparable to the human response. However the test lacks in predictive validity 
(Prut and Belzung, 2003). As a result, it is important to consider that the OFT does 
not measure the effects of treatments on exploratory behaviors, but instead measure 
the treatment-based reaction of the animal to a stressful situation. Therefore, 
anxiolytic drugs do not increase exploratory behaviors, but instead limit the 
inhibitions produced by anxiety. 
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Homecage Activity Monitoring 
 Similar to the OFT, homecage monitoring measures activity. However, activity 
monitoring occurs continuously in the homecage of the animal as opposed to a stress-
inducing behavioral apparatus at discrete timepoints. As a result, homecage activity 
can elucidate psychomotor changes of the animal throughout the entire experimental 
timeline, giving an idea of chronic activity changes instead of snapshots. This is 
particularly important in determining treatment adaptation responses by the animal, as 
most treatments including DBS do not fully show effects as soon as the device is 
powered on. Data is measured by counting every instance when the subject crosses 
and an invisible infrared beam produced by the monitoring device. Over the course of 
the experiment, these activity counts can be integrated to produce periodograms of 
animal activity throughout the day, including at times when they should be sleeping. 
 Homecage activity monitoring also displays circadian rhythm changes as a 
result of different treatments. Most affective disorders perturb healthy diurnal 
patterns, causing sleep and wake periods to phase-shift or change entirely (Wirz-
Justice, 2006). These can further manifest into a mood disorders by genetically 
imprinting mutations on clock genes, which set individual preferences for sleeping 
patterns and timing. Measuring these patterns through activity monitoring can validate 
that depressive-like symptoms are being induced, characterized by increased sleep and 
lowered activity. This can also display the antidepressant effects of experimental 
treatments. As a result, the construct validity of activity monitoring is relatively high, 
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as it translates well to the human condition. It also seems to have sufficient predictive 
validity and face validity. 
 
Sucrose Preference Test 
 The sucrose preference test (SPT) is a reliable measure of anhedonia 
characteristics that are subjected to an animal through pro-depressive treatments. It 
measures the rewarding properties of sucrose-solution consumption compared to 
neutral water consumption (Berridge, 2007). Rodents exhibiting depressive-like 
symptoms will switch preference to that of an anhedonic state; or, increase their 
consumption preference towards neutral water compared to baseline values. This 
increase in anhedonic behaviors can be reversed with chronic administration of 
antidepressants like imipramine (Monleon, Parra et al., 1995). Interestingly, rodents 
naïve to depression-inducing treatments will not increase their sucrose preference 
with antidepressant administration. This demonstrates the high construct validity of 
the SPT as it correlates with human symptom improvements in depressed individuals 
who have experienced stressful and traumatic life events. SPT also demonstrates high 
face validity as there have been experiments done on humans with similar conditions 
and results (Powell, Fernandes et al., 2012). 
It can be argued that the SPT screens for anhedonia only if work is needed to 
procure the reward. Research investigating anhedonia response in nonhuman primates 
determine that depression-like symptoms are associated with decreased effort towards 
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obtaining a sugar pellet. However, two-bottle choice experiments weight equal efforts 
on each bottle choice. Instead, two-bottle choice SPT may be more indicative of 
dopamine related reward tolerance to the sucrose-containing solution. The 
mesolimbic dopamine pathway is an important regulator for feeding behaviors 
(Berthoud, Lenard et al., 2011), and modulating dopamine transmission properties in 
this circuit could result in SPT changes. 
 
Western Blot 
 Pharmacodynamic neuroadaptations and diseased states produce cellular 
alterations in the form of protein expression changes that are detectable, and provide 
important information on disease progression. Western blotting is a powerful 
analytical technique used to measure the amount of protein concentration in a given 
sample. This process is used on a homogenized lysate to separate out proteins based 
on molecular weight and type through gel electrophoresis. The sample can be 
extracted post-mortem from isolated brain tissue, delivering a quantified snapshot of 
protein expression from a specific brain region. Western blotting also incorporates 
selective antibodies that bind specific proteins to be measured. This not only purifies 
the protein quantification but also has the added benefit of selecting out isoforms that 
detect activated versus inactivated proteins. Each sample can then be loaded onto 
agarose gels. With an applied voltage, the proteins then travel down the gel and 
separate into bands indicative of their molecular weight. Chemiluminescence or 
94
radiation detection can then measure the density of these bands, which correspond to 
the relative concentration. Figure 4 summarizes the whole procedure. When 
compared with a controlled standard loaded onto the gel, such as β-actin, an absolute 
concentration can be determined. 
 
 
Figure 4 – A summarized example of the western blot process. Once the sample is 
generated (top row) it is then loaded into a gel cassette (bottom row) to produce 
separated protein bands that can then be quantified. Imaged sourced with permission 
from Bensaccount at English Wikipedia 
(https://commons.wikimedia.org/wiki/File:SDS-PAGE_sample.png), „SDS-PAGE 
sample“, https://creativecommons.org/licenses/by/3.0/legalcode 
and Bensaccount at English Wikipedia 
(https://commons.wikimedia.org/wiki/File:SDS-PAGE_Electrophoresis.png), 
„SDS-PAGE Electrophoresis“, 
https://creativecommons.org/licenses/by/3.0/legalcode 
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Materials and Procedures 
Animals 
 Male Wistar rats were procured at 5 weeks of age through Harlan Laboratories 
(IN, USA). Because of the stress induced by ground transportation between Harlan 
Laboratories and the Mayo Clinic, an acclimatization period of at least 3 days is 
necessary before any experimental procedures are followed. The animals are singly 
housed in a specialized rodent vivarium that is temperature and humidity controlled 
with access to water and chow ad libitum. Furthermore, lights are controlled to mimic 
12:12 hours light:dark cycles, with lights turning on at 6:00AM and turning off at 
6:00PM every day. 
All experiments were conducted in accordance with the NIH guidelines for the 
care and use of laboratory animals and were approved by the IACUC (Silverman, 
Suckow et al., 2014). The number of animals needed for each experiment was justified 
to IACUC for approval. Each experiment aimed to minimize the number of animals 
utilized while maintaining strong statistical power and effect size. A G* Power 
Analysis was used to determine appropriate sample sizes. Typically, an n=6 was the 
minimum amount of animals used for each group. About 5% additional animals are 
requested too in case some animals were to be terminated early from the experiment. 
Animals were removed from an experiment if any problems or complications 
occured. This can include the animal getting sick, demonstrating excessive stress or 
self-mutilation, sustaining injuries, having surgical or procedural complications and so 
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on. Early termination resulted in immediate euthanasia of the animal through 
pentobarbital overdose. 
 
ACTH Protocol 
 ACTH administration induces a reliable state of antidepressant treatment 
resistance after about 7 days of daily intraperitoneal injections. To produce this model, 
rats were injected with ACTH (AnaSpec, CA, USA) at dosages of 100 μg/day diluted 
into 1 mL of sterile water. These dosages remained the same for all injections despite 
changes in animal weight. For non-treatment resistant animal controls, daily 1 mL 
intraperitoneal injections of 0.9% saline solution were administered. This provided 
control from the stress associated with daily injections. 
 
Anesthesia 
 For all experiments involving chronic surgery, such as deep brain stimulation 
electrode implants, isoflurane (Baxter, IL, USA) was administered through direct 
inhalation (3.0% induction, 1.5-2.0% maintenance) via an induction box and a 
stereotactic nose cone. FSCV anesthesia was induced via intraperitoneal urethane 
injection (1.8 mg/kg). Polyurethane solution was produced on the day of injection at 
0.25 mg/mL.  
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Stereotactic Surgery 
 Targeting brain structures, especially deep brain structures, requires stereotactic 
equipment to make reliable implantations. The stereotactic frame keeps the rat’s head 
and neck rigid so that spatial locations of the brain can be established and set. The 
frame also allows for smooth and precise movements of instrumentation attached to 
the stereotactic arms, and these instruments can be interchangeable even during a 
surgery. All tools in contact with the animal are either autoclaved or disinfected in 
70% ethanol. 
 Once the animal is properly anesthetized, the animal is fit into the stereotactic 
frame with a heatpad placed under the rat to prevent hypothermic complications. The 
rat is fit using an incisor holder that holds the animal’s incisor teeth in place and locks 
the head from vertical movements. Ear bars are then fitted and zeroed to keep the 
animal’s head midline and resist any lateral movements or tilting of the head. The 
head now becomes fixed as a firm working environment that does not move when 
pressure is applied to different areas. From here, the head is shaved to expose the 
scalp and liquid eye ointment is applied to keep the eyes from getting dry. Alcohol 
wipes disinfect the whole area to prevent infections. A scalpel is used to remove the 
dermal layers of the scalp and expose the skull. The landmark bregma, which is 
represented as the anterior fontanelle of the exposed skull, acts as a coordinate origin 
point. 
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A rat atlas (Paxino & Watson, 2004) works as a brain map, and was empirically 
produced through analysis of several different rat brains of specified sex, weight, and 
strain. It is used to give precise coordinates of brain regions positions that are 
expected to be located from bregma. These coordinates are mapped using the 
anteroposterior (AP) axis running sagittally, the mediolateral (ML) axis running 
coronally, and the dorsoventral (DV) axis running horizontally. 
A mark is placed on bregma as well as lambda, a landmark in proximity to the 
posterior fontanelle. A needle is stereotactically lowered to both of these landmarks to 
ensure that their DV values are identical, indicating that the skull is flat. If they defer, 
then the head tilt is adjusted until both points are on the same plane. A stereotactic 
drill is then lowered to bregma. The coordinate of this drill is recorded and the AP 
and ML positions are adjusted based on the rat atlas’ coordinates of the brain region 
being targeted. Burr holes are then drilled (bilaterally, for bilateral experiments) into 
the skull to just above the meningeal layer. A sharp needle is used to puncture this 
meningeal layer. Then 6 smaller holes are drilled around the burr holes and jewelry 
screws are inserted. These screws act as anchors for the dental cement that will 
eventually seal the whole surgical site. 
A twisted bipolar electrode (Plastics One, VA, USA) is bent with fingers, placed 
in a stereotactic holder, and straightened. The electrode tip is zeroed over bregma and 
then adjusted to be right over the burr hole. The DV coordinate adjustment 
commences as soon as the electrode touches the liquid of the exposed burr hole, and 
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is then slowly driven down to the brain region of interest. The area is covered with 
dental cement until dried, and the procedure is repeated for the second electrode in 
bilateral implantations. Once the dental cement is completely dried and has good 
enough coverage to conceal the surgical site, the rat is removed from the stereotaxic 
apparatus, placed in its homecage under a heat lamp, and monitored until it is fully 
awake. 
 
Portable Deep Brain Stimulation Device 
 DBS electrical stimulation was generated using a pulse generator that was worn 
by the animal. This portable microdevice allowed for freely-moving behaviors in the 
animal while delivering continuous stimulation throughout the experiment. One 
caveat to this design was the necessity of rat vests (Harvard Apparatus MA, USA) 
worn by each animal receiving DBS, along with a pouch that was affixed to the rat 
vest and contained the pulse generator. The pulse was delivered to the implanted 
electrodes using DBS cords (Plastics One, VA, USA). The pulse generator (Deakin 
University, VIC, Australia) delivered typical clinical parameters (130 Hz; 200 μA; 90 
μs) and weighed only 5 grams with a standard CR battery (Kouzani, Abulseoud et al., 
2013). This device would stimulate for up to 7 days, with more advanced versions 
created that stimulate over 20 days. This device, and its use on a rat, are shown in 
Figure 5. 
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Figure 5 – The pulse generator that delivers the prespecified clinical parameters to 
the implanted electrodes. Two pulse generators were utilized for bilateral stimulation. 
The vest, pouch, and two stimulators weighed approximately 20 grams. Image 
adapted from Kouzani, Abulseoud et al. (2013). Permission for image reproduction in 
thesis not required according to RightsLink. 
 
Fast Scan Cyclic Voltammetry Experiments 
 FSCV is typically performed on an anesthetized rat induced via urethane 
injection (1.8 mg/kg). The surgical procedure is similar to that of DBS electrode 
implantation with some deviations. For example, additional burr holes are used to 
incorporate a reference electrode, the recording electrode, and the stimulating 
electrode. The reference electrode is placed contralaterally to the site of stimulation 
and recording. Cranial screws are unnecessary because this procedure is an acute non-
survival surgery. The twisted bipolar electrode, which targets the medial forebrain 
bundle, has its terminal separated and the tips polished to increase the stimulation site 
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and lower the electrode-tissue interface resistance. Skull burr holes are also made 
larger to allow for the large carbon-fiber electrode to pass through without breaking. 
The carbon-fiber electrode is lowered into ventral and dorsal striatum (nucleus 
accumbens) to record medial forebrain bundle evoked dopamine transmission. The 
electrode position is slowly lowered until evoked stimulation is detected on 
WINCSware. Once the experiment is complete, the animal is removed from the 
stereotax and euthanized through intracardiac injection of ~1 mL urethane followed 
by spinal cord dislocation. 
 
Behavioral Tests 
 Forced Swim Test 
 Animals were placed into acrylic cylinders (height=47 cm; diameter=19 cm) 
with 25°C tap water filled to 28 cm from the base. The FST training and test sessions 
were typically performed on the final days of the experimental timeline. A 15-minute 
FST training session was performed 2 hours after OFT and injections. The following 
day, the 6-minute recorded test session was performed, again 2 hours after injections. 
DBS devices and vests were removed prior to FST to allow mobility. Video recording 
of the test session was analyzed through handscoring to measure the number of 2-
second time intervals that animals spent performing active (swimming, climbing, 
diving) versus passive (immobility) coping behaviors during the session. A summary 
of these behaviors can be visualized in Figure 6. 
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Figure 6 – Typical behaviors of rats in the FST. Total immobility duration provides 
robust antidepressant screening. Image sourced from Abelaira, Réus, et al. (2013). 
Permission for image reproduction in thesis not required according to Creative 
Commons. 
 
 Open Field Test 
 The OFT apparatus is a square shaped box (59.7x59.7x43.2 cm) with access to 
the box floor for the animal to freely move. Animals were individually placed in the 
center of the apparatus floor for 10 minutes prior to injections. Video recording of 
the animal’s movements were analyzed using TopScan software (CleverSys Inc, VA, 
USA) as shown in Figure 7. Mean time spent in the central region as well as distance 
travelled was compared among groups for anxiety-like behavior and psychomotor 
activity.  
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Figure 7 – Example of OFT apparati and analysis program as visualized by TopScan 
software. Animals are allowed to move freely throughout the box floor. Prespecified 
regions of interest are inputted into software, so that central regions and periphery 
region can be distinguished by software. Image sourced from Kim, McGee, et al. 
(2016). Permission for image reproduction in thesis not required according to Nature 
Publishing Group. 
 
Homecage Activity Monitoring 
 Each cage was fitted with an infrared motion sensor at the underside of the 
cage lid pointing directly downwards so that one side of the homecage was 
continuously monitored for activity. The field of detection was about half of the 
entire homecage. The detectors measured homecage activity counts, which were 
streamed to a data acquisition box. Computer software (Clocklab Actimetrics, USA) 
recorded these activity counts and integrated the data into periodograms which were 
later analyzed for activity counts between sleep-wake phases. 
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Sucrose Preference Test 
 Rats were administered 2-bottle choice SPT with one bottle containing a 1% 
sucrose solution and the other containing tap water. Sucrose bottle was switched 
between left and right position for each rat and between each session to eliminate 
location bias. Bottles were weighed before and after SPT to determine the 
consumption preference. SPT was performed for either 4 hours or 16 hours, 
depending on the experimental protocol. 
 
Brain Harvest and Dissection 
 At the end of the experimental timeline, animals were euthanized and biological 
samples were collected. These samples included whole brains and cardiac blood. 
Samples were harvested either 40 minutes after FST or the day after FST, depending 
on the protocol. Animals were intraperitoneally administered 0.7 mL of FatalPlus 
[Vortech Pharmaceuticals, MI, USA; constituents: pentobarbital sodium 390 mg/ml; 
propylene glycol 0.01 mg/ml; ethyl alcohol 0.29 mg/ml; benzyl alcohol (preservative) 
0.20 mg/ml]. 
 Once breathing stopped and no reflexes were present, the animal’s chest was 
surgically opened to expose the heart. A syringe was inserted into the cardiac ventricle 
and about 0.4 mL of cardiac blood was extracted and centrifuged. Serum supernatant 
was segregated and frozen under dry ice. Meanwhile, the animal was decapitated and 
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brain was surgically removed and placed into dry ice. All samples were then stored at -
80°C. 
 Later, brains were thawed to dissect specific brain regions. Brains were placed 
onto cooling blocks (BioCision, CA, USA) dry ice. Coronal sections were sliced by 
hand to reveal brain region of interest. A biopsy micropunch of 1 mm diameter was 
used to punch out bilateral brain regions, which were stored at -80°C for subsequent 
protein analysis. 
  
Histology 
 DBS electrode positions were verified by slicing the brain at the tip of the 
electrode. All electrode tip locations were recorded for each DBS animal. One 
example brain electrode tract was stained to image for the manuscript. This brain 
would be embedded using Cryo-M-Bed (A-M Systems 527738). Coronal sections of 6 
µm were taken around the implant regions. The sections were fixed using ice-cold 
acetone for 10 minutes, followed by 10 minutes of drying time. Hematoxylin and 
eosin (H&E) staining was then performed. After fixation and drying, the slides were 
then incubated in phosphate buffered saline for 10 minutes, followed by 30-second 
incubation in hematoxylin stain, then rinsed under running water for 5 minutes. The 
following dips were done: Blueing 4 dips, water 10 dips, water 10 dips, 95% Ethanol 4 
dips, Eosin 6 dips, 50% Ethanol 12 dips, 70% Ethanol 12 dips, 95% Ethanol 12 dips, 
Absolute Ethanol 12 dips, Xylene 12 dips. Slides were allowed to completely dry 
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before preserving in Vecta-mount (Vector Laboratories LTD, CA, USA) and 
coverslipping. 
 
Western Blot Analysis 
 Once the brain regions of interest are extracted from whole brain slices, 
homogenization of the sample is performed and 50 µg of each sample are isolated. 
These samples are then individually mixed into a loading buffer containing a tracking 
dye to visually identify the samples during electrophoresis. The proteins are then 
denatured through heating in order to maintain their negative charge, which is needed 
to facilitate transfer of the proteins through the gel once a voltage is applied. The 
samples are loaded onto gels and electrophoresis is commenced by producing a 
current of 30 mA/gel to transfer the proteins towards the positive terminal. After 
approximately an hour, protein bands become separated through the gel. The bands 
are then transferred onto a membrane using an electric field and the membrane. 
Membrane blocking prevents antibodies from nonspecifically binding to the 
membrane. The blocking agent is made with 5% skim milk in tri-buffered saline with 
tween 20 or 5% bovine serum albumin and the primary antibody. The membrane is 
washed and blocked with a secondary antibody before incubating with enhanced 
chemiluminescence to visualize quantification using a ChemiDocTM touch imaging 
system (Bio-Rad, Ca, USA). 
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 The chemiluminescence imager can produce densitometry of the bands that 
correspond with the relative protein concentration. An absolute protein concentration 
can be quantified by comparing the densitometry to that of a standard, such as β-
actin.  
 
Statistical Analyses 
 All statistical analyses were performed using Graphpad Prism 6. ANOVA (or 
nonparametric Kruskal-Wallis test) were performed to determine if association is 
present. If significant (p<0.05) or trending (p<0.10) association is present, post-hoc 
analysis was performed as recommended by Prism. In some cases, post-hoc t-tests 
were performed and alpha was adjusted using Bonferroni correction to account for 
multiple comparisons. All original data sets were pre-refined before analysis by 
eliminating outliers. Outliers were defined as those data points rejected by Dixon’s Q 
test where Q=10, or values outside the range of +/- 2 standard deviations from the 
mean. Data were tested for normality to determine parametric or nonparametric 
analysis. In the case where the sample size was too low, visual distribution of 
normality assumed parametric analysis.  
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Abstract 
Background: The antidepressant actions of deep brain stimulation (DBS) are associated 
with progressive neuroadaptations within the mood network.  
Objective: We investigated the effect of nucleus accumbens (NAc) DBS on total and 
phosphorylated levels of glycogen synthase kinase 3 (GSK3) and mammalian target of 
rapamycin (mTOR) in the dorsal (dHIP) and ventral (vHIP) hippocampus of antidepressant 
resistant rats.  
Methods:  Antidepressant-resistance was induced via daily injection of 
adrenocorticotropic-hormone (ACTH; 100 µg/day; 15 days). Portable microdevices provided 
continuous bilateral NAc DBS (130Hz, 100µA, 90µs) for 7 days. A control sham electrode 
group was included, together with ACTH- and saline-treated groups. Home cage monitoring, 
open field, sucrose preference and forced swim behavioral tests were performed. Post-mortem 
levels of GSK3 and mTOR, total and phosphorylated, were determined in the dHIP and vHIP 
using western blot.  
Results: Robust reductions in forced swim test immobilitywere observed for DBS 
animals, relative to ACTH and saline groups. DBS and sham groups displayed elevated home 
cage psychomotor activity compared to ACTH and saline groups. No differences in locomotor 
activity were however observed in the open field test. Additionally, ACTH-treatment increased 
sucrose consumption, an effect that in turn was attenuated by DBS. We further observed 
increased levels of vHIP phospho-GSK3β and phospho-mTOR in DBS group compared to 
ACTH-treated animals. No differences in these protein levels were observed in the dHIP region. 
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Conclusions: Our data suggests that continuous NAc DBS has robust antidepressant 
actions in the ACTH-model of antidepressant resistance, and that DBS upregulates phospho-
GSK3β and phospho-mTOR in the vHIP region of the mood network.  
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sulfate polyacrylamide gel electrophoresis; SPT, sucrose preference test; vHIPP, ventral 
hippocampus; VTA, ventral tegmental area. 
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Introduction 
Deep brain stimulation (DBS) of the ventral striatum has been demonstrated 
by a number of groups to effectively reduce symptoms of depression in severely 
treatment-resistant individuals [1-5]. However, the effective translation of this 
promising neuromodulation therapy in a multisite randomized sham-controlled trial 
of ventral capsule/ventral striatum DBS for treatment resistant depression (TRD) has 
recently failed [6]. Specifically, this trial did not find differences in response rates 
between active or sham stimulation. In contrast to this, strong antidepressant effects 
have been reported for patients receiving active DBS of the nucleus accumben (NAc) 
and ventral anterior limb of the internal capsule (vALIC) when compared to those 
receiving sham stimulation[7, 8]. Similarly, vALIC DBS was shown to significantly 
reduce depressive symptoms in 10 of 25 patients with TRD using a randomized 
crossover design[9]. Other groups have shown that such therapeutic antidepressant 
responses to subcallosal cingulate (SCC) DBS are associated with activation and 
progressive change in critical mood network tracts using a rigorous, retrospective 
connectomics approach [10]. This suggests that specific and progressive 
neuroadaptations within the mood network may be essential for DBS efficacy in 
TRD.  Elucidation of the molecular mechanisms contributing to DBS efficacy may 
help optimize further development and translation of this and other emerging 
neuromodulation therapeutics. 
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The NAc represents an important node in the mood network, and contributes 
to the behavioral expression of motivated behaviors, including stress coping [11-14]. 
Acute changes in mesoaccumbens dopamine activity and neurotransmission can 
rapidly alter depression-like behaviors in rodent models[15]. The progressive nature of 
DBS therapeutic effects suggest that acute responses may serve to initiate longer-term 
neuroadaptations within the mood network[16]. As such, alterations in neural network 
function may depend on structural and functional adaptations in regions distal to the 
electrode target. Converging data across distinct antidepressant classes with reported 
efficacy in TRD suggest that glycogen synthase kinase 3 (particularly its beta variant; 
GSK3β)[17, 18] and mammalian target of rapamycin (mTOR) signaling [19, 20] play 
an important role in this process. Both of these signaling proteins rapidly coordinate 
cellular metabolic and growth processes to enhance neuroplasticity. In line with this, 
they have been proposed to repair stress-induced dendritic atrophy, particularly in the 
hippocampus [21, 22]. Despite well-established direct and indirect projections 
between the NAc and hippocampus, it remains unclear as to how NAc DBS impacts 
hippocampal function. To address this, we aimed to determine the antidepressant 
actions of chronic NAc DBS and their associated impact on hippocampal GSK3β and 
mTOR in an established rodent model of tricyclic antidepressant-resistance [23-25].  
 
Methods 
Animals 
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 All procedures were reviewed and approved by Mayo Clinic’s Institutional 
Animal Care and Use Committee (IACUC). Four cohorts totaling 37 male Wistar rats 
(Harlan, IN, USA) were individually housed with water and chow available ad libitum. 
The animal vivarium was under a 12:12 hours light:dark cycle with lights on at 7:00 
AM. Each cage was fitted with an infrared motion sensor to measure homecage 
activity, which were streamed to a data acquisition box (Actimetrics, IL, USA). 
Activity counts were recorded continuously throughout the course of the experiment. 
The experimental timeline, including treatments and behavioral tests, is described in 
Figure 1. 
 
The experiment was divided into three weekly phases: week 1 (baseline and 
surgery period), week 2 (days 1-7), and week 3 (days 8-15). Injections occurred on 
weeks 2 and 3, and DBS occurred on week 3 as well as day 16 up until euthanasia (no 
injections on day 16). Animals were divided into 4 groups: DBS (n=10), SHAM 
(n=10), ADR (n=8) and SAL (n=9). Treatments administered to each group are 
described in Table 1. 
 
Table 1 – Group treatments 
Groups Treatment NAc Electrodes DBS 
DBS ACTH Yes Yes 
SHAM ACTH Yes No 
ADR ACTH No No 
SAL Saline No No 
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Surgery 
DBS and SHAM groups were bilaterally implanted with twisted bipolar 
electrodes (PlasticsOne, VA, USA) through stereotactic surgery into the NAc core 
using the bregma (flat skull) as coordinate reference (A-P: +1.5mm; M-L: +/-1.5mm; 
D-V: -7.0mm) [26]. Animals received anesthesia through inhalation of isoflurane 
(3.0% induction, 1.5% maintenance) during surgery and were visually monitored 
through breathing and reflexes. Cranial screws were affixed to the skull and anchored 
with dental cement, which sealed the burr holes and held the electrodes in place. All 
tools and equipment were sterilized in 70% ethanol between individual surgeries and 
autoclaved between surgery days to reduce infection risk. Animals were then allowed 
to recover for three days in homecages and checked daily for any movement 
complications and proper weight gain. 
 
Injections 
All animals received daily 1 mL intraperitoneal injections of ACTH (AnaSpec, 
CA, USA) at 100 µg/mL (with the exception of the SAL group, which received 1 mL 
0.9% saline injections) at approximately 4 hours into the light cycle. This corresponds 
to the circadian nadir and lowest plasma corticosterone levels in rats [27]. Injections 
occurred every day from day 1 to day 15 (inclusive). Animals did not receive injections 
on the day of euthanasia. 
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Deep Brain Stimulation Device 
DBS devices were soldered to electrode cords (Plastics One, VA, USA) that 
screw onto the implanted electrode. Each device was tested under an oscilloscope to 
ensure a complete and correct pulse (130Hz, 200µA, 90µs). The single piece back 
mountable DBS devices were designed to produce monophasic constant current 
pulses for over 12 days with a single battery while incorporating passive charge 
balancing [28]. Two DBS devices were enclosed into a pouch and affixed to the back 
of a rat vest (Harvard Apparatus, MA, USA) to deliver continuous stimulation for 
animals in the DBS group during week 3 and day 16. SHAM animals wore the vests 
during this time. 
Sucrose Preference Test 
The 2-bottle choice sucrose preference test (SPT) screens for sucrose-
associated carbohydrate preference, a behavioral model associated with depression. 
Other SPT methods may also screen for anhedonia in cases where the animal has to 
work to obtain the sucrose reward [29], but in this case the two-bottle choice offers 
equal effort for either bottle and doesn’t necessarily detect anhedonia. Changes in 
preference over each experimental phase are used to determine treatment-based 
sensitivity to rewarding stimuli in the form of carbohydrate consumption. The SPT 
consists of 3 recorded preference tests, and one initial exposure session two days prior 
to the first recorded test. During the exposure session, animals were deprived of water 
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for 16 hours prior to the test. The SPT began 4 hours after the start of the light cycle. 
Preference was determined using two-bottle choice, with one bottle containing water 
and the other containing 1% sucrose solution. For the SPT’s the same procedure was 
followed with the addition of measuring the weights of both bottle types before and 
after administration to record the amount consumed by each animal. The left and 
right side for which each bottle is placed was switched between each animal and 
between each SPT trial to avoid place preference. A total of one exposure and three 
SPT’s were run, where the exposure session and first SPT were performed during 
week 1, and the subsequent two SPT’s performed each week following. 
 
Open Field Test 
The open field test (OFT) quantifies psychomotive and anxiety-like behavior in 
a novel low-stress environment by measuring the time spent in the center (high-
anxiety) region compared to the periphery (low anxiety region) of the arena apparatus. 
The apparatus is a square shaped box (59.7x59.7x43.2 cm) with access to the floor for 
the animal to freely move. Rat vests and DBS devices were unplugged and removed 
before initiating OFT in DBS and sham groups. Animals were individually placed in 
the center of the apparatus floor for 10 minutes prior to injections. Video recording 
of the animal’s movements were analyzed using TopScan software (CleverSys Inc, 
VA, USA) for the first 5 minutes after placing the animal in the center. Mean time 
spent in the central region as well as distance travelled was compared among groups 
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for anxiety-like behavior and psychomotor activity. The OFT was performed on Day 
14 prior to treatment injections. 
 
Forced Swim Test 
 The forced swim test (FST) is a measure of psychomotor behavior and a screen 
of antidepressant efficacy under a high-stress environment [30]. Animals were placed 
into acrylic cylinders (height=47 cm, diameter=19 cm) with 25ºC tap water filled to 28 
cm from the base. A 15 minute FST training session was performed 2 hours after 
OFT and injections on Day 14, and the 6 minute recorded test FST session was 
performed on Day 15, again 2 hours after injections. DBS devices and vests remained 
removed from previous OFT for FST training session, and were unplugged and 
removed prior to recorded test FST session. Video recording of the test session was 
analyzed through hand-scoring to measure the time animal spent performing active 
(swimming, climbing, diving) versus passive (immobility) coping behaviors during the 
session. The latency to the first 2-second immobility interval was also recorded for 
each animal. 
 
Euthanasia and Tissue Collection 
Animals were euthanized via anesthetic overdose (FatalPlus; Vortech 
Pharmaceuticals, MI, USA). Whole brains were harvested and stored at -80°C. During 
tissue collections, brains were slightly thawed on a cooling block (BioCision, CA, 
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USA) for tissue collection. 1 mm coronal slices were cut at regions of interest and a 1 
mm diameter biopsy punch collected the samples to be stored at -80°C. 
 
Protein Analysis 
 Ventral hippocampus (vHipp) and dorsal hippocampus (dHipp) concentrations 
of GSK3β, p-GSK3β, mTOR, and p-mTOR at the time of euthanasia were 
determined through western blot. Tissue samples were lysed in 
radioimmunoprecipitation assay (RiPA) lysis buffer. The total protein concentration 
was determined by Bradford assay (BioRAD, CA, USA). 20ug of protein lysate were 
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
and then transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-P). 
Membranes were blocked for 2 hours in tris buffered saline solution with 0.1% Tween 
20 (TBST) and 5% milk. Membranes were incubated with a 1:1000 dilution of 
GSK3β, p-GSK3β (Ser21/9), mTOR, and p-mTOR (Ser2448) primary antibodies 
produced in rabbit (Cell Signaling Technology, MA, USA) in PBST overnight. The 
membranes were washed 3 times (10 minutes each) the following day with phosphate 
buffered saline with 0.1% Tween 20 (PBST), and incubated with a 1:2000 dilution of 
anti-rabbit HRP-linked secondary antibody (Cell Signaling Technology, MA, USA) in 
PBST for 1 hr.  Blots were again washed 3 times (10 minutes each) with PBST before 
being exposed to enhanced chemiluminescence (ECL) substrate (Thermo Scientific. 
Rockford, IL, U.S.A). β-Actin was determined using β-Actin primary antibody 
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produced in mouse (Sigma Aldrich, MO, USA) with dilution of 1:10000 in TBST, and 
anti-mouse HRP-linked secondary antibody (Cell Signaling Technology, MA, USA) 
with dilution of 1:5000 in PBST. The resulting bands were measured using 
densitometric analysis on a Bio-Rad ChemiDoc™ imaging system. Readings on each 
gel were first normalized to β-Actin, and then to the average protein concentration of 
saline animals on each gel. 
 
Histology 
 The remaining portion of brain was embedding using Cryo-M-Bed (A-M 
Systems 527738). Coronal sections of 6µm were taken around NAc. The sections 
were fixed using ice-cold acetone for 10 minutes, followed by 10 minutes of drying 
time. 
H&E Staining: After fixation and drying, the slides were then incubated in 
phosphate buffered saline for 10 minutes, followed by 30-second incubation in 
hematoxylin stain, then rinsed under running water for 5 minutes. The following dips 
were done: Blueing 4 dips, water 10 dips, water 10 dips, 95% Ethanol 4 dips, Eosin 6 
dips, 50% Ethanol 12 dips, 70% Ethanol 12 dips, 95% Ethanol 12 dips, Absolute 
Ethanol 12 dips, Xylene 12 dips. Slides were allowed to completely dry before 
preserving in Vecta-mount (Vector Laboratories LTD, CA, USA) and coverslipping. 
Example of DBS tract and all electrode positions were recorded (Figure 2). 
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Statistical Analyses 
 Animals were excluded from the study if the animal was terminated before the 
end of the experiment or if corresponding protein data was unavailable. Additionally, 
data outliers were identified as values greater than 2 standard deviations above or 
below the mean of the group data, and were excluded from that dataset. D’Agostino 
& Pearson omnibus normality test was then performed. If all groups passed this 
normality test in a dataset (alpha=0.05), parametric one-way analysis of variance 
(ANOVA) was performed to determine overall main effect (p<0.05) or trending 
effect (p<0.1). If no effect was demonstrated, no further actions were taken. If an 
effect was demonstrated (p<0.1), Sidak’s post-hoc multiple comparisons tests were 
performed to determine group differences. Repeated measures ANOVA was 
performed for SPT datasets followed with Tukey’s post-hoc multiple comparisons 
tests if an effect was demonstrated. If any groups failed the normality test in a dataset 
(vHipp GSK3β and p-GSK3β protein levels), non-parametric Kruskal-Wallis H test 
with Dunn’s post-hoc multiple comparisons test was performed to determine group 
differences. Group comparisons were only performed between groups that differed 
by exactly one treatment (i.e. DBS-SHAM; DBS-ADR; SHAM-ADR; ADR-SAL). If 
the sample size of any group was too low for the D’Agostino & Pearson omnibus 
normality test, Shapiro-Wilk normality test was performed for that group to determine 
normality. All analyses and graphs were created using GraphPad Prism 6.0. 
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Results 
Forced Swim Test 
 NAc DBS significantly lowered FST immobility time (p=0.0004). This effect 
was not observed with sham treatment. [Figure 3a; p=0.0002, F (DFn, Dfd)=8.740 (3, 
34).] Latency to first immobility of 2-second duration was significantly increased by 
NAc DBS (p=0.0001) and sham (p=0.0182) treatment. [Figure 3b; p<0.0001, F (DFn, 
Dfd)=11.01 (3, 33).] 
 
Open Field Test 
 No differences were observed in the total distance travelled during OFT. These 
results validate FST screening of DBS antidepressant effects. [Figure 4a; p=0.0807, F 
(DFn, Dfd)=2.446 (3, 34).] DBS (p=0.0020) and sham (p=0.0332) treatment 
significantly lowered the total duration spent in the center region of OFT apparatus. 
[Figure 4b; p=0.0002, F (DFn, Dfd)=8.615 (3, 33).] 
 
Activity Profiles 
Activity was measured with an infrared beam motion sensor attached to each 
cage. Week 1 activity was averaged over 6 days prior to day, excluding surgery and 
recovery days. Week 2 activity was averaged from days 2 through 7 and week 3 was 
averaged from days 9 through 14. Activity profiles are represented as percent change 
in order to minimize variabilities between individual sensor sensitivities. 
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An increase in activity was observed in both the DBS (p=0.0505) and SHAM 
(p=0.0709) groups between weeks 1-2. This activity increase corresponds with 
electrode implantation in these groups. [Figure 5a; p=0.0113, F (DFn, Dfd)=4.299 (3, 
34).] No difference in activity was detected between weeks 2-3. [Figure 5b; p=0.4432, 
F (DFn, Dfd)=0.9166 (3, 34).] Overall, activity between weeks 1-3 was significantly 
higher in DBS (p=0.0199) and SHAM (p=0.0199) groups. [Figure 5c; p=0.0015, F 
(DFn, Dfd)=6.428 (3, 33).] 
 
Sucrose Preference Test 
 No difference was observed in sucrose preference changes for the DBS group. 
[Figure 6a; p=0.3249, F (DFn, Dfd)=1.168 (1.498, 13.48).] Increased sucrose 
preference was demonstrated by week 2 for the SHAM (p=0.0425) and ADR 
(p=0.0148) groups. [Figure 6b; p=0.0263, F (DFn, Dfd)=5.355 (1.575, 12.60). Figure 
6c; p=0.0027, F (DFn, Dfd)=16.03 (1.205, 8.434).] No difference was observed in 
sucrose preference changes for the SAL group. [Figure 6d; p=0.2509, F (DFn, 
Dfd)=1.517 (1.359, 12.23).] 
 
Protein Analyses 
 vHipp protein levels (GSK3β, p-GSK3β, mTOR, p-mTOR) were characterized 
at the time of euthanasia (day 16). No significant differences were detected in vHipp 
GSK3β levels. (Figure 7a; p=0.3265, H=3.456.) NAc DBS elevated p-GSK3β levels 
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(p=0.0081) as well as p-GSK3β/GSK3β levels (p=0.0862). [Figure 7b; p=0.0151, 
H=10.44. Figure 7c; p=0.0578, F (DFn, Dfd)=2.766 (3, 32).] NAc DBS elevated 
mTOR levels compared to SHAM animals (p=0.0065). [Figure 7d; p=0.0084, F (DFn, 
Dfd)=4.661 (3, 31).] Both NAc DBS (p=0.0119) and sham (p=0.0119) treatments 
elevated p-mTOR levels. [Figure 7e; p=0.0108, F (DFn, Dfd)=4.380 (3, 32).] Sham 
treatment elevated p-mTOR/mTOR levels (p=0.0444). [Figure 7f; p=0.0569, F (DFn, 
Dfd)=2.773 (3, 33).] 
 
dHipp protein levels were also characterized, however no significant effects 
were detected between groups. A significant effect was detected in p-GSK3β levels 
[Figure 8b; p=0.0494, F (DFn, Dfd)=2.913 (3, 32)], but neither Sidak’s post-hoc 
multiple comparisons tests nor t-tests with Bonferroni corrections between compared 
groups revealed significant or trending differences. [Figure 8a; p=0.2097, F (DFn, 
Dfd)=1.593 (3, 33). Figure 8c; p=0.1546, F (DFn, Dfd)=1.874 (3, 31). Figure 8d; 
p=0.1247, F (DFn, Dfd)=2.058 (3, 33). Figure 8e; p=0.0424, F (DFn, Dfd)=3.044 (3, 
33). Figure 8f; p=0.0069, F (DFn, Dfd)=4.813 (3, 33). 
 
Discussion 
This study provides further support for the antidepressant actions of NAc DBS 
through reduced immobility as our primary measure of antidepressant efficacy in the 
forced swim test. No significant difference was observed in immobility time between 
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the SHAM group and controls, however both DBS and SHAM groups demonstrated 
elevated latency to immobility. We also observed an enhancement in psychomotor 
activity in both DBS and SHAM groups through increased homecage activity. In 
contrast, acute psychomotor enhancement was not observed in the OFT, and this 
serves to validate the forced swim antidepressant screening efficacy. We further 
observed an increase in sucrose consumption in ACTH and SHAM animals, relative 
to DBS and SAL groups. Increased levels of pGSK3β and pmTOR were also 
observed in the ventral striatum of DBS (pGSK3 and pmTOR) and SHAM groups 
(pmTOR only). 
The marked reduction in passive coping behaviors - immobility - is a clear and 
validated indication of the antidepressant efficacy of NAc DBS, and was SHAM 
responses. This antidepressant effect was validated by the lack of significant change in 
the OFT; this validation is suggested by the lack of stress-related hyperactivity in acute 
behavioral tests, implying the forced swim test is measuring antidepressant effects and 
not stress-related hyperactivity. It is also worth noting that FST does not characterize 
depression-like behaviors, only antidepressant efficacy. Despite this, we posit that an 
analog of depression may be induced in all animals in this study through social 
isolation [34-36]. Homecage social isolation was necessary to employ in this study in 
order to measure individual homecage activity changes and to ensure animals that 
received surgery and/or stimulation would not be harmed during paired housing. We 
model, to some degree, clinical TRD in the ADR rats by combinatory depressive-like 
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symptoms induced through social isolation and antidepressant resistance, HPA-axis 
dysregulation, and dopamine dysregulation induced through ACTH administration. 
The findings in this study therefore contribute towards elucidating the mechanistic 
actions of DBS. 
Previously we have shown that NAc electrode implantation (active or sham) 
induced a state of hyperactivity in a subgroup of rats [31]. Here we confirmed this 
activity increase through 24-hour continuous homecage monitoring. Stress associated 
with daily i.p. injections appeared to increase activity in all groups (between weeks 1-
2). On top of this, electrode implantation also elevated homecage activity between 
weeks 1-2 and between weeks 1-3. These changes in homecage activity may reflect 
changes in mesoaccumbens dopamine signaling. Similarly, dopamine dysregulation is 
inferred by elevations of carbohydrate consumption from ADR and SHAM groups 
during SPT. Indeed, the mesolimbic dopamine pathway acts as an important regulator 
for feeding behavior and food craving [37] and modulating these pathways through 
ACTH and NAc DBS changed consumption in SPT. NAc DBS appears to reverse 
ACTH-induced increases in sucrose consumption and may be indicative of the 
network level neuroadaptations that are produced by mesocorticolimbic DBS.  
The treatments administered in this study also modulated the hippocampal cell 
signaling proteins GSK3β and mTOR, which are critically implicated in 
neuroplasticity. Increased levels of GSK3 within the CNS has been found to be 
associated with depressive-like and mania-like behavior in rats and is thought to play 
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an important role in the pathophysiology of mood disorder [18]. It is also responsible 
for decreased anti-inflammatory responses that can exacerbate depression [38] as well 
as cognitive impairment and neurodegeneration, which is directly link to its activity 
within the hippocampus [39]. Inhibition of GSK3 by phosphorylation, therefore, can 
serve as a biomarker for antidepressant therapeutic responses. Our study suggests the 
efficacy of NAc DBS in treatment-resistance depression as it significantly increased p-
GSK3β level in the vHipp, and such effect was not confounded by sham electrode 
implantation. The signaling cascade of mTOR is responsible for numerous cell 
functions such as synaptic plasticity, mitochondrial metabolism, and neurogenesis. For 
example, activation of mTOR is critical for therapeutic response of antidepressants 
due to its involvement in synthesis of downstream synaptic protein [20]. Activation of 
mTOR by phosphorylation at Serine 2448 can serve as an indicator of enhanced 
neurogenesis that is partly responsible for the antidepressant effect. Our study 
suggests that activated mTOR level in the vHipp was increased in both DBS and 
SHAM groups, which means a therapeutic response is observed in this treatment-
resistance model but a specific mechanism remains unknown. The antidepressant 
effect of electrode implantation regardless of electric stimulation has been observed in 
other studies, and it was suggested that early anti-depressive response in sham 
treatment is possibly due to region inflammation [40]. Finally, treatment effects were 
observed in the vHipp, while treatment effects were not observed in dHipp. Because 
the vHipp has been linked to emotional behavior and neuroendocrine stress-related 
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regulation, and dHipp more to learning and memory [41], an enhanced neurogenesis 
effect by DBS within the vHipp is specifically relevant to the intended antidepressant 
effects. Furthermore,  a recent study showed that neurogenesis in the hippocampus is 
not only necessary but also sufficient to decrease anxiety and depressive-like behaviors 
in rats [42], suggesting that NAc DBS, through its molecular regulation in the 
hippocampus, is a promising treatment strategy for refractory depression.  
This study offers a unique approach to studying DBS in rats using a model of 
treatment resistant depression in that it incorporates continuous bilateral stimulation 
through an untethered device affixed to the rat to maximize portability. Many 
previous studies accomplished intermittent unilateral stimulation for up to a few 
hours [43-45]. Future studies with portable optogenetic microdevices [46, 47] could 
offer precise regional stimulation as well as provide specific inhibition or excitation of 
circuits. Future comprehensive biochemical and genetic analyses could further provide 
insight into causal mechanisms of antidepressant action as well as biomarker 
identification for DBS response efficacy. 
 
Conclusion 
NAc DBS appears an effective antidepressant option for clinical TRD, 
evidenced in our ADR animal model through the FST, as well as through elevated 
homecage activity and a reversal in sucrose consumption behaviors. Because DBS 
might provide antidepressant efficacy in treatment resistant patients, additional animal 
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studies are necessary to investigate the causal role of DBS in antidepressant efficacy. 
Further understanding of the mechanisms of action of NAc DBS, in particular 
examining neurochemical mediators could lead to alternate therapeutic strategies and 
closed-loop DBS approaches. 
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FIGURE LEGENDS 
 
 
Figure 1 – Summary of the experimental timeline with each number corresponding to 
the day following baseline and surgery. Behavioral tests administered to all groups are 
on top of figure and treatments are below. (SPT: sucrose preference test; OFT: open field test; 
FST: forced swim test; train.: training; Euth.: euthanasia; ACTH: adrenocorticotropic hormone; 
NAc DBS: nucleus accumbens deep brain stimulation). 
 
Figure 2 – Hybrid image with left hemisphere of atlas brain [26] at NAc and example 
of H&E stained brain. (left): Electrode tip placements are displayed with a black circle 
in the left hemisphere only for each DBS animal. (right): DBS electrode tract is 
imaged terminating in NAc. 
 
Figure 3 – Forced swim test (a) total immobility time and (b) latency to first 
immobility. Data shown in mean seconds +/- standard error. Significance is 
illustrated as *: p<0.05; ***: p<0.001.  
 
Figure 4 – Open field test (a) distance travelled and (b) time spent in center region. 
Data shown in mean seconds +/- standard error. Significance is illustrated as *: 
p<0.05; **: p<0.01. 
 
Figure 5 – Percent change in homecage activity counts between (a) weeks 1-2, (b) 
weeks 2-3, (c) weeks 1-3. Data shown in mean percentage change of activity counts 
per day +/- standard error. Significance is illustrated as *: p<0.05. Trends illustrated 
as ‡: p<0.1. 
 
Figure 6 – Sucrose preference test at each week for (a) DBS, (b) sham, (c) ACTH, (d) 
saline groups. Data is shown as mean +/- standard error. Significance is illustrated on 
graphs by *: p<0.05; **: p<0.01. Trends illustrated as ‡: p<0.1.  
 
Figure 7 - vHipp protein expression levels of (a) GSK3β, (b) p-GSK3β, (c) p-
GSK3β/GSK3β, (d) mTOR, (e) p-mTOR, (f) p-mTOR/mTOR. Data is shown as 
mean concentration standardized to β-actin and normalized to SAL controls for each 
gel +/- standard error. Significance is illustrated on graphs by *: p<0.05; **: p<0.01. 
Trends illustrated as ‡: p<0.1. 
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 Figure 8 – dHipp protein expression levels of (a) GSK3β, (b) p-GSK3β, (c) p-
GSK3β/GSK3β, (d) mTOR, (e) p-mTOR, (f) p-mTOR/mTOR. Data is shown as 
mean concentration standardized to β-actin and normalized to SAL controls for each 
gel +/- standard error. 
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Abstract 
 Animal models of mood disorders are limited by their inability to 
phenotypically express episodic states of disease. Adrenocorticotropic hormone 
(ACTH; 100 µg/mL/day, 15 days) induces tricyclic antidepressant resistance (ADR) 
in rats as measured through the forced swim test (FST). ADR rats demonstrate 
susceptibility to mania-like states through nucleus accumbens (NAc) deep brain 
stimulation (DBS; 130 Hz, 200 µA, 90 µs), further indicative of dysregulation in 
mesocorticolimbic dopaminergic activity. This study incorporates the ADR model 
with coupled NAc DBS and/or selective dopamine reuptake inhibitor GBR12909 
(GBR; 16 mg/kg/day, 8 days) to investigate behavioral responses to dopamine 
modulating treatments. Male Wister rats (5-weeks) were administered ACTH i.p. for 7 
days before commencing additional treatment of continuous NAc DBS and/or i.p. 
GBR (45 minutes after ACTH) for the remaining 8 days, during which daily open 
field test (OFT) was performed 90 minutes after ACTH administration. Rat homecage 
activity was monitored via infrared beam throughout the experiment. FST was 
performed on day 15, and brains were harvested after 30 minutes for regional protein 
quantification. Results demonstrated the antidepressant effects of NAc DBS 
(supported by infralimbic cortex protein modifications) as well as GBR, as measured 
through FST immobility reduction and validated in the final OFT. Acute effects of 
daily GBR treatment were determined by OFT and demonstrated an attenuated 
psychomotor state in GBR treated ADR rats. Interestingly, chronic elevation of 
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psychomotor state was observed through 24-hour homecage monitoring in this 
group, providing evidence towards susceptibility of the ADR model to dopamine 
modulating drugs for altering mood states. This study elucidates a potential model for 
future development that may facilitate understanding of neurobiological mechanisms 
in mood disorders. 
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Introduction 
A variety of depression- and mania-like animal models have been developed 
separately (Nestler and Hyman, 2010), and while these have served to contribute 
knowledge into the pathophysiological mechanisms contributing to each specific state, 
they lack the capacity to inform on the neurobiological impact of alternating mood 
episodes characteristic of bipolar disorder (BD) (Nestler, Gould et al., 2002; Nestler 
and Hyman, 2010). We have previously demonstrated the occurrence of mania-like 
behaviors in a rat model of antidepressant resistance (ADR), induced via daily 
injections of adrenocorticotropic hormone (ACTH) coupled with deep brain 
stimulation (DBS) of the nucleus accumbens (NAc) region. Such a model may help to 
elucidate important neuroadaptations contributing to alternating depression- and 
mania-like states. The ADR model has face validity in modelling the treatment 
resistant pole of depression as well as antidepressant induced mania observed in BD 
(Kim, McGee et al., 2016). 
ACTH-induced ADR blocks behavioral responsivity to tricyclic antidepressants 
(e.g. imipramine) in the forced swim test (FST) (Walker, Burnett et al., 2013), a well-
established antidepressant screening tool [see: (Porsolt, Bertin et al., 1977) for detailed 
review]. ADR rats demonstrate differential responses to antidepressants under stress 
(Kitamura, Yagi et al., 2010) as well as altered PFC monoamine levels following 
forced swim stress that includes diminished tissue dopamine levels (Walker, Burnett et 
al., 2013). Additionally, we have demonstrated that these animals have decreased 
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capacity for mitochondrial ATP production, with contrasting increased mitochondrial 
efficiency, reflected in elevated respiratory control ratio, in animals spontaneously 
developing elevated psychomotor activity reflective of a mania-like phenotype 
following NAc DBS (Kim, McGee et al., 2016). Mesocorticolimbic DBS has been 
utilized as a clinical treatment for treatment-resistant depression (Bewernick, 
Hurlemann et al., 2010; Dougherty, Rezai et al., 2015; Grubert, Hurlemann et al., 
2011; Mayberg, Lozano et al., 2005; Merkl, Schneider et al., 2013). In some cases, 
mania-like symptoms have precipitated in patients receiving NAc DBS for obsessive 
compulsive disorder (Greenberg, Gabriels et al., 2010; Haq, Foote et al., 2010). The 
role of dopamine in this phenomenon, however, is not well characterized. 
The mesoaccumbens dopamine circuit consists of a projection from the ventral 
tegmental area in the midbrain, which terminates in the NAc core (NAcc) and shell 
(NAcs) regions, thought to mediate psychomotor and stress response behaviors 
respectively (Ito, Robbins et al., 2004; King, Zigmond et al., 1997; Sellings and Clarke, 
2003). Elevated mesoaccumbal dopamine activity is implicated in clinical mania 
symptoms (Swerdlow and Koob, 1987) while diminished dopamine activity has been 
implicated in depression (Dunlop and Nemeroff, 2007). Similarly, NAc lesions have 
been shown to result in hyperactive and mania-like behavioral phenotypes in rodents 
(Cardinal, Pennicott et al., 2001; Parkinson, Olmstead et al., 1999), likely due to 
disruption of the NAc inhibitory GABAergic projections onto ventral tegmental area 
dopaminergic neurons. Clinical manifestations of mood episodes lead to a dopamine 
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dysregulated state (Berk, Dodd et al., 2007), particularly through altered functionality 
and expression of the dopamine transporter (DAT) (Dunlop and Nemeroff, 2007; 
Laasonen-Balk, Kuikka et al., 1999; Meyer, Krüger et al., 2001; Rao, Kellom et al., 
2012).  
DAT function can be effectively blocked by administration of the potent and 
selective DAT inhibitor GBR12909 (GBR), which has established antidepressant 
(Andersen, 1989) and mania-inducing properties (Queiroz, de Araújo et al., 2015; 
Young, Goey et al., 2010). Dose-dependent studies in rodents have shown that GBR 
administered at 16 mg/kg produced hyperlocomotor and elevated exploratory 
behaviors consistent with the mania-like profile of BD patients (Young, Goey et al., 
2010). In the mesocorticolimbic circuit, DAT is expressed on extrasynaptic plasma 
membranes in NAcc and NAcs (Nirenberg, Chan et al., 1997). It is also the primary 
dopamine clearance mechanism in infralimbic cortex (IL) (Cass and Gerhardt, 1995; 
Heidbreder and Groenewegen, 2003), which is the rodent corollary to Broadmann 
area 25 (subgenual cingulate). The IL contains lateral tracts that project to midbrain 
mesoaccumbens regions like NAcs, and to a lesser extent NAcc (Heidbreder and 
Groenewegen, 2003; Hurley, Herbert et al., 1991). Stress activates these 
mesoprefrontal (Horger and Roth, 1996; Kaneyuki, Yokoo et al., 1991) and 
mesoaccumbens (Berk, Dodd et al., 2007) dopaminergic tracts. Dopamine released in 
these circuits binds to type 2 dopamine receptors (D2R) and subsequently modulates 
DAT expression levels through feedback mechanisms (Cass and Gerhardt, 1994; 
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Meiergerd, Patterson et al., 1993; Parsons, Stanley et al., 1993). Downstream signaling 
of D2R includes mammalian target of rapamycin (mTOR) and S6 kinase (p70 S6K 
and p85 S6K). The mTOR-S6K pathway has been implicated in cellular energetics, 
protein production, and nucleotide biosynthesis (Albert and Hall, 2015; Laplante and 
Sabatini, 2009). Therefore, ADR animals treated with GBR may exhibit altered 
mesocorticolimbic D2R, mTOR and S6K expression, as well as modulated 
psychomotor and stress response behaviors. 
The current study investigated ACTH treatment, DAT blockade, and/or NAc 
DBS treatment on mania-like phenotype development in our ADR model. Behavioral 
measures to identify phenotypic neuroadaptations included antidepressant response 
through the forced swim test (FST), acute and chronic psychomotor activity through 
the open field test (OFT) and homecage monitoring respectively, and reward salience 
through the sucrose preference test (SPT). Mesocorticolimbic protein expression of 
D2R, activated mTOR ratio (p-mTOR/mTOR) and S6K, induced after forced swim 
stress, were additionally measured in IL, NAcc, and NAcs regions. Elucidation of 
these mechanisms may help to establish how dopamine dysregulation contributes to 
development of mania-like behavior. 
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Methods 
Animals and Experimental Timeline 
 All procedures were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) of Mayo Clinic. Six cohorts (n=43) of male Wistar rats 
(Harlan, IN, USA) were randomly assigned into one of 6 groups: (DBS, DBS+GBR, 
ACTH, ACTH+GBR, SAL, SAL+GBR). Rats were individually housed and 
acclimatized for at least 3 days upon arrival. Food and water were available ad libitum. 
The animal vivarium was controlled for humidity and temperature, and was under a 
12:12 hour light:dark cycle with lights turning on at 6:00 AM. Cages were fitted with 
infrared beam monitors that measured activity counts every time the animal crossed 
the sensor. An average baseline activity reading was taken during 4 consecutive days 
and compared to the average treatment phase activity during days 9-12. The 
experimental timeline is illustrated in Figure 1. 
 
 
Figure 1 - Timeline of experimental protocol for each day. Behavioral procedures are 
outlined above and group treatments are outlined below. SPT: sucrose preference test; 
ACTH: adrenocorticotropic hormone; NAc: nucleus accumbens; DBS: deep brain 
stimulation; GBR: GBR12909; OFT: open field test; FST: forced swim test. 
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Surgery 
 DBS groups were surgically implanted with 0.127 mm diameter stainless steel 
twisted bipolar electrodes (PlasticsOne, VA, USA). Animals were anesthetized with 
isoflurane (3.0% induction, 1.5% maintenance; Baxter International, IL, USA) and 
placed in a stereotactic frame (David Kopf Instruments, CA, USA). Bregma (flat 
skull) was used as coordinate origin and electrodes were implanted bilaterally into the 
core of NAc (A-P: +1.5mm; M-L: +/-1.5mm; D-V: -7.0mm) (Paxinos and Watson, 
2005). Cranial screws were inserted into the skull to anchor dental cement, which held 
the electrodes in place. Animals recovered over a period of 3 days prior to initiation of 
DBS and drug treatments. 
 
Treatments 
 All animals were administered daily intraperitoneal (i.p.) injections of either 1 
mL ACTH (100 µg/mL; Anaspec, CA, USA) or 1 mL 0.9% saline routinely at ~10:00 
AM on days 1-14. Daily GBR (16 mg/kg i.p.; Sigma-Aldrich, MO, USA) was 
administered on days 8-15, 45 minutes after ACTH/SAL injections. Portable DBS 
microdevices (Kouzani, Abulseoud et al., 2013) were used to stimulate bilateral NAc 
(130 Hz, 200 µA, 90 µs) on days 8-15. Each device was tested with an oscilloscope 
before use. 
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Sucrose Preference Test 
 SPTs were performed using two-bottle choice overnight, during the animal’s 
wake period for a duration of 18 hrs. One bottle contained tap water and the other 
contained 1% sucrose solution. The test was performed prior to initiation of any 
treatments and then again on day 14. Bottles were weighed at the beginning and end 
of each test session to measure the total amount of solution consumed. The left and 
right position of each bottle was alternated between animals and sessions. 
 
Open Field Test 
 The OFT was run daily on days 8-14; 45 minutes after GBR treatment. 
Animals were placed into the center of the apparatus (59.7x59.7x43.2 cm) and allowed 
to move freely for the duration of the experiment (10 minutes). Each session was 
video recorded and analyzed using TopScan software (CleverSys Inc, VA, USA). Total 
distance travelled, peripheral velocity, and duration spent in center region were the 
variables of interest. 
 
Forced Swim Test 
The FST was performed using an acrylic cylinder (height=47 cm, diameter=19 
cm) with room temperature (25 +/- 2°C) tap water. The water was filled to 28 cm 
from the base. On day 14, animals were exposed to a 15 minute FST training session. 
On day 15, a, 6 minute FST session was performed. Each session was recorded on 
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video. The FST session was run 2 hours post-GBR injection. The video was analyzed 
by hand-scoring at 1 second resolution for time spent performing active 
(swimming/climbing) or passive (immobility and latency to immobility) behaviors as 
described previously (Walker, Burnett et al., 2013). 
 
Euthanasia and Tissue Collection 
 Animals were euthanized 30 minutes following FST exposure via anesthetic 
overdose (FatalPlus; Vortech Pharmaceuticals, MI, USA). Brains were frozen on dry 
ice, and stored at -80°C.  
 
Protein Analysis 
Brains were dissected on a cooling block (BioCision, CA, USA) over dry ice. 1 
mm coronal slices were cut at each region of interest and a 1 mm biopsy punch was 
used to collect bilateral tissue samples from the IL, NACc, and NACs regions. 
Tissue was homogenized and lysed in radioimmunoprecipitation assay (RiPA) 
lysis buffer for Western Blotting. Total protein concentration was determined by 
Bradford assay. Equal amounts of protein lysate of the dissected regions were 
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
and transferred to polyvinylidene fluoride membrane (Immobilon-P). Membranes 
were blocked for 2 hours with tris buffered saline solution with 0.1% Tween 20 
(TBST) containing 5% milk. Membranes were incubated overnight with a 1:1000 
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dilution of mTOR (2983 Cell Signaling), 1:1000 dilution of p-mTOR (5536 Cell 
Signaling), 0.2µg/ml concentration of p70S6K (AF8962 R&D Systems which 
recognizes both p70 and p85), or a 1:800 dilution of D2R (ab21218 Abcam) in TBST 
with 5% BSA. The membranes were washed the following day with TBST and 
incubated with a 1:2000 dilution of anti-rabbit HRP-linked secondary antibody (Cell 
Signaling Technology) in TBST for 1 hr. Blots were again washed with TBST and 
exposed to enhanced chemiluminescence (ECL) substrate (Amersham 
Biosciences/GE Healthcare, NJ, USA). The resulting bands were measured using 
densitometric analysis on a ChemiDoc™ imaging system (Bio-Rad, CA, USA). 
Readings were normalized to β-Actin and saline control values for each gel. 
Statistical Analysis 
One-way analysis of variance (ANOVA) was performed on all datasets to 
determine overall main effect (p<0.05). Post-hoc t-tests were performed to determine 
group differences for FST and OFT behavioral data, comparing groups that were 
exactly one treatment different from each other (i.e. DBS-DBS+G; DBS-ACTH; 
DBS+G-ACTH+G; ACTH-ACTH+G; ACTH-SAL; ACTH+G-SAL+G; and SAL-
SAL+G). An F-test was used to determine homoscedasticity, and if violated, a 
Welch’s t-test was used in lieu. Bonferroni correction on alpha was implemented to 
adjust for multiple comparisons. Significant differences were defined as p<(0.05/n) 
and nonsignificant trending differences were defined as p<(0.1/n), where n is the 
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number of comparisons being made from the dataset. Similarly, post-hoc t-tests were 
used to determine whether protein expression differed between groups demonstrating 
significant differences in FST immobility, our primary measure of antidepressant 
efficacy (i.e. DBS-DBS+G; ACTH-ACTH+G; SAL-SAL+G; and DBS-ACTH). 
Individual percentage change from baseline in homecage activity and sucrose 
preference were analyzed using Sidak’s post-hoc analysis. Outliers greater than or less 
than 2 standard deviations from the mean were excluded. Analyses and graphical 
illustrations were performed using GraphPad Prism 6.0 (GraphPad software, CA, 
USA). 
 
Results 
Forced Swim Test 
 FST significance and nonsignificant trending was defined through Bonferroni 
correction as p<0.00714 and p<0.0143 respectively. NAc DBS significantly lowered 
immobility time compared to ACTH group (p=0.0052). GBR significantly decreased 
immobility time to almost negligible levels (DBS: p=7.504e-5, ACTH: p=0.0003; 
SAL: p=3.99e-5 [Figure 2A p<0.0001, F(DFn, Dfd)=26.58 (5, 37)]. GBR increased 
latency to the first 2-second immobility significantly in ACTH (p=6.431e-7) and SAL 
(p=4.591e-9). Among GBR naïve groups, DBS significantly increased latency to 
immobility (p=0.002594). [Figure 2B; p<0.0001, F(DFn, Dfd)=45.14 (5, 35)]. GBR 
significantly increased FST climbing time ACTH (p=9.263e-8) and SAL (p=7.570e-6) 
177
groups and nonsignificantly increased in the DBS group (p=0.008815). Among GBR 
naïve groups, DBS nonsignificantly increased FST climbing time compared to ACTH 
group (p=0.01012) [Figure 2C; p<0.0001, F(DFn, Dfd)=26.93 (5, 37)]. GBR 
significantly decreased FST swimming time in ACTH (p=0.0002838) and SAL 
(p=0.002998) groups [Figure 2D; p<0.0001, F(DFn, Dfd)=8.675 (5, 37)]. 
 
 
Figure 2 - Forced swim test (A) Immobility, (B) latency to immobility, (C) climbing, 
and (D) swimming time for each group. Data shown in mean seconds +/- standard 
error. Significance is illustrated as *: p<0.007143; **: p<0.001429; ***: p<0.0001429; 
****: p<0.00001429. Trends illustrated as ‡: p<0.01429. 
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Open Field Test 
 OFT significance and nonsignificant trending was defined through Bonferroni 
correction as p<0.00714 and p<0.0143 respectively. No group differences in distance 
travelled were observed on day 1 of OFT [Figure 3A; p=0.0521, F(DFn, Dfd)=2.573 
(5, 25)]. No group differences were observed on day 7 of OFT [Figure 3B; p=0.0613, 
F(DFn, Dfd)=2.334 (5, 27)]. No group differences in peripheral velocity were 
observed on day 1 of OFT [Figure 3C; p=0.0592, F(DFn, Dfd)=2.477 (5, 25)]. GBR 
nonsignificantly tended to reduce peripheral velocity in the ACTH group (p=0.0105). 
Among GBR treated groups, ACTH+G animals demonstrated significantly reduced 
peripheral velocity compared to DBS+G group (p=0.0026) and nonsignificantly in 
the SAL+G group (p=0.0116) [Figure 3D; p=0.0090, F(DFn, Dfd)=3.669 (5, 35)]. 
No group differences were observed in duration spent in the center region of the 
arena on day 1 of OFT [Figure 3E; p=0.0491, F(DFn, Dfd)=2.635 (5, 24)]. No group 
differences were observed in duration spent in the center region of the arena on day 7 
of OFT [Figure 3F; p=0.2423, F(DFn, Dfd)=1.417 (5, 35)]. 
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Figure 3 – OFT (A&B) total distance travelled, (C&D) peripheral velocity, and 
(E&F) duration spent in center of arena for day 1 and day 7 respectively. Data shown 
in mean distance/velocity/seconds +/- standard error. Significance is illustrated as *: 
p<0.007143. Trends illustrated as ‡: p<0.01429. 
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OFT significance was defined through Bonferroni correction as p<0.008333. 
Compared to day 1 of OFT, DBS group demonstrated significantly lowered activity 
on day 2 (p=0.0013) and day 4 (p=0.0027) of OFT [Figure 4A; p=0.0118, F(DFn, 
Dfd)=3.474 (6, 26)]. Compared to day 5 of OFT, SAL group demonstrated 
significantly lowered activity on day 5 of OFT (p=0.0062). [SAL: Figure 4D; 
p=0.2615, F(DFn, Dfd)=1.342 (6, 40)]. All other groups did not demonstrate 
difference in activity from day 1 of OFT [DBS+G: Figure 4B; p=0.8490, F(DFn, 
Dfd)=0.4368 (6, 34)], [ACTH: Figure 4C; p=0.7846, F(DFn, Dfd)=0.5252 (6, 30)], 
[ACTH+G: Figure 4E; p=0.4585, F(DFn, Dfd)=0.9719 (6, 35)], [SAL+G: Figure 4F; 
p=0.9708, F(DFn, Dfd)=0.2127 (6, 42)]. 
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Figure 4 - OFT total distance travelled per day for DBS (A), DBS+G (B), ACTH (C), 
ACTH+G (D), SAL (E), and SAL+G (F) groups. Data shown in mean distance +/- 
standard error. Significance is illustrated as *: p<0.008333; **: p<0.001667.  
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Homecage Activity 
Homecage activity percent change significance and nonsignificant trending was 
defined through Sidak’s post-hoc analysis as p<0.05 and p<0.1 respectively. Percent 
change was measured as the change in average homecage activity counts between 4 
consecutive days during acclimation (baseline) and treatment phase (days 9-12). 
Individual percent change calculation was used to minimize individual variability in 
sensitivity and positioning of motion sensors. GBR significantly enhanced total 
homecage activity change in the ACTH group (p=0.0326) [Figure 5A; p=0.0046, 
F(DFn, Dfd)=4.121 (5, 36)]. GBR also nonsignificantly enhanced night (p=0.0906) 
and day (p 0.0764) homecage activity change in the ACTH group [Figure 5B; 
p=0.0241, F(DFn, Dfd)=2.969 (5, 36)], [Figure 5C; p=0.0506, F(DFn, Dfd)=2.477 (5, 
35)].  
 
 
Figure 5 - Percent change in homecage activity counts for each group comparing 
baseline and treatment phases of (a) total, (b) night, and (c) daytime activity. Data 
shown in mean percentage change of activity counts per day +/- standard error. 
Significance is illustrated as *: p<0.05. Trends illustrated as ‡: p<0.1. 
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Sucrose Preference Test 
 Sucrose consumption preference of each SPT session was calculated as the 
ratio of sucrose solution volume consumed over water volume consumed. SPT 
percent change was used for analysis and was calculated as the ratio of treatment 
session sucrose consumption preference over acclimation session sucrose 
consumption preference. Percent difference between these two time points 
demonstrates no significant difference among groups [Figure 6, p=0.0163; F(DFn, 
Dfd)=0.3.266 (5,34)]. Interestingly, all groups decreased their consumption preference 
except for SAL controls receiving GBR administration. 
 
 
Figure 6 -- Sucrose consumption preference change between treatment session and 
acclimation session. Data shown in mean percentage change of activity counts per day 
+/- standard error.  
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Proteins 
 Protein expression significance and nonsignificant trending was defined 
through Bonferroni correction as p< 0.0125 and p<0.025 respectively. Among GBR 
naïve groups, significantly elevated activated mTOR ratio (p-mTOR/mTOR) was 
detected in IL of the DBS group (p=0.007347) [Figure 7A; p=0.0094, F(DFn, 
Dfd)=3.652 (5,34)]. Conversely, IL D2R expression was reduced by DBS among 
GBR naïve animals (p=0.02039) [Figure 7B; p=0.0782, F(DFn, Dfd)=2.173 (5,37)]. 
Nonsignificantly elevated NAcc p70 S6K was detected in the DBS group treated with 
GBR (p=0.01675) [Figure 7C; p=0.5001, F(DFn, Dfd)=0.8877 (5,34)]. 
Nonsignificantly lowered NAcs p85 S6K was detected in the SAL group treated with 
GBR (p=0.02269). Among GBR naïve groups, lowered NAcs p85 S6K was detected 
in the DBS group compared to the ACTH group (p=0.007541) [Figure 7D; p=0.0298, 
F(DFn, Dfd)=2.815 (5,37)]. All other comparisons were non-significant. 
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Figure 7 – Protein expression levels of (A) IL p-mTOR/mTOR ratio, (B) IL D2R, 
(C) NAcc p70 S6K, and (D) NAcs p85 S6K. Data is shown as mean concentration 
standardized to β-actin +/- standard error. Significance is illustrated as *: p<0.0125; 
**: p<0.0025. Trends illustrated as ‡: p<0.025.  
 
Discussion 
 This study aimed to determine the effect of NAc DBS and/or GBR on mania-
like behaviors in our ACTH-induced ADR rat model together with total and 
phosphorylated protein levels of D2R, p-mTOR/mTOR ratio, p70 S6K, and p85 
S6K. Our data validated the antidepressant effects of GBR and/or NAc DBS on 
ADR rats and demonstrated that GBR could elicit mania-like hyperactivity in ACTH 
treated rats. Interestingly, differential effects on activity were observed during 
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homecage and OFT monitoring. Specifically, we observed that ACTH+G rats 
exhibited depressed velocity in the day 7 OFT acutely after GBR administration 
compared to other groups. This was suggestive of behavioral adaptation to the 
chronic treatment, even though no group differences were observed in reward 
salience. Contrasting this, the ACTH+G group demonstrated chronic elevated 
homecage psychomotor activity relative to other groups. These data support the 
mania-like actions of GBR treatment and indicate that results are distinct for acute 
versus chronic measures of behavioral activity.  
 Antidepressant response, confirmed via a reduction in passive coping 
behaviors, was induced either through NAc DBS or GBR treatment. Consistent with 
our previous work, NAc DBS reduced immobility time and elevated immobility 
latency (Kim, McGee et al., 2016). Additionally, GBR treatment shifted active coping 
strategies from swimming to climbing. This is also consistent with our previous 
observation of DBS-treated ADR rats exhibiting mania-like behaviors and was 
associated with elevated mitochondrial function (Kim, McGee et al., 2016). In the 
present study, GBR treatment attenuated immobility time to almost negligible 
durations, as well as elevated latency to immobility. These results demonstrate the 
antidepressant potential of NAc DBS and/or dopamine reuptake inhibition in ADR 
animals non-responsive to tricyclic antidepressants. It is important to also note, 
however, that this FST antidepressant screen needs to be validated against the OFT to 
determine if increased active coping is a true shift in stress coping, considered to be 
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predictive of antidepressant efficacy, or simply just a reflection of increased 
locomotor activity in general. Although ADR animals demonstrated increased 
homecage activity with GBR treatment, the final OFT data demonstrates no 
differences in distance travelled between groups, indicating that acute drug effects, 
following 7 consecutive days of drug treatment, do not significantly alter locomotor 
activity in the OFT. Moreover, only the DBS and SAL groups exhibited any 
significant changes in total distance travelled from the first OFT, and these effects 
were subsequently mediated by the final OFT. Measures of peripheral velocity were 
however impacted by the GBR treatment. An attenuation in velocity was observed on 
day 7 of OFT for the ACTH+G group compared to other GBR and ACTH groups. 
Together, these data suggest that the acute drug effects observed during the FST, and 
again following 7 consecutive days of drug treatment, represent potential 
antidepressant-like augmentation of active coping during stress. 
 DBS and GBR treatments also altered protein expression in the IL, NAcc and 
NAcs. Our prior work has demonstrated significant correlations between mTOR 
expression in the IL and FST immobility time (Walker, Foley et al., 2014). Here we 
determined whether FST behavioral effects were associated with changes in mTOR 
expression as well as D2R and S6K levels. Consistent with our prior work, reduced 
immobility in the FST (antidepressant efficacy) was associated with increased 
activation of mTOR (pmTOR/mTOR) in the IL of DBS-treated animals. 
Additionally, we observed a decrease in IL D2R. Mesoprefrontal stress activation, 
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which enhances dopamine activity (Horger and Roth, 1996; Kaneyuki, Yokoo et al., 
1991), may be potentiated by NAc DBS. Dopamine activity depletion has been 
associated with elevated D2R-mRNA levels (Angulo, Coirini et al., 1991; Dunlop and 
Nemeroff, 2007) and it is possible that the opposite effect is true, however there is no 
evidence that increased dopamine activity reduces D2R expression. Additionally, this 
effect is not observed with GBR treatment. In NAc regions, GBR treatment elevated 
NAcc p70 S6K and lowered NAcs p85 S6K in the DBS and SAL groups respectively. 
Also, NAc DBS also lowered NAcs p85 S6K. S6K levels are typically a good marker 
for mTOR activation because of mTOR’s role in directly phosphorylating S6K. 
However, this association was not represented in the current study’s experimental 
design, and more research is needed to determine what these NAc S6K modifications 
represent. 
 The work presented provides further evidence to support the antidepressant 
effects of NAc DBS as well as the mania-like actions of GBR. It also supports a 
dysregulated dopamine system of the mesocorticolimbic circuit through ACTH 
induction, resulting in altered sensitivity and responsivity to dopamine activity 
modulating drugs like GBR. This is evident through the differential psychomotor 
effects of GBR in acute versus chronic monitoring (24-hour period) in the ADR rat 
model. Future development of this model may facilitate our understanding of this 
debilitating disease as it relates to dopamine dysregulation. 
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Abstract 
 Deep brain stimulation (DBS) provides antidepressant efficacy for treatment 
resistant depressed patients, however its interactions with concurrent psychiatric 
medication is not well investigated. These patients receive therapeutic benefits from 
antidepressant treatment augmented with the atypical antipsychotic risperidone. This 
study incorporates an adrenocorticotropic hormone (ACTH; 100 µg/mL/day, 14 
days)-induced antidepressant resistant rat model to investigate DBS (130 Hz, 200 µA, 
90 µs) interactions with i.p. risperidone (1 mg/kg) treatment on psychomotor 
behavior. Male Wistar rats (5 weeks) were administered i.p. ACTH or 0.9% saline 
(control group) daily for 14 days and some were bilaterally implanted with DBS 
electrodes in infralimbic cortex. On penultimate and final day, risperidone and/or 
DBS treatment was administered 45 and 60 minutes after ACTH respectively. Open 
field test (OFT) and forced swim test (FST) measured psychomotor response to 
treatments, and demonstrated attenuation in activity induced by risperidone. Although 
FST antidepressant screening was invalidated by open field locomotor discrepancies, a 
differential psychomotor response was detected through elevated FST and lowered 
OFT activity in risperidone-DBS/sham coupled groups. These results indicate 
DBS/sham interactions with risperidone treatment that can divergently affect 
psychomotor response to different stressor intensities, and provide future direction 
towards DBS-drug interactions studies for translational and clinical research. 
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Introduction 
The role of mesocorticolimbic dopamine in mood disorders and therapeutic is 
becoming increasingly appreciated (Berk, Dodd et al., 2007; Brown and Gershon, 
1993; Chaudhury, Walsh et al., 2013; Cousins, Butts et al., 2009; Nestler and Carlezon, 
2006; Tremblay, Naranjo et al., 2005). The mesocorticolimbic (Ordway, Klimek et al., 
2002) dopaminergic circuitry, generally implicated in reward and cognition, has also 
been implicated in the pathophysiology of depression (Willner, 1997) and bipolar 
disorder (Berk, Dodd et al., 2007). It is generally hypothesized that diminished 
dopamine output contributes to development of a depression-like state (Dunlop and 
Nemeroff, 2007), whereas elevated dopamine output precipitates symptoms of mania 
and psychosis (Swerdlow and Koob, 1987). Furthermore, the dopamine transporter 
synaptic clearance system has been reported to be expressed in altered concentrations 
(Laasonen-Balk, Kuikka et al., 1999; Rao, Kellom et al., 2012) and functionality 
(Meyer, Krüger et al., 2001) in affective states. Dopamine release in regions such as 
the nucleus accumbens (NAc) binds to and activates g-protein coupled dopamine 
receptors (DRs) type 1 and 2. DRs are expressed in high concentration in the ventral 
striatum and implicated in dysfunctional reward processes and hyperlocomotive 
behaviors (Durieux, Bearzatto et al., 2009). Blocking DRs through antipsychotic drugs 
is clinically effective for treatment for mania symptoms in bipolar disorder (Swerdlow 
and Koob, 1987). Furthermore, patients suffering treatment resistant depression show 
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clinical benefits to antidepressants with augmented atypical antipsychotic therapy such 
as risperidone (Shelton and Papakostas, 2008; Thase, 2002). 
Previous work suggests that facilitation of dopamine neurotransmission has 
antidepressant actions in the ACTH-induced model of antidepressant resistance 
(Kitamura, Yagi et al., 2010). Here we investigate whether risperidone treatment may 
alter behavioral responses to DBS in this model. There is translational significance of 
addressing this question, given recent failures of clinical trials of DBS for depression 
and potential for patients to be on antipsychotics like risperidone. Little is known of 
the impact of risperidone on mesocorticolimbic deep brain stimulation (DBS) therapy. 
DBS of key limbic structures has been shown to be an efficacious intervention 
towards treating affective disorders including antidepressant resistant (ADR) 
depression (Dougherty, Rezai et al., 2015; Grubert, Hurlemann et al., 2011; 
Holtzheimer, Kelley et al., 2012; Kuhn, Lenartz et al., 2007; Mayberg, Lozano et al., 
2005), however this treatment’s underlying mechanism of action remain unknown 
(Dostrovsky and Lozano, 2002; Vitek, 2002). Infralimbic cortex (IL) DBS has been 
shown to produce antidepressant-like effects (Hamani, Diwan et al., 2010b) with 
maximal response being elicited with parameters of 200 µA and 130 Hz (Hamani, 
Diwan et al., 2010a). 
The aim of this study is to investigate the role of DRs for therapeutic DBS in 
our ADR model. This is performed by coupling the antidepressant effects of IL DBS 
with the DR blocking drug risperidone. DBS (130 Hz, 200 µA, 90 µs) is delivered for 
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2 days at 30 minutes per day and antidepressant screening is measured using the 
forced swim test (FST). We hypothesize that mesocorticolimbic antidepressant DBS 
functionally works at these parameters, in part, via the activation of DRs to elicit an 
antidepressant response in ADR animals. This work has important implications for 
the field as we work towards optimizing DBS treatment approaches in patients 
exposed to concurrent pharmacological treatments. 
 
Methods 
Animals 
All animal treatments and procedures were reviewed and approved by the 
Mayo Clinic Institutional Animal Care and Use Committee (IACUC). Five cohorts of 
male Wistar rats arrived at 5 weeks of age and were individually housed with chow 
and water available ad libitum. Animal vivarium was constantly controlled for 
temperature and humidity and had 12:12 hour light:dark cycles with lights on at 6AM. 
Animals were randomly assigned to 7 groups [Ris+DBS (n=9), Ris+Sham (n=8), 
DBS (n=11), Sham (n=8), Ris (n=13), ACTH (n=18), and Control (n=10)] (Table 1). 
 
Treatment Protocol 
Upon arrival, animals were acclimatized to their vivarium for the first 5 days, 
before beginning administration of daily intraperitoneal injections of ACTH (100 µg, 
1 mL) or saline (0.9%, 1 mL) routinely at ~10AM. On days 15 and 16, electrodes were 
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implanted as described below and animals were allowed to recover until day 20, with 
ACTH and saline treatments continuing over this period. After recovery, risperidone-
treated animals received intraperitoneal injections of risperidone 45 minutes after 
ACTH injections. DBS animals then received IL DBS 60 minutes after ACTH 
injections (and/or 15 minutes after risperidone injections) for 30 minutes. Animals 
then underwent the open field test (OFT) for 6 minutes and then FST training 
exposure (15 minutes). On day 21, treatments were repeated prior to the FST test (6 
minutes). Thirty minutes following the FST, animals were euthanized. Cardiac blood 
was collected and centrifuged at 1400 rpm to collect plasma supernascent. Brains were 
then collected and all samples were stored at -80°C. Figure 1 illustrates this 
experimental timeline. 
 
Table 1 - Study treatment groups with each group’s treatments described.
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Figure 1 - Experimental timeline with each treatment and test performed per day. 
Behavioral tests are illustrated above and treatments are illustrated below. 
 
Surgery 
 Animals allocated to the DBS or sham groups were anesthetized with 
isoflurane via inhalation (3.0% induction, 1.5% maintenance) and placed in a 
stereotactic frame (David Kopf Instruments, CA, USA). Twisted bipolar stimulating 
electrodes (PlasticsOne, VA, USA) were implanted bilaterally into the IL (AP: +3.0 
mm; ML: +/-0.6 mm; DV: -5.0 mm from bregma) (Paxinos and Watson, 2005). 
Cranial screws were affixed to anchor dental cement and electrodes in place. Animals 
were monitored closely throughout the recovery period. 
 
Injections 
 All animals received daily intraperitoneal injections of 1 mL ACTH (100 µg; 
Anaspec, CA, USA) or 1 mL saline (0.9%) solution during the animal’s circadian nadir 
(~10AM). Risperidone (Sigma-Aldrich, MO, USA) solution was made on the day of 
the first injections with saline solution as the solvent and was pH controlled with 
203
sodium hydroxide. Risperidone (1 mg/kg) injections occurred 45 minutes after ACTH 
injections on day 20 and 21. 
 
Deep Brain Stimulation 
Animals receiving IL DBS (130 Hz, 200 µA, 90 µs) were connected to ISO-
Flex Master-8 (AMPI, Jerusalem, Israel) stimulator. DBS for 30 minutes was 
administered 60 minutes after initial ACTH injections (and/or 15 minutes following 
risperidone injections) on day 20 and 21.  
 
Open Field Test 
 The OFT was performed 90 minutes after ACTH/saline injections (and/or 45 
minutes after risperidone injections/30 minutes after DBS). Rats were placed in the 
center of the floor of a square-shaped box (59.7 x 59.7 x 43.2 cm) and are allowed to 
freely move while being monitored under overhead camera. Flood lights were placed 
far over each box to diminish shadows in the box that may affect rat position and 
movements. Animals were recorded for 6 minutes and later analyzed using TopScan 
software (Cleversys Inc, VA, USA) for total distance travelled and total time spent in 
center regions. 
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Forced Swim Test 
 Animals were placed into acrylic cylinder (47 cm height, 19 cm diameter) filled 
28 cm from bottom with room temperature (25 +/- 2°C) tap water. A training session 
was performed on day 20 for 15 minutes, prior to the subsequent test exposure on 
day 21. Behavior was recorded by video for later analysis. Following each FST 
exposure, animals were placed under a heat lamp for 30 minutes to dry. As for the 
OFT, animals were administered ACTH/saline (and/or 45 minutes after risperidone 
injections/30 minutes after DBS) prior to the FST-test exposure. Video of the last 4 
minutes of FST-test session were analyzed via hand-scoring by a rater blinded to the 
specific treatment. Time spent performing immobile, swimming, or climbing 
strategies, as well as latency to immobility (first 2 seconds of immobility) were 
quantified. 
 
Euthanasia and Tissue Collection 
 Thirty minutes following the FST-test session, animals were administered 0.8 
mL FatalPlus (Vortech Pharmaceuticals, MI, USA) i.p. Cardiac blood and brain tissue 
were collected. Blood is centrifuged at 1400 rpm for 10 minutes and plasma 
supernatant was collected. Whole brain and plasma were frozen at -80°C. 
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Statistical Analysis 
 One-way analysis of variants (ANOVA) was then performed along with Sidak’s 
post-hoc test. Post-hoc tests were performed only between groups that were different 
by one treatment (i.e. Ris+DBS vs. Ris+Sham; Ris+DBS vs. DBS; Ris+DBS vs. Ris; 
Ris+Sham vs. Sham; Ris+Sham vs. Ris; DBS vs. Sham; DBS vs. ACTH; Sham vs. 
ACTH; Ris vs. ACTH; ACTH vs. Control). For example, saline-controls were only 
compared to ACTH group as all other groups were administered ACTH as well as 
additional treatments. Significant difference was defined as p<0.05 and nonsignificant 
trending difference was defined as p<0.08. Trending differences were incorporated on 
justification that true difference may exist with higher power studies and should be 
noted as such. Behavioral data were analyzed using GraphPad Prism 6.0 software. 
Outliers were identified as datapoints exceeding 2 standard deviations above or below 
the mean for each group’s behavior.  
 
Results 
Forced Swim Test 
 Antidepressant effects of IL DBS were demonstrated through reduced 
immobility (p=0.0456; t-test). Risperidone significantly raised immobility time in all 
groups (DBS<0.0001; sham: p=0.0053; ACTH: p<0.0001). Among the risperidone 
treated groups, immobility time was nonsignificantly decreased by DBS (p=0.0618) 
and significantly decreased by sham (p=0.0240) treatment [Figure 2A; p<0.0001, 
206
F(DFn, Dfd)=20.15 (6, 70)]. No differences in latency to immobility was observed 
[Figure 2B; p=0.2545, F(DFn, Dfd)=1.335 (6, 66)]. Risperidone significantly 
decreased climbing time in DBS (p=0.0422) and ACTH (p=0.0031) groups and 
nonsignificantly in sham (p=0.0649) group [Figure 2C; p=0.0002, F(DFn, Dfd)=5.256 
(6, 67)]. Risperidone also significantly decreased swimming time in all groups (DBS: 
p<0.0001; sham: p=0.0049; ACTH: p<0.0001). Swimming time was also significantly 
decreased by DBS (p=0.0033) among non-risperidone groups [Figure 2D; p<0.0001, 
F(DFn, Dfd)=14.22 (6, 68)]. 
 
 
Figure 2 - FST (A) Immobility time, (B) immobility latency, (C) climbing time, and 
(D) swimming. Data shown in Mean seconds +/- Standard Error. Significance is 
illustrated as *: p<0.05; **: p<0.01, ***p<0.001, ****: p<0.0001. Trends illustrated as 
‡: p<0.08.  
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Open Field Test 
 Risperidone significantly decreased total distance travelled during the 6 minute 
OFT in all groups (DBS: p<0.0001; sham: p<0.0001; ACTH: p=0.0007). Among 
risperidone treated groups, total distance travelled was significantly decreased by DBS 
(p=0.0038) and sham (p=0.0015) treatment [Figure 3A; p<0.0001, F(DFn, 
Dfd)=22.38 (6, 68)]. Risperidone significantly decreased total time spent in center 
region of the OFT arena in sham (p=0.0037) and ACTH (p=0.0010) groups. 
Additionally, ACTH treatment significantly increased total time spent in center region 
of the OFT arena compared to controls (p=0.0412) [Figure 3B; p<0.0001, F(DFn, 
Dfd)=6.799 (6, 67)]. 
 
 
Figure 3 - OFT (A) total distance travelled and (B) total time spent in center region 
of testing apparatus. Data shown in Mean seconds +/- Standard Error. Significance is 
illustrated as *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. Trends illustrated 
as ‡: p<0.08.  
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Discussion 
 Our results indicate the study was underpowered to validly demonstrate the 
antidepressant efficacy of 30 minute IL DBS, accounting for multiple comparisons. 
However, a post-hoc t-test (without Bonferroni correction), demonstrates that 
immobility was significantly reduced by DBS in ACTH treated animals and confirms 
its antidepressant efficacy. Here, we note that effect is small, relative to the drug 
effects of risperidone, due partly to low duration of DBS administration (30 minutes). 
However, in light of our ethical obligation to minimize animal usage, it was 
unreasonable to increase group numbers to specifically address this. In contrast, 
risperidone did significantly elevate immobility time in each group. However, here we 
observe depressed psychomotor activity as a result of risperidone administration in 
total distance travelled in the OFT. This would suggest that the elevated immobility 
time observed in FST may not truly represent depressogenic effects or its blockade of 
antidepressant efficacy, as it is confounded by our observation of depressed 
psychomotor activity. This is consistent with dose-dependent analysis of risperidone 
treatment.  
Risperidone blocks DR type 2-related behaviors in rats at an effective dose of 
0.016 mg/kg, and also blocks central serotonin-S2 receptor-related behaviors at an 
effective dose of 0.014 mg/kg (Janssen, Niemegeers et al., 1988). Locomotor 
inhibition has also been demonstrated at an effective dose of 0.029 mg/kg (Janssen, 
Niemegeers et al., 1988). Our risperidone dose was >30x (1 mg/kg), underscoring its 
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contribution to the observed psychomotor depression. Clinically, low dose augmented 
risperidone (0.25-2 mg/day) therapy provides antidepressant benefits in treatment 
refractory depressed (Mahmoud, Pandina et al., 2007) and major depressive disorder 
(Reeves, Batra et al., 2008) patients. Higher doses (as high as 6 mg/day) however 
provide symptomatic relief for bipolar patients experiencing mania and psychotic 
episodes with or without drug augmentation (Janssen, Niemegeers et al., 1988; Segal, 
Berk et al., 1998; Vieta, Gasto et al., 2001; Vieta, Goikolea et al., 2001; Yatham, 
Grossman et al., 2003) . It seems that risperidone’s primary mode of action at higher 
doses effects dopaminergic activity by blocking DRs, and therefore inducing primarily 
antipsychotic effects in these animals. 
Despite the dominating effects of risperidone on behavioral results, this study 
detects evidence of a treatment interaction between DBS and risperidone. When 
comparing all DBS/sham treatments groups, we observed elevated FST immobility 
and depreciated OFT locomotor activity in risperidone+DBS/sham groups compared 
to DBS/sham treatment alone. This further demonstrates risperidone’s effects in 
attenuating psychomotor behaviors. Interestingly however, between all risperidone 
groups, we observed a reduction in both FST immobility and OFT locomotor activity 
in risperidone+DBS/sham groups compared to risperidone treatment alone. It 
appears activity was attenuated by DBS/sham treatment in the low-stress OFT 
environment, yet was enhanced by DBS/sham treatment during forced swim stress. 
Therefore, there appears to be a differential response to stress-induced psychomotor 
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activity in risperidone groups receiving concurrent DBS/sham treatment. 
Furthermore, this study has potential for scientific and clinical interest as it provides 
evidence of DBS/sham interactions with drug treatment, which currently is minimally 
investigated in clinical research.  
These data encourage our future studies to incorporate longer DBS duration 
and dose-response drug comparisons to re-test our initial hypothesis. Future work will 
also analyze mesocorticolimbic protein modifications as a result of these treatments. 
Protein analysis in this study was not pursued because of the lack in observed 
antidepressant effect. Furthermore, risperidone concentration will be reevaluated to a 
lower dose to prevent significant psychomotor depression. Determining the 
underlying principles behind mesocorticolimbic DBS antidepressant effects continues 
to be an exciting venture and is critically important for the treatment of 
neurodegenerative diseases. 
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 
Abstract—Deep brain stimulation (DBS) devices deliver 
electrical pulses to neural tissue through an electrode. To study 
the mechanisms and therapeutic benefits of deep brain 
stimulation, murine preclinical research is necessary. However, 
conducting naturalistic long-term, uninterrupted animal 
behavioral experiments can be difficult with bench-top systems. 
The reduction of size, weight, power consumption, portability, 
and cost of DBS devices can assist the progress of this research in 
animal studies. A low power, low weight, miniature DBS device is 
presented in this paper. This device consists of electronic 
hardware and software components including a low-power 
microcontroller, an adjustable current source, an n-channel 
metal–oxide–semiconductor field-effect transistor, a coin-cell 
battery, electrode wires and a software program to operate the 
device. Evaluation of the performance of the device in terms of 
battery lifetime and device functionality through bench and in 
vivo tests was conducted. The bench test revealed that this device 
can deliver continuous stimulation current pulses of strength 200 
µA, width 90 µs, and frequency 130 Hz for 22.75 days. The in vivo 
tests demonstrated that chronic stimulation of the nucleus 
accumbens (NAc) with this device significantly increased 
psychomotor activity, together with a dramatic reduction in 
anxiety-like behavior in the elevated zero-maze test.  
Index Terms—Brain, deep brain stimulation, device, low-
power circuit, miniature, neurology, preclinical, psychiatry.  
I. INTRODUCTION
LINICAL deep brain stimulation (DBS) currently 
necessitates a neurostimulation device to supply electrical 
signals to a specific region of the brain through a chronically 
implanted electrode. Electrical stimulation of neural tissue has 
A. Z. Kouzani is with the School of Engineering, Deakin University, 
Geelong, Victoria 3216, Australia (corresponding author; phone: 
+61352272818; e-mail: kouzani@ deakin.edu.au). 
R. P. Kale is with the School of Engineering, Deakin University, Geelong,
Victoria 3216, Australia and the Department of Psychiatry and Psychology,
Mayo Clinic, Rochester, MN 55905, USA (e-mail: rajas.p.kale@gmail.com). 
P. P. Zárate-Garza is with the Department of Psychiatry of the Universidad
Autonoma de Nuevo León, Mexico (e-mail: dr.ppzg@gmail.com). 
M. Berk is with IMPACT Strategic Research Centre, School of Medicine,
Deakin University, Geelong, Victoria 3216, Australia (e-mail:
michael.berk@deakin.edu.au). 
K. Walder is with the School of Medicine, Deakin University, Geelong,
Victoria 3216, Australia (e-mail: ken.walder@deakin.edu.au). 
S. J. Tye is with the Department of Psychiatry and Psychology, Mayo
Clinic, Rochester, MN 55905, USA (e-mail: Tye.Susannah@mayo.edu). 
been employed to treat symptoms of neurological motor 
disorders such as Parkinson’s disease, as well as refractory 
neuropsychiatric indications, including obsessive-compulsive 
disorder and Tourette’s syndrome. DBS has also been trialed 
for treatment-resistant depression, severe drug and alcohol 
addiction, epilepsy, and chronic pain [1-2]. Understanding the 
chronic neurobiological adaptations occurring in response to 
DBS for psychiatric indications is necessary for optimizing 
these clinical approaches for the most severe, treatment 
refractory patients. In addition, DBS is used to model and 
study the pathophysiology of these disorders in preclinical 
murine models [3-4]. 
Small laboratory animal research enables investigation into 
the underlying therapeutic mechanisms and the benefits of 
DBS over time. DBS devices utilized in this research usually 
involve sophisticated circuitry, are large in size and weight, 
consume considerable power, require long cords to be 
connected to the implanted electrodes which impede mobility, 
and are costly. Accordingly, performing uninterrupted animal 
behavioral tests, which require long-term and continuous brain 
stimulation has been difficult. Therefore, a reduction in size, 
weight, power consumption, and cost of DBS devices, along 
with the elimination of the long connecting wires, can 
augment the progress of research studies that aim to uncover 
the therapeutic mechanisms and benefits of DBS. 
Several DBS devices have been reported in the literature 
that only minimally interfere with animal movement and 
behavior, and are consequently suitable for delivering chronic 
stimulation of the animal brain. These devices do not require 
the animal to be tethered, and are thus referred to as wireless 
DBS devices. 
Millard and Shepherd [5] reported an implantable stimulator 
which generates charge-balanced biphasic current pulses for 
chronic stimulation of neural tissue. The device is 
magnetically coupled, where the subject is placed in a 
chamber surrounded by orthogonal coils. Currents are induced 
in the coils of the stimulator to produce biphasic current pulses 
of up to 500 µA in amplitude. Pulse duration is adjustable 
within 25 to 250 µs per phase. Charge balance is maintained 
by capacitive coupling and shorting of the electrodes between 
pulses and stimulus rates can be varied. The stimulator was 
used for chronic stimulation of the auditory nerve. 
Liu et al. [6] described a head mountable device for DBS in 
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rats. The effect of chronic DBS of the rat nucleus accumbens 
on morphine reinforcement was evaluated. An electrode was 
implanted into the left hemisphere NAc core and was 
connected to the DBS device, which was fixed to the rat skull. 
The rat was administered a 130 Hz stimulation pulse once per 
day. However, the details of the circuitry of the developed 
device were not provided. 
Haas et al. [7] presented an implantable stimulation device 
for mice. It includes a stimulator, two electrodes, an infrared 
camera system, and a programming fixture to program the 
stimulation current. The stimulator housing consists of a 
polycarbonate cylinder with a screw top, and is 30 mm in 
length with a diameter of 8 mm. The total length of the lead 
system from the stimulator to the electrodes was 45 mm. The 
stimulator provides biphasic pulse patterns, and is battery 
powered. A coin magnet is used to switch the stimulator on or 
off. To maximize the battery life, the on-board microcontroller 
was put in standby mode in between two consecutive biphasic 
pulse patterns. The bench top validation and in vivo 
implementation of the device was presented. The details of the 
circuitry of the stimulator were not given. 
Rhew et al. [8] constructed a single-chip device involving 
low noise amplifiers, an analogue to digital converter, digital 
filters, a processor running a control algorithm, current 
stimulators, a wireless transceiver, and a radio frequency 
energy harvester. The device detects low-frequency brain field 
signals and uses them to provide closed-loop DBS. The size 
and weight of the device were not reported. The device is 
powered by the energy harvester, however, the on-board high-
current digital to analogue converters require a 5 V battery. 
Lee et al. [9] proposed a low cost brain stimulation device 
for animal studies. It consists of a silicone elastomer-
encapsulated stimulator and a liquid crystal polymer-based 
electrode array. The stimulator has a diameter of 22 mm, 
thickness of 5 mm, and a planar coil for data exchange and 
power delivery. The stimulation parameters are specified by 
the external controller through the planar coil.  The fabrication 
of the system is relatively simple and low-cost. 
Forni et al. [10] reported a microstimulator for rat DBS. The 
device is clipped to a support fixed on the animal’s head. It 
consists of a stimulating electrode, a stimulator support, and 
an electrical portable microstimulator. The microstimulator is 
made of an adjustable pulse generator and a voltage-to-current 
converter. The power supply consists of two 3 V lithium coin 
batteries connected in series. The microcircuit is coated with a 
polyurethane resin. Its weight is 5.6 g with the resin protective 
coat, and 7.4 g with the batteries. The initial setting of the 
current parameters was done using an oscilloscope and a 15 
kΩ resistance. Continuous DBS of the subthalamic nucleus in 
a classical rat model of Parkinson’s disease was performed. 
Lee et al. [11] developed a head-mounted wireless DBS 
system, which contains a current-controlled stimulator that 
reads stimulation site potentials and automatically adjusts the 
stimulation voltage, and a rectifier that creates variable DC 
voltages between 2.5 V and 4.6 V at 2.8 mA loading from a 5 
V peak AC at 2 MHz power supply through active 
synchronous switching. The stimulator consists of a closed-
loop active charge balancing module, and can receive the 
stimulation parameters wirelessly. The wireless DBS system 
was fabricated into a CMOS chip. The size and weight of the 
device were not reported. The prototype wireless stimulating 
system was verified in vitro. 
Ewing and Grace [12] presented a device for continuous 
DBS in rats. It was configured to stimulate with square, 
monophasic, anodic, constant current 100 ms pulses at a 
frequency of 130 Hz and amplitude of 100 mA. The device 
was placed in a rodent jacket and linked to the electrodes via 
an external cable. It was used to examine how five days of 
stimulation affected rhythmic brain activity in freely moving 
rats. The details of the device circuitry were not given. In 
another paper, Ewing et al. [13] defined a set of design criteria 
and proposed an improved preclinical DBS device. This 
device is programmable in relation to: current strength, 
frequency, and pulse duration. It has a rechargeable battery, 
and delivers biphasic, charge-balanced stimulation pulses to 
two electrodes. The device can stimulate the target tissue over 
a range of electrode/tissue impedances with stimulation 
currents up to 1 mA. It can be implanted or used externally 
with the aid of a rodent jacket. The weight of the device is 
11.5 g, and its dimensions are 33 mm × 20 mm × 8 mm. It 
uses a supply voltage of 3.6 V. 
Previously, Kouzani et al. [14] developed a low power and 
lightweight portable DBS device for laboratory animals. The 
device employs passive charge balancing. It can be carried by 
the animal during the course of a preclinical trial, and that it 
can produce stimulation current pulses of desired 
characteristics for over 10 days. 
Considering the key devices described in the above notes, 
as well as others reported in the literature, most of the existing 
devices have certain shortcomings. The device by Millard and 
Shepherd [5] requires a magnetic field produced by applying a 
high voltage to the excitation coil, which can have unwanted 
effects on the animal. Also, the animal is restricted and can 
only move in a small chamber. The device by Liu et al. [6] 
does not consider charge balancing of the stimulation pulse. 
Also, the weight and the internal circuitry of the device were 
not given. The device by Haas et al. [7] needs fixed resistors 
to be replaced for altering the properties of the stimulation 
current. The size of the device is large, and it can only 
stimulate for several hours. The device by Rhew et al. [8] 
needs both an energy harvester and a battery to operate. The 
size and weight of the device were not reported. The device by 
Lee et al. [9] is relatively large in size. The weight of the 
device was not reported. The device by Forni et al. [10] is of 
large size, and can operate for only seven days. The device by 
Lee et al. [11] needs a 5 V peak AC power supply. The size 
and weight of the device were not reported. The device by 
Ewing et al. [13] offers many features, however, it has a large 
size and weight compared to other existing devices. 
The costs of the majority of existing devices reported in the 
literature have not been reported in the associated 
publications. Considering the features of the current devices 
including size, weight, battery life, cost, and so on, it is 
evident that further research is still required to develop yet 
220
1534-4320 (c) 2016 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/TNSRE.2016.2628760, IEEE
Transactions on Neural Systems and Rehabilitation Engineering
TNSRE-2015-00418.R1 3
new devices that can help improve such characteristics as size, 
weight, power consumption, cost, safety, stereotactic 
mounting procedure, maintenance requirements, and so on. 
II. DBS SYSTEM
The developed DBS system comprises hardware and 
software components. The hardware component includes: (i) a 
low-power DBS device including a pico-power 
microcontroller, an adjustable current source, an n-channel 
metal–oxide–semiconductor field-effect transistor 
(nMOSFET), a micro pushbutton, an LED, two capacitors, 
two resistors, a coin-cell battery, a battery holder, a two-way 
surface mount communications microheader, a four-way 
surface mount in-system programming (ISP) microheader, a 
two-way surface mount electrode header, two electrode wires, 
and an electrode, and (ii) a programmer device including an 
Arduino Nano, a universal serial bus (USB) interface, 
communications wires and connector, and power wires and 
jumper. 
The software component includes: (i) a program in C 
language implementing the operation of the device including 
delivery of the desired DBS current pulses, as well as polled 
software universal asynchronous receiver transmitter (UART) 
serial communications for receiving stimulation parameters 
from the programmer, and (ii) a program in C language that is 
executed on the Arduino-Nano-based programmer for 
receiving the stimulation parameters from the user and 
sending them via a serial port to the DBS device.  
III. LOW-POWER DBS DEVICE 
The schematic diagram of the proposed miniature, portable, 
and low power DBS device is given in Figure 1. The hardware 
and software parts of the device are described in the following. 
A. ATtiny 44A
The key part of the device is an Atmel ATtiny 44A
microcontroller [15]. It is a pico-power 8-bit microcontroller 
featuring 4KB flash program memory, 256B data static 
random access memory (SRAM), 256B electrically erasable 
programmable read-only memory (EEPROM), 12 general 
purpose input/output (I/O) lines, an 8-bit timer/counter, a 16-
bit timer/counter, internal and external interrupts, an 8-channel 
10-bit analog to digital converter (ADC), a programmable
watchdog timer, an internal calibrated oscillator, and four
power saving modes. It can operate with a voltage source
within the range 1.8-5.5 V. Its program memory can be
reprogrammed in-system through a serial peripheral interface
(SPI). The ATtiny 44A provides four software selectable
power saving modes. In idle mode, the central processing unit
(CPU) ceases operation while the timers/counters, watchdog
timer, ADC, analog comparator, and interrupt module
continue operating. In ADC noise reduction mode, the CPU
stops working but the ADC, external interrupts, and watchdog
timer can operate. In this mode, the switching noise during
ADC conversions is reduced enabling higher resolution
measurements. In power-down mode, the internal oscillator is
stopped, however the external interrupts, and watchdog
continue operating. This mode halts all clocks, allowing
operation of asynchronous modules only. In standby mode, the
internal oscillator is active while the rest of the device is
sleeping, allowing very fast start-up combined with low power
consumption.
The microcontroller is supported by a suite of programs as 
well as system development tools such as C compiler, macro 
assembler, and a program debugger/simulator. Atmel Studio is 
an integrated development platform for developing and 
debugging the Atmel microcontroller based applications. 
A 100 nF capacitor is used between the VCC and GND pins 
of the microcontroller to bypass any undesired high-frequency 
signals to ground. The 16-bit Timer/Counter 1 unit of the 
ATtiny 44A is used to create the required stimulation 
waveform. It facilitates precise wave generation, event 
management, and signal timing measurement. The unit is 
programmed to work as a free running timer. It can be clocked 
Fig. 1.  Circuit diagram of the DBS device.
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internally, via a prescaler. In this work, it is set to clock 
internally with the frequency of 1MHz. A double buffered 
output compare register is compared with the timer/counter 
value at all times. The result of this comparison is then used 
by a waveform generator to generate a pulse width modulated 
or variable frequency output on an output compare pin. The 
output compare pin A (OC1A) of the timer/counter, which is 
available on Pin 7 of the microcontroller, is used to create the 
stimulation waveform. 
The ATtiny 44A has an 8-channel 10-bit successive 
approximation ADC, which can be used to measure the 
voltage at eight single-ended input pins. The single-ended 
voltage inputs are measured against 0V (GND). In this work, 
VCC is used as reference voltage for the single-ended 
channels. The channel 0 input of the ADC (ADC0) which is 
available on Pin 13 of the Microcontroller is connected to the 
main terminal of the two-way electrode header to determine 
the presence of connection to the stimulation electrode 
implanted into the target brain tissue. When present, the pre-
specified current goes through the target brain tissue and the 
associated voltage drop across the stimulation electrode can be 
sensed by reading the ADC data register. When absent, the 
flow of stimulation current to the stimulation electrode will 
not be established. 
Bit 1 of Port B, which is available on Pin 3 of the 
microcontroller, is used as an input pin driven by a micro 
pushbutton. The internal pull-up resistor is activated for this 
pin to support the operation of the pushbutton. Bit 2 of Port B, 
which is available on Pin 5 of the microcontroller, is used as 
an output pin to control an LED through a 100 Ω resistor. 
A polled software UART port for providing the user 
selected stimulation parameters to the device is established via 
bits 0 and 1 of Port A, which are available on Pins 13 and 12 
of the microcontroller respectively, where PA0 implements 
RxD and PA1 realises TxD lines. An ISP port for in-system 
programming of the main C program into the ATtiny 44A is 
formed via bit 3 of Port B (Reset), bit 4 of Port A (SCK), bit 5 
of Port A (MISO) and bit 6 of Port A (MOSI). 
B. PSSI2021 
The PSSI2021 [16] is a constant current source with 
stabilized output current of between 15 µA and 50 mA. The 
output current can be adjusted by connecting an external 
resistor Rext to the chip as follows: 
ܫ௢௨௧ ൌ ଴.଺ଵ଻ோ೐ೣ೟ ൅ 15	μA                               (1) 
Without an external resistor, the output current will be 
typically 15 µA. For our desired current amplitude of 200 µA, 
Rext = 3.3 kΩ is attached to the PSSI2021. 
C. SSM3K03FE 
SSM3K03FE is an nMOSFET device with high input 
impedance, low gate threshold voltage Vth = 0.7~1.3 V, and 
2.5 V gate drive for analogue and high-speed switching 
applications. The nMOSFET operates as a switch whose 
ON/OFF state is controlled by the OC1A pin of 16-bit 
Timer/Counter 1 unit. A 100 nF ac-coupling capacitor is used 
to establish passive charge balancing to minimize unwanted 
effects including tissue damage. When the nMOSFET is OFF, 
the PSSI2021 current output is delivered to the stimulation 
electrode via the capacitor. Alternatively, when the nMOSFET 
is ON, the electrode is connected to the ground to allow the 
capacitor to discharge.  
D. Electrode 
To achieve charge administration into the target tissue, a 
stimulation electrode is used. An electrode by PlasticsOne that 
includes a stainless steel twisted wire electrode extending 
below a threaded plastic pedestal is employed. The threaded 
plastic pedestal accepts the captive collar of a plug. The 
pedestal is secured with dental cement and mounting screws 
affixed to the skull. A surface mount 2-way header as well as 
32 AWG lead wires are used to connect the output of the DBS 
device to the stimulation electrode. 
E. Battery 
A cell button lithium manganese dioxide battery CR2032 of 
nominal voltage 3 V is used to supply power to the DBS 
device for the duration of a pre-clinical experiment. The 
diameter and the height of the battery are 20 mm and 3.2 mm, 
respectively. The average weight of the battery is 2.8 g, and its 
rated capacity is 235 mAh. 
F. Software 
A software program was developed in C language and 
uploaded into the program memory of the ATtiny 44A. The 
pseudo-code for the program is presented in Figure 2. 
In the first step, data direction for output port pins is set. 
The two data direction registers DDRA and DDRB are 
initialized to set the OC1A (PA6), TxD (PA1), and PB2 pins 
as output pins. The other I/O pins are configured as input pins. 
In the second step, the status of the pushbutton is read from 
PB1.  
In the third step, a stimulation-parameters programming 
mode is entered if the pushbutton is pressed. In this mode, a 
polled software UART function, which is run on the ATtiny 
44A, receives from the Arduino Nano-based programmer four 
bytes representing the width of the stimulation pulse (bytes 0 
and 1) as well as the frequency of the stimulation pulse (bytes 
2 and 3) provided by the user. The four received bytes are then 
written into locations 0 to 3 of the internal EEPROM of the 
ATtiny 44A. Then, the programming mode is terminated and 
the normal operation of the main program is resumed. It 
should be noted that initially a default stimulation waveform 
of width 90 µs and frequency 130 Hz is selected during the 
programming of the main program into the ATtiny 44A by 
writing the corresponding values into the four EEPROM 
locations. This means that if the user never selected to enter 
the programming mode, the device will output the stimulation 
waveform of width 90 µs and frequency 130 Hz by default. 
In the fourth step, the contents of the EEPROM locations 0 
and 1 are read to obtain the stored stimulation width before 
commencement of the stimulation. 
In the fifth step, the contents of the EEPROM locations 2 
and 3 are read to obtain the stored stimulation frequency 
before commencement of the stimulation. 
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Fig. 2.  Pseudo-code for the program that operates the DBS device. 
 
In the sixth step, the LED is continuously flashed for the 
user until the user presses the pushbutton commanding the 
start of the device operation. 
In the seventh step, the ADC is enabled by setting its 
ADMUX and ADCSRA registers. VCC is used as the analog 
reference. Single ended input ADC0 is selected. We then write 
one into ADEN bit to enable the ADC. Also, to enable the 
conversion, one is written into ADC bit. 
In the eighth step, a polling approach is used to 
continuously read the voltage on ADC0. The examination of 
ADC0 is repeated until the presence of connection to the 
electrode is detected. 
In the ninth step, power reduction is activated through 
disabling unnecessary peripheral clock signals by initializing 
the PRR register. 
In the tenth step, the 16-bit Timer/Counter 1 module is 
initialized to produce the desired stimulation waveform. It acts 
as a free running timer. A clocked of frequency 1 MHz is 
internally connected to the timer. The fast pulse width 
modulation (PWM) mode 14 of the timer is chosen. The timer 
counts from a bottom value to a top value, then restarts from 
the bottom value. The stimulation waveform is selected by 
initializing the ICR1 and OCR1A registers. By varying the 
content of the control registers of the timer, the output 
waveform can be adjusted. 
In the final step, the ATtiny 44A is programmed to enter the 
idle mode to maximize the battery lifetime. Accordingly, all 
unused modules in the microcontroller are shut down. The 
CPU and the execution of the program is halted as well. 
Nonetheless, the timer 1 continues providing the desired 
waveform on OC1A. 
G. Whole Device 
A two-layer printed circuit board is designed to host the 
components of the DBS device. The shape of the board is 
selected in such a way to allow the board to be secured under a 
20 mm coin-cell battery holder. All the components are 
mounted on the top layer. The board is then soldered to the 
two terminals beneath the battery holder. The size of the board 
is 15mm × 18 mm. Figure 3 shows the assembled DBS device, 
the lead wires, and the electrode. The weight of the board is 
0.92 g, the weight of the battery is 2.83 g, the total weight of 
the battery and the battery holder is 3.83 g, and the overall 
weight of the entire device is 4.75 g. The device, battery 
holder and battery are placed inside a pouch hooked to a rat 
jacket. The jacket is secured by using a velcro fastener for a 
firm fit. The jacket is then placed on the back of the animal. 
This configuration allows the battery to be replaced. 
 
 
Fig. 3.  Complete DBS device including DBS board, battery holder, battery, 
lead wires, electrode terminal, and electrode. 
IV. PROGRAMMER 
To receive the desired stimulation parameters (width and 
frequency) from the user and send them to the DBS device, a 
programmer device was developed. It includes an Arduino 
Nano, a USB cable, communications wires and connector, and 
power wires and jumper. A picture of the programmer device 
which is attached to a computer via the USB interface, and 
connected to the DBS device undergoing the programming is 
shown in Figure 4. The main hardware and software parts of 
the programmer device are described in the following. 
A. Arduino Nano 
Arduino Nano is a small board incorporating an ATmega 
328 microcontroller [17]. The board can be powered via a 
mini-B USB interface. It has 32 KB of program memory for 
storing code include a 2 KB bootloader. It has 14 digital pins 
that can be programmed as input or output pins, or some 
specialized functions such as serial communications interface, 
external interrupts, PWM outputs, SPI port, etc. The board 
also has 8 analog input pins, each providing 10-bit resolution. 
Two of these pins can also provide an I2C interface. The board 
is programmed with the Arduino software. A bootloader 
Begin  
1. Set data direction for output port pins. 
2. Read the pushbutton status at start. 
3. If pushbutton is pressed enter programming mode: 
 a. Obtain the first byte of stimulation width from 
programmer.  
 b. Obtain the second byte of stimulation width from 
programmer. 
 c. Obtain the first byte of stimulation frequency 
from programmer.  
 d. Obtain the second byte of stimulation frequency 
from programmer. 
 e. Store the two bytes of stimulation width into 
locations 0-1 of EEPROM. 
 f. Store the two bytes of stimulation frequency into 
two locations 2-3 of EEPROM. 
4. Read stimulation width from locations 0-1 of 
EEPROM. 
5. Read stimulation frequency from locations 2-3 of 
EEPROM. 
6. Flash LED and wait for pushbutton press. 
7. Program ADC Channel 0.  
8. Read ADC0 voltage and wait if electrode not 
connected.    
9. Set power reduction by disabling unnecessary 
peripheral clock signals.  
10. Program Timer 1 in fast pulse width modulation 
mode 14. 
11. Put the microcontroller in the idle mode. 
End 
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residing in the program memory of the ATmega 328 enables 
uploading of the main program via the USB interface. 
The board provides a 5V output pin which is used to power 
the DBS device connected to the programmer during the 
course of the stimulation-parameters programming. The DBS 
device can operate with a power source within the range 1.8-
5.5V. A 2-wire serial interface is used to transmit the user 
selected stimulation parameters to the DBS device. Pins 2 and 
3 of the Arduino Nano are used as RxD and TxD pins to 
implement a software UART for communications with the 
DBS device. This 2-wire interface is plugged into a 2-way 
surface mount microheader placed on the DBS device for 
establishing the serial communications. The reason for not 
using the UART hardware unit of the ATmega 328 is that this 
unit is needed for serial communications with the computer. 
This communications interface is used to interact with the user 
for receiving the desired stimulation parameters from the user. 
Fig. 4.  Programmer. 
B. Software
A software program was developed in C language and
uploaded into the program memory of the ATmega 328. The 
program implements a user interface on a computer, and serial 
communications with the DBS device. The pseudo-code for 
the program is given in Figure 5. 
Fig. 5.  Pseudo-code for the code that operates the programmer. 
In the first step, data direction for Pins 2 and 3 (RxD and 
TxD) is set. In the second step, a serial interface with the 
computer is opened using 8-bit data, and 9600 baud rate. In 
the third step, the user is prompted to enter the stimulation 
width. This parameter is then received from the user. In the 
fourth step, the user is prompted to enter the stimulation 
frequency. This parameter is then received from the user. In 
the fifth step, the program waits until receiving a control byte 
from the DBS device. In the sixth and seventh steps, the two 
bytes associated with the stimulation width will be transmitted 
to the DBS device and the program waits to receive the echo 
of each transmitted byte as acknowledgement. In case of an 
error, the whole operation is terminated and an error message 
is displayed for the user. In the eighth and ninth steps, the two 
bytes associated with the stimulation frequency will be 
transmitted to the DBS device and the program waits to 
receive the echo of the transmitted bytes as acknowledgement. 
In case of an error, the whole operation is terminated and an 
error message is displayed for the user. In the final step, a 
message is displayed for the user and the communication is 
terminated. 
The Serial Monitor tool of the Arduino software is used as 
the user interface tool. As an example, Figure 6 shows an 
example of the programming of the DBS device by the user. 
In this example, the user has set the stimulation width to 100 
µs and the stimulation frequency to 150 Hz. 
Fig. 6.  User interface for the programmer. 
V. EXPERIMENTAL RESULTS
The DBS device was constructed and its performance 
evaluated in terms of battery lifetime and device functionality. 
In order to test the device, first a resistive model of rat brain 
tissue was first used. A new 235 mAh cell button battery 
CR2032 was inserted into the battery holder. The default 
stimulation waveform of width 90 µs and frequency 130 Hz 
was used. During the continuous operation of the device, its 
steady state current consumption was measured using a 
Keithley 2401 SourceMeter which can measure current in the 
range 10 pA - 1 A. In its steady state operation, the device 
consumed around 425 µA. The SourceMeter was programmed 
to measure and store the battery voltage every 15 minutes. The 
measurement was performed at non-regulated room 
temperature. Figure 7 shows the change in the battery voltage 
during the course of the bench test. It can be observed from 
Begin  
1. Set data direction for Pins 2 and 3 (RxD and TxD).
2. Initiate a serial interface with computer.
3. Receive stimulation width from the user.
4. Receive stimulation frequency from the user.
5. Wait for DBS device to connect.
6. Send the first byte of stimulation width, and wait
for echo of the same byte.
7. Send the second byte of stimulation width, and
wait for echo of the same byte.
8. Send the first byte of stimulation frequency, and
wait for echo of the same byte.
9. Send the second byte of stimulation frequency, and
wait for echo of the same byte.
10. Terminate communications.
End 
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the figure that the battery voltage was stable for 22 days. After 
that, the voltage deteriorated rapidly. Overall, the device 
produced the stimulation pulses for 22.75 days at which points 
the battery voltage dropped below 1.8 V which is the lowest 
operating voltage of the ATtiny44A microcontroller. 
Next, in vivo tests were carried out at Mayo Clinic 
Rochester to validate the DBS device through effects on 
measures of anxiety-like behaviour in a laboratory rat. The 
default stimulation pulses of width 90 µs, frequency 130 Hz, 
and amplitude 200 µA were employed. 
Fig. 7.  Variation of the battery voltage under continuous operation of the 
DBS device in a laboratory setup. 
A. Surgery
The device was used on a Wistar rat after recovery from
surgical implantation of a bipolar twisted electrode into the 
left NAc. The animal was placed under stereotaxis with 
isoflurance anesthesia inhalation (3.0% during induction and 
2.0% during maintenance) and the electrode was implanted 
into the NAc core. Coordinates from Bregma (flat skull) are 
A-P = +1.5 mm, M-L = +1.5 mm, D-V = -7.2 mm. Figure 8
demonstrates proper post mortem electrode implantation into
the NAc core of the DBS animal with expected levels of tissue
damage around the electrode tract consistent with our previous
studies [18].
Fig. 8.  Left: Schematic illustration of coronal rat brain slice at NAc region 
(+1.5 mm AP from bregma). Image modified from Paxinos & Watson “The 
Rat Brain in Stereotactic Coordinates (2005). Right: Whole brain photograph 
of NAc DBS animal that was sliced to the site of electrode implantation. 
Partial electrode tract mark is visible from this slice. 
The animal was allowed to recover for three days post-
surgery before the DBS device was attached and activated. 
The device was placed inside of a pouch and affixed to a rat 
vest (Harvard Apparatus) such that it was secured on the back 
of the animal. Two sham rats were used as controls to 
compare anxiolytic results of electrical stimulation with 
electrode implantation alone. The sham electrodes were 
implanted with the same coordinates as the DBS rat. 
B. Clocklab
The DBS animal was housed under a 12:12 hour dark:light
cycle (lights on at 6:00AM). Psychomotor activity was 
recorded using an infrared motion detector interfaced with a 
computerized data acquisition system (Clocklab) and further 
analyzed using Matlab. Activity profiles were recorded based 
on total counts detected, and subsequently analyzed for time 
periods before surgery, during surgical recovery, and during 
DBS over 2 days for each condition. 
C. Elevated Zero-Maze Test
One day prior to surgery and again after 3 days with DBS or
sham treatment, the animal was placed onto an Elevated Zero-
Maze (EZM) Test, which is a validated model of anxiety [19], 
and behavior was recorded with an overhead video camera. 
The EZM Test monitors the animal’s anxiety by recording the 
duration of time the animal spends in either the enclosed zone 
(area associated with low anxiety) or the open area (area 
associated with high anxiety). The animal was placed into one 
closed-wall side for a duration of 10 minutes and monitored 
for time spent in each zone. During these times the animal is 
free to wander throughout the maze. DBS device, pouch, and 
jacket were removed for the duration of the test for safety 
reasons so that the animal or the device does not get stuck in 
the narrow corridors of the maze. It is established that the 
animal will reside in regions of the maze in accordance with 
its level of anxiety [20]. Figure 9 shows the DBS device setup, 
rat jacket used in the test, rat on the circle maze with 
implanted electrode without DBS device, and rat with the 
DBS device. 
D. Results and Discussions
A significant increase in psychomotor homecage activity
was observed between both pre-surgery and DBS (p=.003) and 
between recovery and DBS (p=.015) (Figure 10). Activity was 
averaged to reflect number of counts per day. These data 
indicate that NAc DBS increased behavioral activity for these 
animals. Stimulation of the NAc is typically correlated with 
the observed increase in psychomotor behavior and 
impulsivity [21]. A reduction in anxiety-like behavior was 
observed in the EZM Test following DBS (Figure 11). No 
such observation was made for both sham animals. Instead, 
the sham treatment increased animal preference for the 
enclosed zone associated with higher anxiety levels. DBS 
results correlate well with reported anxiolytic effects of NAc 
DBS [22] and demonstrate behavior modifications through 
electrical stimulation. Electrode implantation alone may have 
opposite effects as demonstrated by the consistent percent 
increase (~9.5%) in both sham animals. 
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Fig. 9.  (a) DBS device setup. (b) Rat jacket. (c) Rat on the zero-maze without 
DBS device. (d) Rat with the DBS device. 
 
Table I gives a comparison of the DBS device versus some 
current devices that employ batteries as their power source. 
The device offers a small size, and longer term higher strength 
stimulation current pulses. 
VI. CONCLUSION 
This paper presents the design, implementation, and 
evaluation of a low power, low weight, miniature deep brain 
stimulation device for use in preclinical research involving 
laboratory animals. This device enables long-term brain 
stimulation in freely moving laboratory animals to study 
therapeutic benefits of DBS and model neuropathological 
features in preclinical models in a number of neuropsychiatric 
disorders. The device is placed in a jacket and mounted on the 
animal’s back and carried by the animal during the course of 
the trial. It delivers non-stop current pulses of desired 
characteristics. It includes a low-power microcontroller, an 
adjustable current source, an n-channel metal–oxide–
semiconductor field-effect transistor, a coin-cell battery, 
electrode wires, an electrode, and a program implementing the 
operation of the device. After construction, the performance of 
the device was evaluated through bench and in vivo tests. 
During the bench test, the device was able to deliver on-going 
current pulses for over 22 days using a single 235 mAh coin-
cell button battery. During the in vivo test, the device was used 
to perform stimulation of the NAc. The stimulation increased 
physical activity in the animal. Moreover, after stimulation 
there was a significant change in relative anxiety-like behavior 
of the animal in an elevated zero-maze. The device offers the 
following benefits: long operation time, small size, low 
maintenance, ease of use, and simple battery replacement 
enabling chronic stimulation. The device will cost about $5 
when the production volume is in many thousands of units due 
to the reduction in the cost of acquiring electronic 
components, fabrication of printed circuit board, and 
automated assembly and testing of the device. 
 
 
Fig. 10.  Mean activity counts per day taken over 2-day intervals for the three 
periods: pre-surgery (1254 +/- 172.0 counts per day), surgical recovery (2050 
+/- 77.5 counts per day), and during DBS (3216 +/- 114.5 counts per day). 
ANOVA (p=.004) with Sidak’s post-hoc test demonstrated significant 
increases in activity between DBS and pre-surgery (p=0.003) and between 
DBS and recovery (p=0.015). 
 
 
Fig. 11.  Percent change in time spent in enclosed zone of EZM between 
baseline and following DBS or sham treatment. DBS animal had a 6% 
reduction in preference for enclosed zone. Two sham animal data were 
averaged, with one animal showing 9.03% increase and the other showing 
9.60% increase towards enclosed area. 
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TABLE I 
COMPARISON OF SEVERAL WIRELESS DBS DEVICES 
Ref. Size Source Weight Term Parameters Advantages/Limitations 
[6] 20mm 
diameter 
Battery (3V/200mAh)    NA NA 0.2-0.5mA, 0.03-
1.4ms, 1-200Hz 
Adjustable parameters/Large size 
 
 
[7] 8mm × 
30mm 
Battery (4.65V) 2.1g 10 hours 20-100μA, 60μs, 
131Hz 
Adjustable parameters, low weight/Large 
size, very short operation term  
 
[10] 15mm × 
28mm 
Battery (6V/36mAh)  7.4g 7 days 50-120μA, 0-80μs, 
0-130Hz 
Adjustable parameters/Large size, large 
weight, short operation term  
 
[23] 25mm 
diameter 
Battery (3V/280mAh) 7.8g 9 days 200μA, 90μs, 130Hz -/Fixed parameters, large size, large 
weight, short operation term  
 
[14] 15mm × 
22mm 
Battery (3V/250mAh) 5.08 g 12 days 200μA, 90μs, 130Hz Good operation term/ Fixed parameters, 
large size, large weight 
 
[13] 33 mm × 
20 mm 
 
Battery 
(3.6V/250mAh) 
11.5 g 10 days 13-1000μA, 0-100% 
of period, 2-500 Hz 
Adjustable parameters, good operation 
term/Large size, large weight 
 
Prop
osed 
15mm × 
18mm 
Battery (3V/250mAh) 4.75g 22 days 200μA, 90μs, 130Hz 
adjustable 
Long operation term,  adjustable 
parameters, good size/large weight 
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 
Abstract— The therapeutic actions of deep brain stimulation 
are not fully understood. The early inflammatory response of 
electrode implantation is associated with symptom relief 
without electrical stimulation, but is negated by anti-
inflammatory drugs. Early excitotoxic necrosis and subsequent 
glial scarring modulate the conductivity of the tissue-electrode 
interface, which can provide some detail into the inflammatory 
response of individual patients. The feasibility of this was 
demonstrated by measuring resistance values across a bipolar 
electrode which was unilaterally implanted into the nucleus 
accumbens of a rat while receiving continuous deep brain 
stimulation with a portable back-mounted device using clinical 
parameters (130Hz, 200µA, 90µs) for 3 days. Daily resistance 
values rose significantly (p<0.0001), while hourly resistance 
analysis demonstrated a plateau after an initial spike in 
resistance, which was then followed by a steady increase 
(p<0.05; p<0.0001). We discuss that the biphasic nature of the 
inflammatory response may contribute to these observations 
and conclude that this method may translate to a safe 
predictive screening for more effective clinical deep brain 
stimulation.  
I. INTRODUCTION 
Deep brain stimulation (DBS) is a potentially effective 
late-stage treatment option for a variety of chronic 
neurological disorders including Parkinson’s disease (1-3), 
dystonia (2, 4, 5), neuropathic pain (2, 6) epilepsy (7, 8), 
Tourette’s syndrome (2, 9, 10), obsessive-compulsive 
disorder (3, 11), and depression (12-14). Despite years of 
clinical utility however, the underlying mechanisms of DBS 
efficacy are yet to be fully understood. A transient early 
mitigation of disease symptoms occurs in many of the above 
disorders (15-18) and has been hypothesized as related to the 
sham “insertional effect” caused by regional 
neuroinflammation (19). Supporting this, the combination of 
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anti-inflammatory drugs after electrode implantation 
attenuate these early therapeutic effects in both preclinical 
and clinical settings (20).  
Following DBS electrode implantation, a tissue reaction 
ensues, and the electrode becomes enveloped in an 
encapsulating layer of glial cells. This inflammatory response 
changes the electrical properties of the surrounding tissue by 
increasing the tissue-electrode interface impedance, which 
can be analyzed through impedance spectroscopy (21). The 
primary factors that determine this impedance are thickness 
and conductivity of this encapsulation layer (22). Therefore, 
this foreign-body inflammatory response seemingly dictates 
electrical impedance and gives indication that measuring 
these resistive properties can characterize the inflammatory 
profile. Furthermore, because of the prevalent sham 
“insertional effect” of the DBS procedure along with the 
therapeutic attenuation caused by anti-inflammatory drug 
administration, it is logical that characterizing the DBS 
inflammatory profile may predict which candidates may have 
higher clinical response rates. 
Despite some work investigating the resistance properties 
of neural tissue in in vitro and computational modeling (22), 
relatively little work exists in in vivo models using 
continuous DBS stimulation. Of these studies, the primary 
measurement is impedance (23, 24). Impedance 
quantification is a good method for characterizing electrical 
conductivity change, however obtaining these measurements 
requires impedance spectroscopy, which measures the 
impedance over a very large range of stimulation frequencies. 
Therefore, subjecting patients to these high-energy 
stimulation pulses has the potential of negatively impacting 
neural tissue by ablating healthy neurons or inducing 
unintended widespread electrical diffusion. Because nucleus 
accumbens DBS is a key target for an assortment of 
neurological diseases (25-28), we aimed to characterize the 
early resistance changes of DBS in this region during 
continuous stimulation of a rat using clinically relevant 
stimulation parameters. 
II. METHODS 
A. Surgery and Stimulation 
All procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) of 
the Mayo Clinic. One male Wistar rat (Jackson Labs, USA) 
at age 7 weeks was individually housed with water and chow 
available ad libitum. The animal vivarium was under a 12:12 
light:dark cycle with lights turning on at 6:00 AM and with 
no sources of light during the dark cycle. The room was 
actively controlled for humidity and temperature at all times. 
The animal was surgically implanted with a twisted bipolar 
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Figure 1. Circuit diagram of the DBS device. 
electrode (PlasticsOne, USA) through unilateral stereotactic 
surgery into the core of the nucleus accumbens of the right 
hemisphere using the bregma as coordinate reference (A-P: 
+1.5mm; M-L: -1.5mm; D-V: -7.0mm). Anesthesia was 
administered through isoflurane inhalation (3.0% induction, 
1.5% maintenance) during surgery. Cranial screws were 
affixed to the skull to anchor dental cement, which held the 
electrode in place. All tools and equipment were sterilized in 
70% ethanol to prevent infection. 
 One day after surgery, a portable resistance-recording 
DBS device was connected to the implanted electrode to 
deliver continuous DBS stimulation (130Hz, 100µA, 90µs) 
and record the resistance every 4 minutes onto an onboard 
data logger. Before initiating DBS, devices were connected to 
an oscilloscope to ensure stimulation delivery to electrode. 
The resistance-DBS device commenced stimulation and 
recording at around 1PM on each day of the experiment. The 
data logger was capable of storing data for up to 7 hours at a 
time before data retrieval was necessary. Thus the resistance-
recording DBS device was replaced by a portable non-
recording DBS device with the same stimulation parameters 
for continuous overnight stimulation. Both portable DBS 
devices were back mountable and secured using a rat vest 
(Harvard Apparatus, USA) to produce monophasic constant 
current pulses while incorporating passive charge balancing 
(29). Only the pulse generator component of the device was 
switched when changing devices and therefore electrode 
connections maintained consistent polarity and direction of 
current. The same battery was used for each type of device 
for the duration of the experiment. 
 Resistance data was analyzed and plotted using 
GraphPad Prism 6.0. One-way analysis of variance 
(ANOVA) was conducted and followed by Sidek’s post-hoc 
tests to identify significant differences (p<0.05).  
B. DBS Device 
The DBS system comprises of hardware and software 
components. The hardware component includes: (i) a low-
power DBS device including a pico-power microcontroller, a 
serial flash memory, an adjustable current source, an n-
channel metal–oxide–semiconductor field-effect transistor 
(nMOSFET), a light emitting diode (LED), two capacitors, 
two resistors, a coin-cell battery, a battery holder, a two-way 
surface mount communications microheader, a four-way 
surface mount in-system programming (ISP) microheader, a 
two-way surface mount electrode header, two electrode 
wires, and an electrode, and (ii) a programmer device 
including an Arduino Nano, universal serial bus (USB) 
interface, communications wires and connector, and power 
wires and jumper.  
The software component includes: (i) a program in C 
language that implements the operation of the device 
including generation and delivery of the DBS pulses, 
sampling and digitization of tissue resistance values, 
formatting and storage of the resistance values into the serial 
flash memory, as well as universal asynchronous receiver 
transmitter (UART) serial communication for sending out the 
resistance values, and (ii) a program in C language that is 
executed on the Arduino-Nano-based programmer for 
receiving the resistance values from the DBS device and 
displaying them on the screen for the user. 
Fig. 1 illustrates the circuit diagram of the portable DBS 
device. It employs an ATmega88PA pico-power 8-bit 
microcontroller with 8KB of flash program memory and 1KB 
of SRAM. A 1.7V minimum 64-Mbit DataFlash serial flash 
memory AT45DB641 is used for local storage of the 
resistance values. It contains two buffers of 256/264 bytes 
each. Interleaving between both buffers will increase its 
ability to write a continuous data stream. LM334 is a three-
terminal adjustable floating current source providing current 
regulation. It can produce a desired current level by using a 
single external resistor, RSET. For our desired current 
amplitude of 200µA, RSET = 330Ω is used. SSM3K03FE is an 
nMOSFET device with high input impedance and low gate 
threshold voltage. It operates as a switch whose ON/OFF 
state is controlled by the OC1A pin of a 16-bit Timer/Counter 
unit. When OFF, the LM334 current output is delivered to the 
stimulation electrode. A 100nF ac-coupling capacitor is used 
to implement passive charge to minimize unwanted effects 
including tissue damage. A lithium manganese dioxide cell 
button battery CR2032 of nominal voltage 3V is used to 
supply power to the DBS device for the duration of a pre-
clinical experiment. The diameter and the height of the 
battery are 20mm and 3.2mm, respectively. Its rated capacity 
is 235mAh. 
 A two-layer printed circuit board is designed to host the 
components of the DBS device. The shape of the board is 
selected in such a way to allow the board to be secured under 
a 20mm coin-cell battery holder. All the components are 
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mounted on the top layer. The board is then soldered to the 
two terminals beneath the battery holder. The weight of the 
stimulation board is 0.98g, the weight of the battery is 2.83g, 
the total weight of the battery and the battery holder is 3.83g, 
and the overall weight of the entire device is 4.81g. The 
device, battery holder and battery are placed inside a pouch 
hooked to a rat jacket. The jacket is secured by using a velcro 
fastener for a firm fit. The jacket is then placed on the back of 
the animal. This configuration allows the battery to be 
replaced. The DBS unit gives stimulation current pulses of 
duration 90µs, frequency 130Hz, and amplitude 200µA. 
When the current passes through the electrode and the target 
tissue, the device records the voltage observed across the 
electrode terminals and calculates resistance values, which 
give a snapshot of the tissue-electrode impedance at a given 
time. Comparing the change in the recorded values gives an 
indication of the changes in the tissue resistance due to 
electrical current stimulation in time.   
III. RESULTS 
Electrode resistance measurements from the first, third, 
and fifth hour of recording were analyzed (Fig. 2A, B & C). 
The first 40 minutes (10 data points) for each of these hours 
were used for analysis. Day 1 resistance, corresponding to the 
first day that the animal received DBS, indicated an initial 
resistance value of 12kΩ (Fig. 2A). This value increased 
significantly (p<0.0001) and rapidly in a nonlinear manner 
before stabilizing by the third hour to 12.3-12.4kΩ. After 
overnight continuous stimulation, resistance recording 
resumed on Day 2 at 12.5kΩ, indicating a gradual yet small 
increase in resistance value overnight (Fig. 2B). The 
resistance continued to increase in a relatively linear fashion 
and was significantly elevated with each interval (p<0.0001) 
to a final value of 12.9kΩ. This trend continued on Day 3, 
with a starting value of 13.1kΩ and peaking at 13.5kΩ at the 
end of the experiment, resulting in an overall increase of 
1.5kΩ over the three days of the experiment (Fig. 2C). Fig. 
2D displays the summary of daily resistance changes 
represented by the mean resistance obtained from the first 4 
hours of stimulation per day (60 data points). These data 
demonstrate a broader overview of resistance changes, which 
appears to be relatively linear over the course of 3 days. 
IV. DISCUSSION 
The current study utilized continuous DBS stimulation to 
measure early tissue resistance over three days in a rat. We 
demonstrate that tissue resistance increased steadily at the 
electrode terminals when DBS is initiated (Fig. 2D). These 
findings are consistent with studies that observe an increase 
in tissue impedance over time (29). When observing shorter 
time intervals, this study indicated a sharp increase in 
electrical resistance at the very beginning of DBS stimulation 
(Fig. 2A). This may be the result of electrical current 
facilitating the inflammatory response. It may also indicate a 
rapid sensitivity change in the tissue-electrode interface once 
stimulation is initiated. This initial sharp rise in resistance 
values is then mediated by a prolonged (several hours) 
plateau of tissue resistance values as illustrated between the 
third and fifth hour of stimulation. From here there seems to 
be a steady increase in resistance values for the duration of 
the experiment, including during overnight stimulation when 
resistance is not recorded (Fig. 2B & C).  
 
 
Figure 2. Data is illustrated as Mean +/- Standard Error. *: p<0.05; ****: 
p<0.0001. A: Resistance values for each 40-minute interval during Day 1 
(1st Hour: 12016 +/- 67.51Ω; 3rd Hour: 12349 +/- 4.609Ω; 5th Hour: 12371 
+/- 13.25Ω) [ANOVA p=<0.0001; F(DFn, DFd)=5.983 (2, 27) with Sidek’s 
post-hoc tests]. B: Resistance values for each 40-minute interval during Day 
2 (1st Hour: 12505 +/- 26.83Ω; 3rd Hour: 12779 +/- 11.63Ω; 5th Hour: 12921 
+/- 5.217Ω) [ANOVA p=<0.0001; F(DFn, DFd)=11.75 (2, 27) with Sidek’s 
post-hoc tests]. C: Resistance values for each 40-minute interval during Day 
3 (1st Hour: 13135 +/- 10.63Ω; 3rd Hour: 13265 +/- 5.829Ω; 5th Hour: 13394 
+/- 56.33Ω) [ANOVA p=<0.0001; F(DFn, DFd)=1.604 (2, 27) with Sidek’s 
post-hoc tests].Circuit diagram of the DBS device. D: Data is illustrated as 
Mean +/- Standard Error. ****: p<0.0001. Average daily resistance values 
(Day 1: 12304 +/- 20.85Ω; Day 2: 12726 +/- 18.29Ω; Day 3: 13262 +/- 
14.73Ω) [ANOVA p=<0.0001; F(DFn, DFd)=1.169 (2, 177) with Sidek’s 
post-hoc tests]. 
 
 The plateau in resistance values observed on Day 1 may 
be attributed to the brain’s early immune response to neural 
injury. This stage is characterized by insufficient energy 
production as a result of unfavorable anaerobic glycolysis 
(30). This is associated with a rapid production of reactive 
oxygen species that contribute to excitotoxic necrosis, as well 
as edema, hemorrhaging and lipid peroxidation (30, 31). This 
is proceeded by the delayed neuroinflammatory response 
where glial cells migrate to the site of injury and create a 
barrier known as glial scarring to isolate the brain from the 
surrounding tissue (32, 33). This progressive glial scarring or 
the recruitment of immune cells may be illustrated by the 
late-response rise in resistance values in Day 2 and 3, while 
the initial plateau may indicate the early necrotic phase in 
Day 1 following initial sensitivity changes from stimulation 
activation. 
V. CONCLUSION 
 The work described demonstrates that there are 
potentially feasible methods to calculate resistance in rat 
neural tissue. These values can act as viable biomarkers to 
establish important properties that may in part predict patient 
response rates. Future studies are planned to histologically 
compare inflammation profiles with electrode resistance. 
Subsequently, animal model studies are planned to correlate 
the inflammatory profile with treatment response rates for 
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debilitating neurological diseases that are treated with DBS, 
such as for treatment resistant depression (Kim et al. 2016 in 
press). These prospective preclinical studies may further 
translate to individualized treatment options for patients 
suffering with these conditions through biomarker analysis 
including tissue resistance. 
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CHAPTER 9 
General Discussion of Preclinical Studies 
 
 Understanding the pathophysiology of depression has been a challenging 
endeavor in preclinical research. Depression divides into clusters of heterogeneous 
symptoms in patient populations, and is not clearly based on individual 
pathophysiology. Instead, the clinical presentation of depression, and other mood 
disorders, suggests that these illnesses lie along a continuum of disease 
pathophysiologies. This is evident in the distinct disease course of unipolar depression 
and bipolar disorder (Goodwin and Jamison, 2007). Inadequate classification of 
disease symptoms can result in misdiagnosis (Bowden, 2001). Consequently, 
unintentional potentiation of the disease can result from poor treatment choices, 
through response failure and subsequent disease progression, or direct adverse events 
such as antidepressant-induced mania (Culpepper, 2014). A key measurement that 
may help to facilitate accurate diagnosis of mood disorders and precision medicine 
approaches is biomarker analysis (Phillips and Kupfer, 2013). 
Unfortunately, viable biomarkers remain elusive and those that have been 
identified need to be better understood within the context of the individual’s state of 
disease progression (Davis, Maes et al., 2015). While many identifiable markers do 
exist, such as inflammatory markers and neurotrophic factors, both the mechanistic 
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causation for these biomarker pathophysiologies, as well as their reproducibility in all 
clinical variants of disease are yet to be reliably validated (Schwarz and Bahn, 2008). 
Preclinical studies can help to resolve this issue by linking disease pathophysiology to 
treatment response. This issue has been addressed in the previous chapters of this 
thesis using a rat model of antidepressant resistance (ADR) as a primary probe of 
disease pathophysiology. The studies presented in this thesis induce elevated or 
depressed mood-like states as characterized by behavioral phenotyping tests, and 
utilize neurostimulatory or pharmaceutical interventions to evaluate treatment 
response in ADR rats.  
 Induction of the ADR model is achieved through daily administration of 
adrenocorticotropic hormone (ACTH) to activate the hypothalamic-pituitary-adrenal 
(HPA)-axis during the circadian nadir. This spikes levels of plasma corticosterone, 
which is the rat’s endogenous stress response hormone, at the time of injection 
without producing hypercortisolemia (Walker, Burnett et al., 2013). Stress hormone 
HPA-axis activation is corollary to stress stimuli exposure, and repeated activation can 
lead to HPA-axis dysregulation and even manifestations of mood disorders in animal 
models and patients (McEwen, 2003). ADR induction via ACTH administration not 
only diminishes a rat’s response to tricyclic antidepressant intervention, it concurrently 
induces a state of dopamine dysregulation. We study these effects through the 
neurostimulation technique, deep brain stimulation (DBS), and develop the devices 
and technologies to advance this field of research. We find that the antidepressant 
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effects of mesocorticolimbic DBS seem to be mediated, at least in part, through 
dopaminergic mechanisms.  
The following section represents an overview of key findings from each of the 
preclinical experiments chapters of this thesis. These studies contribute to our further 
understanding of mood modulations in neuropsychiatric diseases, as well as to the 
development of neurostimulation systems for translational research. Discussions of 
chapters 4 through 6 focus on the behavioral and protein neuroadaptations that 
occurred in our ADR rat model through neurostimulatory and pharmaceutical 
treatments. Implications towards translational research are also explored. Discussions 
of chapters 7 and 8 detail the development of our portable DBS microdevices for 
greater animal research functionality, along with the preclinical validations of each 
device through induced behavioral and neurophysiological modifications. The general 
limitations of these experiments are then summarized. Concluding remarks of these 
preclinical studies then highlight the role of dopamine in mood modulations and the 
need for further development in neurostimulation techniques, through neural-
interface engineering, to elucidate mechanisms of neuropsychiatric disease 
pathophysiologies and treatment. Future directions in neurostimulation techniques are 
also introduced, which lead into the neural-interface engineering chapters of this 
thesis (chapters 10 through 13). The neural-interface engineering chapters investigate 
the emerging technologies in neurostimulation delivery systems and detail our 
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development and benchtop validation of a novel portable optogenetic microdevice for 
future preclinical neuromodulation research. 
 
Key Experimental Findings 
 
CHAPTER 4 – Study 1: Chronic Nucleus Accumbens Deep Brain Stimulation Increases 
mTOR and GSK3 Phosphorylation in Ventral Hippocampus 
The effective antidepressant effects of nucleus accumbens (NAc) DBS in ADR 
animals was repeatedly demonstrated throughout this thesis. We observe this effect 
through DBS-induced decreases in passive coping behavior in the forced swim test 
(FST), our primary measure of antidepressant efficacy (Porsolt, Le Pichon et al., 
1977). As described in detail in the methodology chapter, the FST is considered to 
have robust predictive validity as a preclinical screen of antidepressant treatment 
efficacy. However, in addition to this antidepressant effect, we also observe an 
increase in homecage psychomotor activity in animals treated with NAc DBS as well 
as anxiolytic behaviors in NAc DBS and sham-treated animals that did not receive 
stimulation. Attenuation of ACTH-induced reward-salience sensitivity was also 
measured in NAc DBS animals by the sucrose preference test (SPT). We hypothesize 
that these effects occur through a combination of electrical stimulation of neural 
circuitry and through direct cellular effects as a result of immune activation and tissue 
lesioning resulting from electrode insertion. It is well documented that 
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mesocorticolimbic dopamine alterations are linked to depression and therapeutic 
antidepressant effect (Dunlop and Nemeroff, 2007; Meyer, Krüger et al., 2001; 
Nestler and Carlezon, 2006). Mesolimbic dopamine is also an important regulator in 
food craving and feeding behaviors (Berthoud, Lenard et al., 2011). Dysregulation of 
dopamine in ADR animals progressively increased sucrose preference and this effect 
was also observed in sham animals. However, DBS and saline-control animals did not 
increase their sucrose consumption, implicating a reversal of ACTH-induced reward-
salience sensitivity and possibly mediated by regulation of dopamine release by DBS. 
These data suggest that electrical stimulation and/or the lesion effect with associated 
inflammatory responses may serve to modulate dopamine activity in this circuit to 
increase homecage psychomotor activity, but DBS is specifically necessary for 
behavioral coping in the FST and reward-related feeding behaviors. 
In this study, electrodes were bilaterally implanted into the core of the NAc. 
Dopamine neurotransmission in this region is associated with dopamine-induced 
psychomotor behavior (Ito, Robbins et al., 2004; King, Zigmond et al., 1997; Sellings 
and Clarke, 2003). We hypothesize that inflammation from chronic NAc implantation 
may facilitate dopaminergic transmission to precipitate an increase in homecage 
activity and may be related to antidepressant-like effects. Previous studies have 
demonstrated that rats implanted with DBS electrodes in depression-therapeutic 
targets demonstrated similar antidepressant responses (Perez-Caballero, Perez-Egea et 
al., 2014). This was shown to be dependent on the local inflammatory response. 
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Specifically, regional glial-fibrillary-acidic protein (GFAP) was temporally correlated to 
this antidepressant response. Antidepressant effects were reversed with the use of 
anti-inflammatory drugs. Furthermore, patient studies with major depressive disorder 
demonstrated a lowered antidepressant response to DBS when coupling with anti-
inflammatory medication. Other studies have related mesocorticolimbic GFAP 
expression with increased drug-seeking behaviors, and indicate that dopamine 
regulation may correlate with GFAP expression in disease models (Beitner‐Johnson, 
Guitart et al., 1993).  
These sham antidepressant effects were demonstrated to be temporary, 
dissipating by 6 weeks post-surgery and further studies are needed to investigate the 
temporal impact of inflammation post-surgery and antidepressant response. In our 
study, we observed no significant difference between sham FST immobility time and 
controls. The SPT also demonstrates a phenotypic difference between the DBS and 
sham group. DBS appears to nullify the sucrose-consumption increase that is 
observed with ACTH administration, indicating a reversal of dopamine dysregulation 
in reward-salience sensitivity (Berridge and Robinson, 1998) and making their sucrose-
consumption behaviors similar to that of saline controls. In contrast, sham animals 
progressively increased sucrose consumption, which is similarly observed in our ADR 
model with ACTH treatment alone. Therefore, sham treatment did not attenuate the 
effects of ACTH-induced dopamine dysregulation. This provides evidence that 
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network levels changes occur with electrical stimulation but only target regions are 
affected with electrode implantation alone. 
 
CHAPTER 5 – Study 2: Antidepressant and locomotor effects of nucleus accumbens deep brain 
stimulation and dopamine transporter-blockade in ACTH-treated rats 
The critical role of dopamine regulation in affective disorders, and in our model 
of ADR, was further illustrated by the coupling of mesocorticolimbic DBS with 
dopamine transporter (DAT) blockade. Our current hypothesis being that NAc DBS 
exerts its therapeutic effects by functionally modulating mesolimbic dopamine 
neurotransmission. GBR12909 (GBR) enhances dopamine transmission by selectively 
blocking reuptake of synaptic dopamine in mesocorticolimbic circuits (Andersen, 
1989; Cass and Gerhardt, 1995). A secondary goal of this study was to determine 
whether facilitation of mesolimbic dopamine neurotransmission, alone or in 
combination with NAc DBS, elicited mania-like behavior in ADR animals, given 
previous naturalistic observations of this phenomenon. We hypothesized that the 
coupling of DBS with GBR administration (16 mg/kg) may potentiate dopaminergic 
transmission, to elicit mania-like behavior. 
Prescribing a strong antidepressant regimen to bipolar depressed patients can 
inadvertently cause mania to emerge (Ghaemi, Boiman et al., 2000). Patients who had 
received DBS for diseases involving dopamine dysregulation have also manifested 
mania-like symptoms (Kleiner‐Fisman, Herzog et al., 2006; Kulisevsky, Berthier et al., 
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2002). However, this was not observed in our ADR model. Instead, DBS appears to 
regulate the dopamine state in ADR animals. Here we reproduced antidepressant 
effects from NAc DBS (as measured through FST). Changes in mesocorticolimbic 
protein levels relating to dopamine activity, particularly in infralimbic cortex (IL), 
indicate that NAc DBS modulates dopamine activity in these regions and may be a 
contributing factor towards the antidepressant properties of NAc DBS. 
NAc DBS coupled with GBR administration did not produce the significantly 
elevated mania-like behavior that was hypothesized. Surprisingly, GBR in ACTH-
treated animals alone produced a depressed acute psychomotor state by the 7th day of 
administration in terms of lowered peripheral velocity, yet it also produced an elevated 
chronic psychomotor state that was observed when monitoring continuous homecage 
activity. This divergent behavioral response may be indicative of mesolimbic hypo- 
and hyper-dopaminergic transmission levels in these rats, as these are related to 
depressed and elevated (mania-like) behavior respectively (Dunlop and Nemeroff, 
2007; Swerdlow and Koob, 1987). Further investigations in dopamine activity levels 
of these animals would be important to understanding the dopaminergic implications 
in alternating episode-like behavior for a rat model of BD. 
This study produces some preliminary indication that mood-switching is 
possible in the ADR mode. This model may therefore become a valuable tool for 
studying the neuroprogression of bipolar disorder as it relates to severity and 
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frequency of symptomatic episodes, and may help isolate specific pathophysiological 
markers associated with progression of disease stages. 
 
CHAPTER 6 – Study 3: Deep brain stimulation interaction with risperidone produces 
differential stress-induced psychomotor response 
The antipsychotic treatment risperidone (1 mg/kg) was administered in this 
study to block dopamine receptors (DRs) type 1 and 2. This was to investigate the 
efficacy of DBS in ADR animals with DR inhibition. We had hypothesized that DRs 
play an important role in the therapeutic value of DBS, and that blocking the function 
of DRs would attenuate these effects. In contrast to Chapter 5, which utilized GBR to 
potentiate dopaminergic transmission, this study is hypothesized to attenuate 
dopaminergic transmission. Additionally, this study incorporates acute DBS on the IL 
region, which is also implicated in the stress response and demonstrates 
antidepressant efficacy to DBS (Hamani, Diwan et al., 2010; Kim, Morath et al., 
2016). 
 These results demonstrate that 30 minutes of IL DBS is not sufficient to 
produce antidepressant effects in FST. There was no significant difference in FST 
immobility time from IL DBS compared to ACTH-control group, even though 
previous IL DBS studies have shown this effect with longer duration stimulation (60 
minutes) (Kim, Morath et al., 2016). We conclude that future investigations in this 
model would require longer duration of DBS and/or more days of DBS therapy. We 
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did observe a depressed psychomotor state as a result of risperidone administration in 
all groups. Risperidone decreased OFT total distance travelled, and these results 
invalidate the FST as a screen for antidepressant efficacy. Because of this, further 
investigation into mesocorticolimbic protein levels becomes irrelevant and was not 
pursued. However, this study provides excitement towards future direction in 
determining a dose-dependent response of DBS antidepressant efficacy, as well as 
utilizing a lower dosage of risperidone. This is because lower or higher doses of 
risperidone are clinically utilized for antidepressant or antipsychotic treatment, 
respectively.  
There is also evidence of a DBS-risperidone interaction in this study, as 
DBS/sham treatment produced divergent psychomotor activation behaviors in 
response to different intensities of stress. The low-stress OFT environment produced 
attenuated psychomotor activity in Risperidone+DBS/Sham animals than for 
risperidone treatment alone, yet the high-stress FST environment elevated 
psychomotor activity by lowering immobility. With the previous studies in this thesis, 
there is strong evidence of a dopamine-centric role in the modulation of observed 
behaviors, however this study demonstrates that combinatorial dopamine modulating 
interventions can interact to profoundly impact behavioral outcomes. Stress-induced 
behavioral response can also be unpredictable under different conditions, and the 
importance for controlling stress environment in animal models is additionally 
justified through this study. Neurostimulation studies have the inherent caveat of 
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utilizing relatively bulky technologies, which can further induce stress on animals in 
behavioral studies. However, through the further development of advanced 
neurostimulation microdevices for small animal research, studies can continuously 
deliver neurostimulation with minimal animal stress through device miniaturization, 
reliability, power consumption, and functionality development. 
 
CHAPTER 7 – Study 4: Validation of a Portable Low-power Deep Brain Stimulation Device 
through Anxiolytic Effects in a Laboratory Rat Model 
The use of DBS microdevices in behavioral research is vital to translating the 
outcomes to the clinical setting. This is because microdevices attempt to minimally 
impede the animal’s freely-moving behaviors and therefore lessen interference with 
the animal’s behaviors during behavioral testing. In order to function optimally, 
neuromodulation microdevices need to be low power, low weight, reliable, and small 
enough to be worn by the animal. Our previous DBS microdevice functioned well for 
short-term DBS studies, but required further development for longer stimulation 
studies. The goal of this study was to increase the duration of continuous stimulation 
from a single CR battery (3 Volt). This paper features the adaptations in electrical 
circuitry and component changes that enabled the device to deliver continuous 
stimulation for over 22 days. This is a large step from the previous iterations of the 
device, which delivered up to 7 days of stimulation. When working with animal 
models that require a long stimulation duration, extending the battery to this amount 
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was important to ensure that stimulation was delivered throughout the experimental 
timeline. 
This device, once developed and constructed, was validated on an animal 
model. The results demonstrate the efficacy of this device in producing anxiolytic 
behavior from NAc DBS, which has been previously reported (Denys, Mantione et 
al., 2010; Gabriëls, Cosyns et al., 2003; Greenberg, Gabriels et al., 2010). We observe 
similar effects in psychomotor activity with this device, as activity counts are 
significantly elevated after the commencement of electrical stimulation, when 
compared to pre-surgery and surgery recovery periods. Additionally, we compared 
DBS results with a sham animal, who received unilateral DBS electrode implantation 
but received no stimulation. In the elevated zero maze (EZM) test, the sham animal 
increased its anxiety-like behavior, whereas the DBS animal decreased its anxiety-like 
behavior. This was observed by the sham animal increasing its duration of time spent 
in enclosed areas of the EZM whereas the DBS animal decreased this behavior and 
spent more time in the anxiety-inducing open areas of the maze. These results 
demonstrate that NAc DBS produces anxiolytic effects as observed through 
psychomotor activation and through decreased anxiety-like behaviors.  
Furthermore, NAc DBS-induced elevation in psychomotor activity was 
demonstrated in this study through homecage monitoring, as was previously observed 
in Chapter 4. Activity counts increased from baseline (pre-surgery), both during 
electrode implantation surgery recovery, and also after the commencement of DBS. 
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We therefore conclude that this new iteration of our DBS microdevice is delivering 
continuous stimulation, and therefore has been successfully validated for future 
animal stimulation studies. 
 
CHAPTER 8 – Study 5: Electrical Resistance Increases at the Tissue-Electrode Interface as an 
Early Response to Nucleus Accumbens Deep Brain Stimulation 
As discussed in chapter 4, the antidepressant properties of DBS may result, in 
part, from electrode implantation-induced inflammation. This insertional effect is 
hypothesized to be related to regional neuroinflammation (Hirshler, Polat et al., 2010). 
Cellular modulations occur due to immune activation at the tissue-electrode interface. 
An association between antidepressant effects of electrode insertion and expression of 
GFAP has been reported, and this association can be nullified by anti-inflammatory 
medication (Perez-Caballero, Perez-Egea et al., 2014). This study aimed to determine 
if quantification of this inflammatory profile was possible through non-invasive 
methods.  
Using a portable back-mountable DBS device that additionally measures tissue 
resistance, we observe a steady increase in daily average tissue resistance values. When 
comparing these values hourly, there appears to be an initial spike in tissue resistance 
at the commencement of DBS, followed by a leveling off before continuing to rise 
again on the second day onward. This follows a similar relationship to neuro-
inflammatory activation, which is a biphasic process. The initial response to foreign 
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body detection is rapid release of reactive oxygen species to signal cellular necrosis 
(Shalak and Perlman, 2004; Vannucci, Yager et al., 1994). This is followed by 
migration of glial cells to the site of the electrode to create a barrier from the rest of 
the brain, known as glial scarring (Leonardo and Pennypacker, 2009; Silver and Miller, 
2004). This scarring continues to grow and change the electrical resistance at the 
tissue-electrode interface. 
This study deemed it feasible to measure resistance change over time using a 
non-invasive method. This has future implications towards clinical DBS therapy. 
Because of the association between the inflammatory profile and the effective sham 
therapy, characterizing inflammation in patients who are receiving DBS therapy can 
be valuable to increasing the response rate and effectiveness. Furthermore, measuring 
tissue resistance can provide feedback capabilities to create smarter devices that adjust 
stimulation parameters and timing based on the brain’s current neurophysiological 
properties. 
 
Limitations 
The works presented in this thesis contain inherent limitations and should be 
interpreted with consideration to these limitations. These experiments attempt to 
anthropomorphize very specific animal conditions in order to identify therapies for 
diseases affecting a heterogeneous proportion of the population. The animal’s strain, 
age, sex, and other conditions are kept consistent to minimize variability in data. We 
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set these parameters in our model to observe very specific conditions of depression 
manifestation and treatment resistance. Wistar rats were primarily used in these 
experiments for their vulnerability to various stressors as a means to desensitize their 
HPA-axis response (Belda, Márquez et al., 2004), and because of previous studies 
demonstrating ACTH-induced antidepressant resistance (Walker, Burnett et al., 2013). 
We set the animal age to 5-6 weeks after birth, corresponding to periadolescence 
(Sengupta, 2013). While induction of antidepressant resistance gives us an illustration 
of adolescent stress vulnerability during animal development, it limits our findings to 
this stage of development from that of mature animals. Additionally, only animals of 
male gender were utilized to remain consistent with other studies in the field and 
allow for direct comparison. However, this limits the interpretation of findings in 
these studies to conditions in males and underscores the importance of pursuing 
future research across both genders. Finally, environmental conditions for the rat, 
including cage design, spacing, and vivarium conditions, were all set according to the 
International Animal Care and Use Committee (IACUC) of Mayo Clinic. These 
conditions also demonstrate limitations; examples include a consistent yet 
monotonous diet, no natural light or exposure to outdoors, inability to observe 
changing seasons, and other naturalistic conditions. With this in mind, controlling of 
parameters and confounding variables is an important aspect in reproducing scientific 
findings and to help increase the validity of these studies. 
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A specific set of behavioral tests were performed in these studies. Although 
FST has demonstrated high validity in antidepressant screening, other depression-
related behavioral tests exist such as the tail-suspension test for learned helplessness, 
fear conditioning for aversive event prediction, and novelty suppressed feeding for 
anxiety. While behaviorally relevant, these tests also produce additional stressors on 
the animal. Therefore, the implementation of each additional test could alter the 
animal’s behavior to other behavioral tests, which could nullify the effects in our 
primary measures such as the FST. 
Finally, these animals were housed in social isolation. Before arrival, the 
animals were raised together as a litter with the ability to socialize. Upon delivery to 
the vivarium, the animals are suddenly caged in isolation, which has depressogenic 
effects in animals. Social isolation alone alters the brain in terms of neurotransmission, 
neurotrophic factor expression, forced swim test immobility times, and other 
behavioral changes associated with depression (Brenes, Rodríguez et al., 2008; Lapiz, 
Fulford et al., 2003; Sáenz, Villagra et al., 2006). Therefore, these studies incorporated 
both social isolation and stress hormone challenge to induce our model of ADR. 
Additionally, social isolation was necessary for animals undergoing any surgery or 
DBS. Rats engage in rough-and-tumble play and therefore anesthetized rats and rats 
with electrode implantation or with a wearable DBS device could undergo serious 
injury during play, as well as risk damaging the device. Either would result in early 
termination of the animal from the study, thus the social isolation protocol is 
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implemented into these studies. It is worth noting then that the results obtained from 
these studies reflect conditions on socially isolated animals, and this alone can induce 
depressogenic effects. Social isolation may be a good addition to the ACTH model, 
however it is likely that depressogenic effects were induced in control animals as well. 
Thus, control data should ideally be compared with socially housed controls to 
determine whether socially isolated controls are themselves more reflective of 
depression-like phenotypes than socially abundant controls. 
 With these limitations in mind, the studies presented in this thesis aimed to 
minimize confounding variables by implementing as rigid of a study design as 
possible. The results that were obtained aim to reflect the human condition, and 
although these findings cannot directly apply to the clinical setting without inherent 
caveats, they may reflect some important characteristics in clinical disease progression. 
We use these results primarily to understand the basic neurobiology in models with 
specific conditions, and with the goal to add knowledge to the scientific literature. 
Accumulation of various scientific studies may help generalize patterns in these 
disease, so that ultimately the integrated knowledge can be applied to helping patients.  
 
Conclusion and Future Directions  
 In summary, the preclinical studies presented in this thesis contribute to our 
growing knowledge in understanding affective disorders by utilizing animal models 
coupled with neurostimulation techniques. The research and scientific contributions 
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made in the previous 5 chapters encompasses the preclinical experiments segment of 
this thesis. The following 4 chapters describe the fabrication and benchtop validation 
of our novel portable optogenetic microdevice for preclinical neurostimulation 
research, as well as critical reviews of different optogenetics systems and the emerging 
neurostimulation technologies that are being incorporated into emerging neuroscience 
research. Together, these final 4 chapters encompasses the neural-interface 
engineering segment of this thesis, which aims to pave the way for technological 
advances that can serve as foundations for innovation in preclinical studies, such as 
those presented here (Chapters 4-8).  
Technologies continue to evolve as battery life, computational power, 
component functionality, and miniaturization of devices are advancing rapidly. 
Neural-interface engineering research can incorporate these technologies into novel 
systems and devices that directly interface with the brain’s neural circuitry. Applying 
these advances to rodent studies will continue to improve our potential to delineate 
the neurobiological mechanisms implicated in mood disorder manifestation and 
neuroprogression. As such, developing these tools can directly contribute to 
understanding neuropathological mechanisms that can be translated to ultimately 
benefit patients through the utilization of novel therapeutic options in both 
neurostimulation and/or pharmacology.  
From the investigations described in this thesis, it becomes clear that dopamine 
plays a critical role in mood-disorder pathophysiology and the antidepressant 
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response. Mood states are intricately linked to dopamine activity through a variety of 
molecular mechanisms and circuitry pathways that are still not fully understood. 
Neuroprogression of pathophysiological mood states, particularly related to dopamine 
activity, is therefore likely to be complex. Elucidating key dopamine-modulating 
treatments remains a challenging endeavor for researchers and clinicians. We are too 
limited by our current knowledge to fully grasp the complexities of the dopaminergic 
system. However, the diseased brain offers multiple mechanistically distinct 
approaches for treatment interventions. This makes research in the field of 
translational neuroscience all the more exciting and fruitful. All methodological 
research ventures contribute in some way to our understanding of the brain and how 
it interacts with our internal and external environments. Discovery and development 
of novel neural-interfacing systems can further facilitate our understanding of the 
brain. Furthermore, future neural-interface engineering of devices and systems can 
provide more refined avenues to exploit maladaptive neural circuitry and induce 
regulatory stimulation for the attenuation of disease progression. 
Specifically targeting dopamine transmission by engineering advanced 
neurostimulation techniques can facilitate our understanding of causal roles in 
circuitry modulations relevant to mood disorders. At present, DBS radially diffuses 
electrical current and therefore many unintentional regions and fibers are stimulated. 
Optogenetics however delivers more targeted neurostimulation and will therefore be 
pivotal in future translational research. Furthermore, the development of optogenetic 
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microdevices will be imperative in future research in animal models of mood 
disorders. Therefore, the following neural-interface engineering segment of this thesis 
is provided to highlight our contributions to this field and for future preclinical 
research. The next chapter (“Chapter 10 – Benchtop Validation of a Portable 
Optogenetic Microdevice for Rodent Photostimulation”) describes our development 
and benchtop validation of a portable optogenetic microdevice intended for rodent 
neuromodulation research. This microdevice was engineered for future 
implementation in preclinical behavioral research because, like our portable DBS 
microdevice, it enables an animal to receive continuous photostimulation to neural 
tissue while being minimally restricted from performing freely-moving behaviors. 
Subsequently, a published review (“Chapter 11 – Evolution of Optogenetic 
Microdevices” published in SPIE Neurophotonics) is provided to characterize key 
components of optogenetic systems for future developers, and compare recently 
developed optogenetic systems used in research settings including benchtop systems, 
portable microdevices, and implantable devices.  
Current research is being performed on coupling advanced neurostimulation 
systems, specifically DBS, with recording electrodes that interface neural tissue to 
create a closed-loop system. Closed-loop systems acquire neural signals from the 
recording electrode, interpret the information, and manipulate the stimulation 
parameters and timing in a feedback process. This in turn enables the system to 
monitor brain activity for certain patterns related to disease, and subsequently trigger 
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DBS. Stimulation at triggered timepoints can therefore perform neuromodulatory 
control of neural networks with optimized parameters for therapeutic benefits. In 
contrast, unmonitored open-loop systems continuously deliver stimulation at 
predefined parameters. Smart closed-loop systems have the potential to maximize 
patient response to DBS treatment. As a result, closed-loop systems are a highly 
sought-after clinical intervention strategy, however their utility is currently limited 
because of difficulty in defining adequate recording signals for the DBS trigger. There 
is consequently much research interest in developing this technology. The exciting 
advances emerging in clinical DBS research, especially for closed-loop systems, are 
discussed in the third chapter of the neural-interface engineering segment in this 
thesis (“Chapter 12 – Physiological Monitoring in Deep Brain Stimulation: Toward 
Closed-Loop Neuromodulation Therapies”). This thesis chapter was accepted for 
publication as a book chapter in “Emerging Trends in Neuroengineering and Neural 
Computation” book published by Springer Series in BioEngineering.  
It is important to keep in mind that research on animal models of ADR, and 
other disease models, encompass a very specific etiology of mood disorders, and 
translational properties are limited to findings relevant to the particular model. Much 
research emphasis is applied to reproducing a human disease condition in an animal 
model, and therefore manipulations of specific pathways or systems that facilitate 
disease induction are singled out. This effectively neglects other physiological systems 
that would also contribute to disease progression in humans. Representing disease in 
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model with all relevant biological systems affected will be imperative for future 
research. Very recent genetic technologies involving clustered regularly interspaced 
short palindromic repeats (CRISPR) can utilize phenotypically chimeric organisms 
that combine animal and human genetic hybrids. Although controversial, chimeric 
models of disease have the potential to enhance preclinical research by producing 
animal models of disease that more closely resemble the human condition. 
Interestingly, optogenetics has been shown to control CRISPR activation. The final 
chapter in the neural-interface engineering segment, and final chapter of this thesis, 
discusses the emergent technologies being incorporated for optogenetic systems, 
including CRISPR, to advance optogenetic photostimulation functionality (“Chapter 
12 – Revolutionizing Causal Circuitry Neurostimulation Utilizing the Optogenetic 
Technique through Advanced Microsystems Development”). This thesis chapter was 
also accepted for publication as a book chapter in “Emerging Trends in 
Neuroengineering and Neural Computation” book published by Springer Series in 
BioEngineering. With the incorporation of future technologies, studying disease models 
would have greater validity in translational research and important clinical findings 
could rapidly be incorporated to suffering patients. 
Overall, there exists a great need for further development in animal models of 
mood disorders that represent greater diversity and phenotypic range of disease, as 
well as development of novel neurostimulation technologies that offer causal 
neuromodulatory control of diseased circuits. Progress in these fields continuously 
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facilitates our understanding of the neural mechanisms implicated in disease 
manifestations and treatments. It is important to remember that paradigm changing 
breakthroughs do not occur in a vacuum; we all stand on the shoulders of giants 
because of the individual contributions that many have made before us. Each of these 
contributions accumulate to enlighten our perceptions of reality and the universe, and 
to further motivate progression of humanity’s achievements. The motivation for the 
works presented in this thesis was to help optimize treatment value for the people 
who struggle every day with their perceptions of reality. And yet, even after personally 
synthesizing this thesis it still remains difficult, at best, to internalize the reality that 
these debilitating diseases originate from physical, chemical, and neurobiological 
maladaptations to the brain alone. The hope is that in the near future we will have 
gained the sufficient knowledge of the brain’s intricate complexities to fully conceive 
mood disorder pathophysiologies and to accurately identify, treat, and ideally prevent 
affective disorders and their neuroprogression. 
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 Abstract 
 There is a great need in translational research of animal models with mood 
disorders for novel forms of causal neurostimulation. Optogenetics is an emergent 
technique that incorporates pulses of light to activate opsin-expressing neurons with 
unparalleled spatiotemporal resolution. Here, we describe the development of a 
portable optogenetics microdevice for rodent photostimulation. Manufacturing of an 
LED to optical fiber coupler is described that couples elicited photons from the light 
source to into an optical fiber for neuromodulation of deep brain regions, such as 
those implicated in mood disorders. Specific LED and optical fiber parameters are 
described for ideal efficiency, as well as the circuitry to drive pulse generation from a 
battery power source. The completed prototype is benchtop validated to ensure a 
minimum of 0.1 – 1 mW/mm2 optical power is achieved. Here we demonstrate 
optical power production of 1.25 mW/mm2 from the optical fiber, which is more 
than sufficient to activate transfected opsins in deep brain structures. This device has 
potential to be incorporated into translational research settings for behavioural studies 
once in vivo validation is performed. 
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 Introduction 
 The emergence of optogenetic neurostimulation has expanded the boundaries 
of neuromodulation research to previously unprecedented levels in terms of targeting 
precision and neuronal control. This technique has introduced greater spatial and 
temporal resolution compared to its widely established neurostimulation predecessor, 
deep brain stimulation (DBS). Both techniques, when first introduced, incorporated 
benchtop rigs that often required the animal to be anesthetized or tethered to an 
external pulse generator. In behavioral studies, tethered systems hinder the animal’s 
naturalistic behavior and makes it difficult to implement complex behavioral 
paradigms such as wheel running and social interactions (McCall, Kim et al., 2013). 
Since the emergence of optogenetics, a variety of portable systems and implantable 
microdevices have been engineered that utilize small batteries and even wireless 
energy transfer as their power source (for a detailed review, see (Kale, Kouzani et al., 
2015))). Device dimensions are minimized to attenuate movement and behavior 
restrictions of the animal while maintaining reliable and continuous photostimulation. 
However, to meet the intensive quality standards for research settings, advanced 
electrical components and careful circuit engineering are necessary for reliable 
photostimulation. 
 Our previous development of a portable low-power DBS microdevice for 
rodent neurostimulation has been incorporated into behavioral research (Kouzani, 
Abulseoud et al., 2013). Since introduction of this device, more recent iterations have 
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 been developed. The stimulation pulses are generated using a microcontroller, a 
current source, and an n-channel metal–oxide–semiconductor field-effect transistor 
for current-controlled stimulation with passive charge balancing (Kouzani et al., 
accepted for publication in IEEE Transactions in Neural Systems & Rehabilitation 
Engineering). Stepwise development of the initial DBS device has enabled long-duration 
continuous stimulation (over 22 days), greater durability for portable rodent research, 
better battery connection, and programmable stimulation parameters. 
 Power consumption becomes an important issue when delivering 
photostimulation from a portable system. With battery-based devices, optimizing 
energy consumption is imperative to maximizing the output duration of a single 
battery. Along with this, an adequate level of irradiance must be delivered to the site 
of stimulation, or else the opsins that have been transfected into the neurons will not 
be activated. Typically, channelrhodopsin-2 is activated with an irradiance of 0.1 – 1 
mW/mm2 (Degenaar, Grossman et al., 2009). Most optogenetic microdevices 
primarily utilize a light emitting diode (LED) over laser as the light source because of 
its benefits in price, beam stability, instrumentation size, and high-frequency temporal 
precision (Clements, Gnadea et al., 2013). The LED, if small enough, can be 
implanted into the skull for cortical stimulation. For deep neural stimulation, an 
optical fiber and coupler is necessary to deliver sufficient photostimulation directly to 
the neurons. The optical fiber transfers photons from the light source to the region of 
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stimulation, while the coupler efficiently channels the emitted photons into the optical 
fiber.  
Certain factors can be implemented to a device to maximize the coupling 
efficiency. For example, an LED can be chosen with a small angle of incidence, which 
will facilitate more of the photons to channel into the optical fiber. An optical fiber 
with a larger core diameter is able to receive more incident light than a smaller core 
diameter. These are typically referred to as multimodal optical fibers, and generally 
have a higher numerical aperture (NA). The higher the NA of an optical fiber, the 
greater the light-gathering capacity of the fiber, which therefore means that the light is 
transferred more efficiently. 
A portable battery-based optogenetic microdevice was developed for rodent 
continuous photostimulation. This manuscript describes the hardware and software 
design of this device, and the fabrication of a customized LED to optical fiber 
coupler that houses the components and transfers photons into the optical fiber. The 
device is then benchtop validated to ensure that a minimal irradiance of 1 mW/mm2 
is achieved. This is to ensure that future animal model implementation can satisfy 
minimal opsin photoactivation thresholds. 
LED to Optical Fiber Coupler 
Construction of the LED-optical fiber coupler requires durability and precision 
engineering to fit component dimensions and efficiently transfer photostimulation 
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through the optical fiber. The size and shape of the coupler was minimized and 
smoothed to be minimally invasive and to be least likely grabbed by the animal while 
grooming. Therefore, a cylindrical shape was utilized with outer diameter of 5000 µm 
and a height of 4500 µm. The material of this cylinder was chosen to be aluminum for 
its relatively lightweight, inability to conduct electricity, its biocompatibility, durability, 
and its ability to be precision-drilled with relative smoothness in the cut.  
The coupler contained two chambers. One chamber was a cylindrical cut that 
was drilled through the axial plane at the radial center. This chamber was used to 
house the optical fiber. Two different types of couplers were made, each compatible 
with a different optical fiber diameter. Therefore, either a 225 µm or a 425 µm drill 
was used to produce a chamber for 200 µm and 400 µm optical fibers, respectively. A 
slightly larger diameter drill was utilized to make these cuts than the optical fiber 
diameter to compensate for any troughs and ridges along the cut, as well as any 
imperfections in the optical fiber. After many trials, these drill bit sizes were utilized to 
ensure a secure fit and ensure quality post-processing of the coupler was not 
necessary. 
The second chamber housed the LED. This rectangular prism recess had 
dimensions that would precisely fit the LED securely and flushed. This was to ensure 
that most emitted light would transmit into the optical fiber and not escape through 
the top of the coupler via internal reflection. After deciding on a set of LEDs with 
different optical wavelengths, yet exact dimensions and other parameters, a 
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 rectangular prism recess was chosen with dimensions: 3200 µm length; 1600 µm 
width; and 1500 µm height. This recess was precision cut with the same machine as 
the optical fiber chamber. The LED was placed into the coupler so that the light-
emitting side of the LED faced downward into the optical fiber chamber. Once 
inserted, the LED came flush with the top of the LED recess so that only the 
electrical contact points on the bottom surface were exposed for soldering. Figure 1 
illustrates the LED to optical fiber coupler using computer-aided design (CAD) 
software in Solid Works. The 3D model created by using this software was uploaded 
to the precision cutting instruments to produce the final coupler. 
 
 
 
Figure 1 – Schematic representation of the coupler illustrated in CAD with 
dimensions. The left and middle image are the final product views, and the right 
image is the wireframe model. 
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LED and Optical Fiber 
We incorporate butt-coupling of the LED to the optical fiber interface to 
maximize transfer efficiency of the light source (Wetzel, 1993). An alternative would 
be to use lenses to focus the emitted light into the optical fiber. However, this 
requires spatial separation from these components. In order to minimize size 
dimensions and manufacturing costs, lenses were disqualified for this product. An 
OSRAM LBCP7P-GYHY-35 high brightness LED (Element14, Australia) was 
utilized for 470 nm blue light output. This LED model runs on maximum 350 mA 
and emits 16.8 cd illuminance. 
Two types of optical fibers were utilized for the device. A FP400ERT 0.50 NA 
400 µm diameter core multimodal fiber, low OH (Thorlabs, NJ, USA) or a 
FT200UMT 0.39 NA 200 µm diameter core multimode optical fiber, high OH 
(Thorlabs, NJ, USA) were used for a 400 µm and 200 µm coupler respectively. Only 
the core of these fibers were used for the device, so the outer coating and the fiber 
cladding were stripped using a fiber stripping tool: a T21S31 425 µm fiber stripping 
tool (Thorlabs, NJ, USA) and a T12S21 230 µm fiber stripping tool (Thorlabs, NJ, 
USA) for 400 µm and 200 µm fiber cores respectively. An S90R Ruby Dualscribe 
Fiber Optic scribe was then used to cut the fiber cores to desired lengths. The optical 
fiber was then placed into the coupler along with the LED, and the LED is terminals 
were soldered to the printed circuit board (PCB). 
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 Optogenetics Circuitry 
 A circular PCB with diameter 12 mm was designed to sit directly on top of the 
coupler and be flushed with it. The PCB is responsible for delivering the optogenetic 
stimulation parameters to the LED and is powered by a single coin battery. A circuit 
diagram of this stimulator is shown in Figure 2. This stimulator comprises of a pico-
power microcontroller (ATmega88PA), a constant current LED driver (CAT4104), 
two rectifier diodes (MSE1PB), and a battery holder.  
The circuitry utilizes the ATmega88PA pico-power 8-bit microcontroller with 8 
KB of flash program memory, 512 KB of EEPROM, and 1 KB of SRAM. The 
CAT4104 provides low dropout current sinks to enable high−brightness output from 
the LED. An external resistor sets the LED channel current. The MSE1PB rectifier 
diodes is used to reduce the overall battery voltage to 5 V. The ATmega88PA 
microcontroller is programmable using C language to control the operations of the 
device, such as setting the stimulations pulses at desired pulse frequencies.  
 
 
Figure 2 – Circuit diagram of optogenetic stimulator. 
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 Benchtop Testing 
 In order to ensure that this device can be incorporated in animal research, 
benchtop validation was performed to ensure that a minimum of 1 mW/mm2 is 
achieved, as channelrhodopsin necessitates a minimum of 0.1 – 1 mW/mm2 
irradiance for photoactivation (Degenaar, Grossman et al., 2009). A PDA36A Si 
Switchable Gain Detector (Thorlabs) was utilized to measure irradiance produced 
from the terminal of the optical fiber. The following equation, which is found in the 
PDA36A Gain Detector manual, was used to determine the optical power output 
from the optical fiber terminal: 
𝐼𝑛𝑝𝑢𝑡 𝑃𝑜𝑤𝑒𝑟 (𝑊)  =  
𝑉𝑜𝑢𝑡
(𝑇𝑟𝑎𝑛𝑠𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒 𝐺𝑎𝑖𝑛 ∗ 𝑆𝑐𝑎𝑙𝑒 𝐹𝑎𝑐𝑡𝑜𝑟
 (1), 
where Input Power is the optical power, Vout is the voltage displayed on an oscilloscope 
by the detector, Transcription Gain is the gain setting selected on the detector, and Scale 
Factor is determined by the equation: 
𝑆𝑐𝑎𝑙𝑒 𝐹𝑎𝑐𝑡𝑜𝑟 =  
𝑅𝑙𝑜𝑎𝑑
𝑅𝑙𝑜𝑎𝑑 + 𝑅𝑠
 (2), 
which was determined to be 0.1. The transcription gain was set on the detector to be 
10 dB. Mimicking the voltage of a coin battery, an input voltage of 3.1 V was set. This 
produced irradiance from the LED equivalent to 1.25 V measured by the detector and 
observed through an oscilloscope as the output voltage. This setup can be seen in 
Figure 3. Therefore, an optical power of 1.25 mW/mm2 was produced at the terminal 
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end of the optical fiber. This irradiance is theoretically sufficient for photoactivation 
of transfected neurons in deep neural regions. 
Figure 3 – Pictures of optogenetic coupler with LED while being recorded by optical 
power detector (left) and out of detector (right). The produced output voltage was 
measured at 1.25 V, which equates to 1.25 mW/mm2 optical power at the terminal of 
the optical fiber. 
Conclusion 
This manuscript describes the fabrication of an optogenetic microdevice for 
rodent photostimulation. It incorporates an LED, an optical fiber for deep brain 
photostimulation, a coupler to house and efficiently transfer emitted light to the 
optical fiber, and the PCB for photostimulation control. We benchtop validate this 
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device to ensure an adequate irradiance of at least 1 mW/mm2, and produce optical 
power of 1.25 mW/mm2. This device can be implemented in rodent behavioral 
photostimulation studies for its relatively minimal hindrance on animal movement and 
naturalistic behavior. This device can be helpful for determining causal relationships 
of stimulated neurons in preclinical research. 
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Abstract. Implementation of optogenetic techniques is a recent addition to the neuroscientists’ preclinical
research arsenal, helping to expose the intricate connectivity of the brain and allowing for on-demand direct
modulation of specific neural pathways. Developing an optogenetic system requires thorough investigation
of the optogenetic technique and of previously fabricated devices, which this review accommodates. Many
experiments utilize bench-top systems that are bulky, expensive, and necessitate tethering to the animal.
However, these bench-top systems can make use of power-demanding technologies, such as concurrent elec-
trical recording. Newer portable microdevices and implantable systems carried by freely moving animals are
being fabricated that take advantage of wireless energy harvesting to power a system and allow for natural
movements that are vital for behavioral testing and analysis. An investigation of the evolution of tethered, port-
able, and implantable optogenetic microdevices is presented, and an analysis of benefits and detriments of each
system, including optical power output, device dimensions, electrode width, and weight is given. Opsins, light
sources, and optical fiber coupling are also discussed to optimize device parameters and maximize efficiency
from the light source to the fiber, respectively. These attributes are important considerations when designing and
developing improved optogenetic microdevices. © 2015 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1
.NPh.2.3.031206]
Keywords: optogenetics; portable microdevices; fiber coupling; tethering; behavioral tests; psychiatry; neurology.
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1 Introduction
The introduction of targeted photostimulation on opsin-express-
ing neuronal cells provides the potential to transform our insight
into the neural circuitry associated with complex behaviors. In
particular, research on treatment of psychiatric mood disorders
is expected to benefit from optogenetic techniques.1–4 More
broadly, neuroscience will benefit, and preclinical psychiatric
research models stand to gain much through this approach.
This may aid in our comprehension of how conscious behaviors
are altered through pathway modulations that resemble disease
states.5,6 Furthermore, conventional treatment options have lim-
ited efficacy and significant side-effects, and the development of
novel therapies is dependent on advances in neurobiology to
identify druggable targets.7,8 Therefore, in order to both under-
stand the brain’s complexity and determine safe treatment
methods, it is necessary to advance behavioral research by
modulating brain activity through the optogenetic method in
appropriate animal models. However, caveats exist to conven-
tional benchtop optogenetic systems in that they are bulky,
expensive, inefficient, and require the animal to be tethered to
receive photostimulation.
Tethering of the animal is one particular limitation of current
optogenetic systems. Tethering increases experimental risks due
to tangling of the optical fiber cord around the animal or through
the experience of unintended rotational forces when connected.
These issues confound natural behaviors that are essential for
interpreting behavioral data. In general, behavioral tests should
mimic previously validated studies rather than be unnecessarily
modified.9 Having these established comparisons allows
researchers to better correlate behaviors with the induced neural
modulations. In the optogenetic technique, tethering the animal
to the benchtop light source and control system substantially
reduces the reproducibility of validated behavioral tests. One
solution to this issue is to miniaturize the entire system such
that photostimulation can be controlled and delivered through
a wearable or implanted microdevice, ensuring minimal behav-
ioral disturbances originate from the optogenetic system.
Despite the advantages for investigators to utilize a portable
optogenetic system for neuromodulation research, the complex-
ities in developing these microdevices necessitate advanced fab-
rication techniques and novel electronic components. Another
difficulty arises when optimizing the coupling efficiency
between the light source and the optical fiber to deliver adequate
light power output while minimizing energy consumption.
Therefore, many research groups continue to evolve tethered
systems, focusing advances on unique optical electrodes and
recording capabilities. As many research groups aim to develop
their own device for their specific research protocols, taking an
optogenetic microdevice from conception to production requires
an extensive examination of both previously developed devices
and cutting-edge technologies that can be implemented. To do
*Address all correspondence to: Abbas Z. Kouzani, E-mail: abbas.kouzani@
deakin.edu.au 2329-423X/2015/$25.00 © 2015 SPIE
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this effectively, a current investigation of tethered, portable, and
implantable devices is required for the analysis of the techno-
logical direction that these devices are taking, the studies they
are facilitating, the advanced components each utilizes, as well
as important parameters critical to each of their designs.
2 Optogenetics
2.1 Opsins
Optogenetics induces modulations in the activity of transfected
neurons that express opsins on their membrane surface. When
activated by light, these opsins function as channels that allow
passage of specific ions to either depolarize or hyperpolarize the
cell, affecting signal transmission. The result is the ability to
control activation patterns of specific transfected cells through
light delivery.10 Viral vectors are commonly used to transfect
neurons in vivo. The virus is modified to only target certain
cell types, for example, only those cells with Cre-positive
expression.11 Once targeted, the virus splices the opsin-encoding
DNA into the neuronal cell genome at the site of virus injection.
Global opsin expression can alternatively be accomplished
by genetically engineering transgenic animals. Each type of
opsin has unique properties in terms of which ions it gates
and what wavelengths activate it. Opsins commonly used for
optogenetics research include halorhodopsin, channelrhodopsin,
and archaerhodopsin (Table 1). Here we include the optimal
activation wavelength for these opsins, as well as their effective
power density for 50% activation (EPD50). EPD50 measures
photostimulation sensitivity of opsins independent of opsin
expression levels, indicating how much optical output an
optogenetic system needs to activate certain opsin types. With
advances in genetic engineering, opsins can be developed to
respond to a wider range of stimulation parameters, function
through unique gating types, and have different sensitivities to
light. Opsins have traditionally acted as channels to change ionic
concentrations inside the cell. Opsins have also been engineered
to activate second messenger systems, such as the OptoXR’s
Opto-α1AR (IP3, DAG Recruiting GPCR) and Opto-β2AR
(cAMP Recruiter GPCR), which both activate at 473 nm.12
2.2 Light Sources
Optimizing light sources and a delivery system is necessary to
activate opsins at the region of interest, as optical penetration
through brain tissue is relatively low from the cortical surface.
Therefore, in order to modulate deeper brain regions, the light
beam would need to be sufficiently strong at the site of stimu-
lation. This is typically achieved through the use of optical
fibers, but miniature light sources implanted into the brain
can also be used. The light source must be powerful enough
to penetrate enough tissue volume and stimulate the entire
region of interest. Modeling light transmission through brain
slices aids in determining how much light is required and can
be calculated using the Kubelka-Munk equation for diffuse scat-
tering media.
T ¼ 1ðS × zÞ þ 1 ; (1)
where T is the transmission fraction, S is the scattering coeffi-
cient per unit thickness, and z is the thickness of the sample.19
This simplified model demonstrates that transmission efficiency
is inversely proportional to the scattering coefficient. Among the
visible light spectrum (∼400 to 900 nm), transmission loss from
scattering is much greater than transmission loss from tissue
absorption.20,21 This implies that the tissue scattering coefficient
is an important indicator of light transmission through the brain
tissue. For mice, the best fit scattering coefficient is 11.2 mm−1,
while for rats, the best fit scattering coefficient is 10.3 mm−1.15
Aravanis et al. measured a 50% reduction in fiber-coupled
optical power through 100 μm of brain tissue penetration that
increased to 90% after 1 mm of tissue depth using a 20 mW
laser diode system.15 Laser systems penetrate through tissue
with greater efficiency due to their low angle of incidence and
high numerical aperture (see Sec. 2.3). The light exiting this
200 μm multimodal fiber outputs is considerably high at
∼380 mW∕mm2 and spreads at an angle of 32 degwith a numeri-
cal aperture of 0.37. Neuronal activation is achievable at least
1.4 mm from the fiber tip, where optical power is at least
1 mW∕mm2 and covers a 1 mm diameter cross-section. With
such high levels of tissue penetration and optical power, laser-
based systems have proven useful in early optogenetic experi-
ments. The first experiments demonstrating neuronal activation
through a light source were performed in 1971 by Richard
Fork using a 488 nm blue laser light at Bell laboratories.22
Their experiments required an extremely high level of irradiance
(140 mW∕mm2), achievable through laser systems, to activate
native abdominal ganglia of marine mollusks. Karl Deisseroth,
who coined the term “optogenetics,” first demonstrated millisec-
ond-timescale activity control of Channelrhodopsin-2 (ChR-2)
transfected mammalian cells using a 300 W xenon lamp in
2005.16 Since then, several light delivery devices have been intro-
duced, including light-emitting diodes (LEDs), organic LEDs
(OLEDs), liquid crystal displays (LCDs), halogen lights, and arc
lamps.More recent systems have adoptedLEDsystems over laser
systems due to benefits in price, instrument size, beam stability,
Table 1 Characteristics and parameters of various opsins used in optogenetics.
Opsin type Opsin subfamily Gate type Activation λ (nm) EPD50 (Ref. 13)
Channelrhodopsin ChR-2 Cation channel 46014–16 1.3 mW∕mm2
Channelrhodopsin VChR1 Cation channel 58917,18 ∼0.5 mW∕mm2
Halorhodopsin eNpHR3.0 Chloride pump 58913 5.4 mW∕mm2
Archaerhodopsin Arch Proton pump 56612 ∼7.5 mW∕mm2
Note: EPD50, effective power density for 50% activation.
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and high frequency temporal precision.23 Despite the high power
intensities achievable through laser-based systems, sufficient
levels to activate ChR-2 proteins with 470 nm photostimulation
are modest, with the minimum spiking irradiance being between
0.1 and 1 mW∕mm2 (or 106 to 107cd∕mm2).24 At intensities
<0.1 mW∕mm2, ChR-2 response falls below 10%.25 High-inten-
sity light sources, such as arc lamps16,26 and lasers,15,27,28,29 can
achieve these optical outputs, as well as many LEDs;30–32 how-
ever, their function is limited to single-point illumination and
whole-field illumination. OLEDs and LCDs, on the other
hand, produce greater spatial resolution on two-dimensional
arrays, but fall short on providing adequate irradiance for photo-
activation (on the order of 1 × 10−4 mW∕mm2, three orders of
magnitude too low to activate ChR-2).33Many newer optogenetic
systems rely on LED light such as that developed by Clements
et al.23 Their LED optogenetic system delivers adequate photo-
stimulation to ChR-2 transfected neurons in mice to induce a
freeze behavioral response,with peak light output from the device
measuring at 29.6 mW through a 465 nm LED. With a total time
lag of 328 microseconds from the trigger to 90% peak output,
this LED-based device ensures the reliable temporal precision
necessary for optogenetic stimulation parameters.
Photostimulation, especially with LEDs, has the benefit of
producing relatively low stimulation artifacts during simultane-
ous neural recording. In contrast, when electrical recording
devices are used with deep brain stimulation, large stimulation
artifacts are present during pulse delivery. These recording
systems include electroencephalogram recordings,34 evoked
potential recording,35,36 local field potential recording,37 and
single neuron recording.38 Each of these recording techniques
needs to actively control artifact suppression through filtering
and other methods to optimize signal-to-noise ratio during
electrical stimulation. Three sources of stimulus artifacts can
be identified at the recording electrode, including voltage gra-
dients, common-mode conversion, and capacitive coupling.39,40
However, an analysis by Clements et al.23 of electrical recording
during optogenetic stimulation revealed stimulation-induced
noise that occurred at microvolt-scale detection levels compared
to much larger millivolt-sized neuronal signals.23 Therefore, the
perturbations of optogenetic stimulation artifacts are dwarfed by
the electrical signals generated by the cells. These artifacts
were recorded using a multielectrode array (platinum-iridium,
pure iridium, tungsten); however, these low-frequency optical
artifacts can also be picked up by electroencephalogram record-
ings or by local field potential electrodes.41 Low-frequency
artifacts can be produced by a variety of processes ranging
from temperature kinetics changing the electrode conductance
to direct illumination of the metal electrode causing electron
emissions (known as the photoelectric effect).42 These particular
artifacts can be removed through high-pass filtering of the
signal.29
Delivering enough optical power to the site of stimulation is
imperative and requires powerful light sources and efficient
delivery systems. However, other parameters such as pulse
width and frequency of light pulses are important characteristics
of optogenetic stimulation parameters that need to be estab-
lished for each study. Generally, a pulse width range of
100 μs to 10 ms and a pulse frequency up to 200 Hz covers
the operating spectrum of optogenetic research.43 These param-
eters, however, are specific to the neuronal cell type, the
expressed opsin, and the activation patterns specified for the
experiment, and can vary greatly between experimental designs.
Determining the ideal parameters for an optogenetics study
requires extensive research and experimentation.
2.3 Fiber Coupling
One of the challenges in building a novel optogenetic microde-
vice is deciding on an interface to optimally transmit light from
the LED source to the neuronal tissue. Because power consump-
tion is a major concern with both battery-based and energy-har-
vesting systems, the interface coupling should be as efficient
as possible to reduce electrical demands. Some authors cited
in this paper are satisfied with cortical surface stimulation to
validate their device. However, most behavioral neuromodula-
tion research focuses on deeper brain structures and requires
a delivery method for the light. Optical fiber coupling is, there-
fore, an appropriate solution, as optical fiber materials effi-
ciently transport light while being biocompatible and inert to
organic tissue. Although some tissue damage does occur from
optical fiber insertion, a relatively small “kill zone” is created
when using small-diameter inert materials.44 Smaller-diameter
optical fibers are more preferable than larger ones because they
minimize neural necrosis along the insertion tract, as well as the
resulting inflammatory response.45 However, smaller fibers trans-
mit light less efficiently because of their more restrictive fiber
cores. In rodents, fiber diameters of up to 300 μm can be tolerated
by mice, while up to 400 μm can be tolerated by rats.46
Maximizing the coupling efficiency between the LED and
the optical fiber is important but can be difficult due to the
incredibly small optical fiber core compared with most source
LEDs. Typical LEDs fall in the hundreds of micrometers to
millimeter range, while micro-LEDs (μLEDs) are in the tens
of micrometers range.33,47,48 Although the dimensions of most
μLEDs are comparable in size to the diameter of an optical
fiber core, transmission efficiency is dependent on many factors
including the LED’s angle of incidence. A smaller core allows
for less incident light to enter and accepts only smaller angles
that propagate from the source. Therefore, multimodal optical
fibers, which have much larger core diameters compared with
single-mode fibers, offer better light transmission. A higher
numerical aperture (NA) will also offer better coupling effi-
ciency as it allows less light to escape through the fiber cladding
once it has entered the core. The NA can be defined as
NA ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n2core − n2clad
q
; (2)
where ncore is the refractive index of the core, and nclad is the
refractive index of the cladding around the core. The NA is,
therefore, an important value to define the light-gathering capac-
ity of the fiber.49 Using a lens also aids in focusing the light
directly into the fiber; however, this increases the dimensions
of the microdevice, as spacing is needed between the lens and
the fiber equivalent to the focal length of the lens. Many cost-
effective lenses in the market have relatively large focal lengths
(∼3 mm), while lenses made of more sophisticated materials
have smaller focal lengths but can be costly. Lenses can greatly
increase the coupling efficiency of the light to the fiber as shown
by the following equation:
η ¼

NAðfiberÞ
NAðlensÞ

2
; (3)
where η is the coupling efficiency. This equation demonstrates
that the coupling efficiency can be increased with a lens as long
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as the NA of the fiber is greater than the NA of the lens
Typically, it is important to consider lenses with a refractive
index of 1.9 or greater; otherwise, the peak coupling efficiency
becomes equal to butt-coupling.50
Conventional methods for light delivery rely on acute optical
fiber stimulation, where the optical fiber can be inserted and
removed. The fiber is inserted only when the stimulation is
required, for example, during behavioral testing.15 This design
makes use of permanently fixed cannulas,15 such as those avail-
able from Doric Lenses.51 These cannulas are patched to min-
imize infection of exposed neural tissue, but can be opened
whenever a fiber needs to be inserted for experimentation.
The drawbacks from this method are apparent, in that continu-
ous reinsertion of the fiber can increase the likelihood of
breaking the fiber and clogging the cannula,46 as well as slightly
changing the placement of the stimulation site and altering
different neuronal activities during each fiber placement.50 In
contrast, permanently fixing only the optical fiber into the
brain without using a cannula leads to less tissue damage during
chronic behavioral experiments due to the thinner implant.50,52
Many researchers use only a short fiber segment that is perma-
nently implanted into the brain.53 When stimulation is needed, a
fiber-to-fiber connector can couple this segment to a longer fiber
that is connected to the light source. However, this connector
can result in up to a 50% loss in transmission efficiency and,
therefore, requires a powerful light source. Some limitations to
this approach do exist, such as unintended escaping of LED
light acting as a behavioral cue during stimulation.54,55
3 Devices
3.1 Tethered Systems
The optogenetic system by Clements et al.23 is a tethered device.
This means that throughout light delivery, the animal must be
connected by an optical fiber cord to a light source that is exter-
nal to the animal’s testing environment, as shown in Figs. 1(a)
and 1(b). Tethered systems typically face a problem with tan-
gling between the optical fiber cord and the animal, especially
if more than one animal is needed to study social behaviors. A
rotary connector can be used to ensure free-moving behavior
and uninterrupted optical connection within an open-topped
behavioral apparatus, but they restrict experiments that require
an enclosed home-cage top.56 Although a rotary connector
seems to be an ideal solution for tethered experiments, it causes
continuous pulling forces on the animal due to retraction of the
cord, and frictional torques during animal rotations. Careful
consideration of the animal species is important when using
a rotary connector, as mice are able to withstand torques of
up to 150 μN · m, while rats can exceed torque tolerations of
>300 μN · m.57 Therefore, optimization of pulling forces by
the rotary connector is necessary to keep the cord taunt without
causing unnecessary cord retracting stress to the animal. Despite
achieving rotary optimization, tethering can still alter behavior
and disrupt the naturalistic testing environment being sought,
potentially confounding behavioral experiments. Another
issue with the use of rotary connectors is the transmission effi-
ciency of the light source. Some commercially available rotaries
yield relatively high transmission efficiencies, while some give
much less (Prizmatix: 89%, Doric Lenses: 85%, ThorLabs:
65%). Tethered systems are not limited by the electrical
demands of their light source and can, therefore, deliver higher
optical power. Compared with portable devices, which are
restricted by their power supply and energy consumption, rotary
connectors do benefit an experiment when tethering cannot be
avoided.
Another function that can be conducted concurrently with
photostimulation is neuronal recording. Recording the electrical
signals of neurons produced by optogenetic stimulation gives
insight into the robustness of the photostimulation response
and subsequent spatial activity changes. Confirmation of con-
tinuous neuromodulation by the optogenetic system is achieved
through these recording electrodes, providing both temporal and
spatial information. Single recording electrode implants can
measure the effectiveness of the optogenetic device and are,
therefore, important tools to validate the device’s functionality.
Multielectrode arrays can measure the distribution of neuronal
activation from the light beam as it disperses out of the fiber
and into the tissue. This is because of the two-dimensional
spatial recording abilities of multielectrode arrays. Previous
applications of multielectrode arrays include neural network
dynamics,59 synaptic plasticity,60 visual perception,61 and phar-
macotherapies.62 Because optical transmission decreases as the
light passes through neural tissue [as shown by Eq. (1)], multiple
recording electrodes can help determine how much area of
activation is produced by the photostimulation. This is a useful
tool to ensure that a specific brain region of interest can achieve
the desired spatial coverage to ensure complete stimulation.
Although each recording electrode on the array can be replaced
with an electrical stimulator, conventional stimulation arrays are
only able to stimulate, and not inhibit electrical activity.
Current technology allows for multielectrode arrays to be fit-
ted with single optical fibers such as that by Wang et al.58 As
shown in Figs. 1(c) and 1(d), a Pt-tipped 6 × 6 multielectrode
array tapered to 1 mm length with 400 μm spacing was used
to provide verification that electrical activity was modulated
locally in response to the light. Additionally, this system can
be adapted with closed-loop control features to set stimulation
triggers based on surrounding activity. These triggers ensure
that activity is modulated only when certain neural criteria
are met, helping to achieve the relevant behaviors at optimized
Fig. 1 (a) and (b) Optogenetic system by Clements et al.23 with a teth-
ered animal. (c) and (d) A multielectrode and optrode array by Wang
et al.58 capable of recording and stimulating a tethered animal.
[Source: (a) and (b) reprinted from Clements et al.23 with permission
from SPIE. (c) and (d) reproduced with permission fromWang et al.,58
Copyright year 2012, IOP Publishing. All rights reserved.]
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times without overstimulating the brain. This is an important
control feature in attenuating neurobiological diseases in animal
models, such as epilepsy, because they can be turned on as soon
as seizure-like waveforms are detected.63–65 However, one
drawback that can arise with such multielectrode arrays is that
multiple deep penetration points can cause brain injury during
insertion, especially when trying to stimulate and record from
deeper brain regions. Each recording electrode in the array
can be hundreds of micrometers in diameter, and each causes
neuronal damage as the array is driven into the brain. For
this reason, most studies using multielectrode arrays restrict
their measurements to cortical recording. The recording array
of Wang et al.,58 for example, only penetrated 0.5 to 1 mm
into the brain. This kind of invasive surgery can trigger a pro-
longed inflammatory and immune response66 that could sub-
sequently affect neural activity and confound behavior.
To avoid multiple penetration points during insertion of the
optical fiber and recording electrodes, as well as to record from
deeper brain regions, a solution is to combine the electrode and
LED onto a biocompatible material as a single piece, commonly
referred to as an optrode, and insert this into the desired region.
This combined optrode can simultaneously stimulate and record
from the same site and is a feature in the optogenetic system
fabricated by Cao et al.67 The team incorporated the LED and
electrode onto a single optrode for dual stimulation and record-
ing as shown in Figs. 2(a) and 2(b). Their design minimizes
power consumption by allowing full exposure of the LED to
the stimulation site without losing efficiency through optical
fiber coupling. This particular optrode is relatively wide,
measuring 900 μm. In contrast, commercially available optical
fibers for preclinical research are between 200 and 400 μm.
The system of Cao et al.67 also uses a particularly large
LED, measuring 1000 μm×600 μm×200 μm (PicoLED, Rohm
Semiconductor, Kyoto, Japan). However, technology is contin-
uously advancing to produce smaller and more efficient LEDs
that may be implemented in future designs. With advanced fab-
rication technologies and components, this device has potential
to be reduced in size for less traumatic implantation. Early optr-
odes for tethered freely moving experiments were first devel-
oped by Anikeeva et al.68 to record medial prefrontal cortex
response by local optical excitation and inhibition. Their group
produced four 25-μm-diameter polymer-coated nickel-chro-
mium alloy tetrode bundles that wound around a single 200 μm
optical fiber. The optrode was attached to a headstage to allow
open-field movement while tethered to the light source.
In their experiment, Cao et al.67 bypassed the ChR-2 trans-
fection process by procuring a transgenic Thy1-ChR2-YFP
mouse line. While anesthetized and in stereotaxis, the mouse
received blue light at 465 nm to the visual cortex created by an
LED, which changed neuronal electrophysiology monitored by
the recording optrode. Using transgenic animals can be advanta-
geous in that the opsin molecules are persistently expressed
throughout the brain. Unfortunately, obtaining such transgenic
animals requires greater resources and time than utilizing the
transfection process, as transgenic animals need to be geneti-
cally engineered and bred for several generations. Therefore, in
most cases, recombinant viral vectors are used to administer the
virus several weeks prior to the optrode insertion at the site of
Fig. 2 (a) and (b) An optrode fabricated by Cao et al.67 for dual stimulation and recording from a single
site. (c) and (d) An intricate recording/stimulating optrode by Rubehn et al.69 with a microfluidic channel
capable of delivering a virus for neural transfection. [Source: (a) and (b) are reprinted from Cao et al.67
with permission from IEEE. (c) and (d) are reprinted from Rubehn et al.69 with permission from Royal
Society of Chemistry.]
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stimulation. The virus is typically administered by direct injec-
tion into the brain region of interest using a micro-syringe. The
optrode is then implanted into the same spot after the virus is
completely transfected. This double-surgery approach, however,
adds surgical stress to the animal through anesthesia induction.
Although unavoidable in most nontransgenic animals, the initial
transfection surgery would have relatively little consequence in
neurodegeneration because neuronal loss and the glial-inflam-
mation response are considerably higher with persistent foreign
body implantation than acute stab wounds followed by object
removal.70 In general, glial response is biphasic with an early
activation of microglia and astrocytes followed by a restriction
of glial activity at the site closest to the implant (glial scarring).71
Nevertheless, maintaining opsin expression at the site of stimu-
lation can be difficult after the optrode has been implanted.
When retransfection is necessary for longer experiments, a con-
tinuous local viral transfection can be accomplished through the
implementation of microfabrication techniques and microfluidics.
Advances in microelectromechanical systems fabrication
techniques have allowed scientists to shrink down medical devi-
ces to the size of tiny chips. Lab-on-chip devices utilize micro-
fluidic channels to transport fluids to specific targets in order to
perform extensive laboratory-grade research in tiny settings.
Rubehn et al.69 have incorporated this technology to deliver
the soluble virus through microfluidic channels while also per-
forming optical stimulation and electrical recording on one sin-
gle microfluidic optrode, as shown in Figs. 2(c) and 2(d). Not
only does this allow a single invasive surgery to accomplish both
transfection and stimulation, it also enables microfluidic injec-
tion of the virus for on-demand, continuous transfection. This is
because cellular expression of virally transfected opsins dimin-
ishes over time, therefore, experimental timelines need to be
kept shorter or retransfection needs to take place. Once suffi-
cient time has elapsed to ensure recombinant viral transfection,
optical stimulation can begin to modulate neural activity and
concurrent electrical recording can take place. With such precise
fabrication processes, this fluidic delivery optrode hybrid has a
thickness of ∼250 μm, about the same thickness as many optical
fibers used. However, manufacturing such an optrode is not typ-
ically possible in most laboratories, as it needs a sophisticated
fabrication process. Prior research in design, materials, and
transport simulations must be realized before even the first
prototype can be constructed, therefore, fabricating this device
from scratch can be a laborious task even after all of the fabri-
cation equipment and machinery has been procured. Despite all
of these issues, the authors were able to successfully inject both
ChR-2 and NpHR at multiple depths when inserting this micro-
fluidic-optrode hybrid. After six weeks of recovery, they were
able to optically stimulate brain cells with both 473-nm light and
593-nm light with output powers of 21 and 14 mW, respectively,
while concurrently recording neuronal activity changes.
The current paper focuses on the advances in device compo-
nents and functionality to illustrate the evolution of optogenetic
microdevices from simple tethered systems to novel wireless
devices. However, it is worth noting here that technologies
have not progressed solely in electrical components. Optical
fibers, for example, have also seen improvements recently,
such as the tapered optical fiber developed by Pisanello et al.72
This fiber allows for dynamic illumination control along each
taper, which acts as a window for light to escape from the
fiber. Tapers are formed by locally removing the coating at
each site where it is needed. This optical fiber technology allows
multiple areas of the brain to be selectively targeted by photo-
stimulation along the track of the optical fiber through the use of
a single light source. However, sophisticated calculations and
simulations are necessary to predictably deliver enough optical
power through the desired tapers.
3.2 Portable Microdevices
Although the technologies described thus far (summarized in
Table 2) represent significant serial improvements in research
since the inception of optogenetic devices, a critical factor
for device development is portability. Some of the previously
described optogenetic systems were only able to stimulate anes-
thetized animals while they lay motionless under stereotaxic
conditions, while other studies used tethered systems to allow
some movement. Acute stereotactic optogenetics studies may
be suitable for research on neural connectomics, but behavioral
experiments require free-moving animals, with minimal devia-
tions from the animals’ natural settings to gather relevant data.
Tethering the animal to the optogenetic system deviates from
this natural setting as it restricts home-cage activity, spontaneous
pain, wheel running, and freely moving social interactions.73
With emerging technologies allowing biomedical devices to
become smaller than previously imagined, researchers have
designed devices that are small enough to be implanted subcu-
taneously,57,74,75 some with only minor components exposed
externally. These implantable devices allow the animal to
perform measureable behavioral tasks while freely moving.
Affixing headstage devices or optical fibers and cannulas to
the animal requires the skull to be largely exposed during sur-
gery. This exposure allows for adequate anchoring of cranial
Table 2 Parameters of tethered systems. Blank fields indicate no information given.
Parameter Ref. 23 Ref. 58 Ref. 67 Ref. 69
LED pulse width 500 μs 20 ms 25 to 100 ms 300 μs
Pulse frequency 1 HZ 8 Hz 1 to 20 Hz 0.5 Hz
Wavelength 465 nm 473 nm 465 nm 474∕593 nm
Light output 29.6 mW 1.8 mW 25 mcd 21 mW∕14 mW
Electrode width 16 μm 200 μm 900 μm 250 μm
Power density 916 mW∕mm2 0.7 mW∕mm2
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screws and coverage of dental cement to ensure a strong bond is
formed, helping keep the fixtures attached to the skull. The large
surgical site, use of bonding cement, and drilling of cranial
screws increase the stress on the animal associated with surgery,
and should be minimized. Smaller and implantable devices help
minimize these issues; this is one advantage of miniaturizing
portable devices. Just as important, small devices give the ani-
mal less material to grab on-to during self-grooming. A problem
associated with animal termination from a study is the animal’s
ability to grab a device or electrode and forcibly detach it from
their skull. This leads to damage to the device, a loss of resour-
ces and time spent on surgery and treatments, and increase in
the risk of injury or death to the animal.
The ability to implant a microdevice with no bulky compo-
nents can remedy animal mortality rates. By eliminating the
battery and harvesting energy through alternative sources, newer
and smaller devices can be fabricated that are easier to imple-
ment in preclinical research. A small chip measuring <9 mm2,
constituting the bulk of the device, is an important aspect of the
device of Yeh et al.,74 as seen in Fig. 3(a). This is achievable
through electromagnetic (EM) midfield energy harvesting,
which the device gathers from an exposed coil measuring
only 3 mm2. This energy accumulates onto a capacitor to
power the LED. The source of this propagating field comes
from a circuit board transmitting 500 mW of power, which is
about the average power level of cell phones, to sustainably
power the receiving coil even at distances of 15 cm. This system
propagates energy in the gigahertz spectrum within a range that
is safe when absorbed by biological tissue. This desired fre-
quency range can be sufficiently estimated as a time scale of
the amplitude variation of the EM field falling largely between
upper-bound and lower-bound values. The upper-bound value is
represented by the dielectric relaxation time constant of the tis-
sue, and the lower-bound value is represented by the electric
time constant. Finding an ideal frequency range for energy
harvesting is vitally important for the animal’s wellbeing.
The animal’s wellbeing is scrutinized by institutional research
ethics committees, and impacts on animal welfare profoundly
affect experimental outcomes.76 Reported values for muscle
tissue electric time constant and dielectric relaxation time con-
stant are 2.3 ns and 7.2 ps, respectively, giving a safe midfield
frequency range between 690 MHz and 2.2 GHz. The Federal
Communications Commission mandates that the maximum
permissible exposure to radio frequency (RF) power for humans
in controlled environments is 3.03 mW∕cm2.77 Although this
particular device was developed to stimulate cardiac muscle
cells in mice, it could be modified for optogenetic stimulation
of neural tissue either directly by cortical stimulation or through
the use of a fiber-optic cord for modulations in deep regions.
Other wireless and battery-less devices that can take advan-
tage of power transmission are available. This concept is becom-
ing more critical in the medical device field because of the
inherent problems associated with thermodynamic chemical
reactions that occur in them, including having a slow recharging
rate of several hours, limited charge/discharge cycles, and being
a biohazard if toxic materials are leaked.79,80 Batteries that sus-
tain sufficiently long stimulation periods are inherently large
and heavy, thus battery-based devices can interfere with the
movements of animals. Therefore, it is beneficial to fabricate
smaller battery-less microdevices to power the LED, which
can have greater potential in recreating the animal’s natural envi-
ronment during photostimulation. One solution is substituting
battery charging with capacitor charging through energy trans-
mission as previously described. However, charging a capacitor
to deliver energy to the LED would require multiple stacked
capacitors to meet the high energy demands of most medical
devices. Whereas batteries have sufficiently high energy den-
sities, their power densities are relatively low, while capacitors
have much higher power densities but lack in energy density.81
In order to solve this issue, a middle-ground is necessary, and
one solution lies in the use of supercapacitors. Supercapacitors
can achieve power densities several orders of magnitude greater
than batteries.82 Meng et al.81 describe the fabrication of such
supercapacitors that are flexible, solid-state, and are only 1 mm2
in size, yet offer a high area of capacitance at 1.3 mF∕mm2.
They proposed combining the supercapacitor circuit with a
boost converter in order to minimize the current load on the
supercapacitor, which will then charge a regular capacitor that
regulates the power to the load.
Using a supercapacitor for miniature optogenetic devices
powered by RF has the potential to substantially advance current
behavioral research, enabling investigators to run multiple
Fig. 3 (a) Transmission coil and circuit board described by Yeh et al.74 on a penny for size comparison.
The tiny size of this system allows it to be implantable within the cranial skin of the animal. (b) The head-
stage and antenna developed by Wentz et al.43 (c) Headstage fabricated by Ameli et al.78 incorporating a
recording electrode. [Source: (a) is reprinted with permission from Yeh et al.74 Copyright 2013, AIP
Publishing LLC. (b) is reprinted with permission from Wentz et al.43 Copyright 2011, IOP Publishing.
All rights reserved. (c) is reprinted from Ameli et al.78 with permission from IEEE.]
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animal studies in parallel. Devices with these capabilities are
able to continuously transmit neurostimulation signals to a wear-
able or implanted optogenetic device while the animal is in its
home cage. As shown in Fig. 3(b), Wentz et al.43 have developed
such a device to demonstrate control of animal behaviors by
stimulating adult Thy-ChR2 transgenic mice pyramidal cells
of the motor cortex and analyzing subsequent rotational move-
ments. Their device incorporated a low-strength oscillating
magnetic field peaking at 300 A∕m to charge a supercapacitor,
and power a 1 × 1 mm2 LED with 2 W of power in steady state
and 4.3 W in burst LED. Although their experimental setup was
to stimulate cortical cells at the surface of the brain, their device
can be adapted with fiber-optic cords to stimulate deeper
regions. The whole device was fitted on a headstage that the
animal wears and totals just 2 g in weight. Additionally, this
device can be equipped with a 1 g wireless telemetry compo-
nent, such as light detection or thermal data, to output data
back to a computer. Throughout operation of the device, the ani-
mal is electrically insulated from the device components to
ensure safety. The device is also monitored for heat generation
from the LED and integrated circuit. The maximum temperature
rise in steady-state operation was 0.6°C, representing a worst
case scenario and well within a safe range.
One additional method to further advance an optogenetic
microdevice would be incorporating a recording electrode to
wirelessly send information back to a computer for stimulation
readouts. Ameli et al.78 have accomplished this task as shown in
Fig. 3(c). Using a fiber-optic cord concurrently with electrodes
coupled to a headstage device with a wireless signal rectifier,
their device incorporates many of the evolutionary advances
discussed throughout this review. Their device is relatively
heavy at 7.4 g, but implementing technological advances to
the device, such as smaller components and custom integrated
circuits, can solve this problem as discussed by the authors.
Nevertheless, the device is small at 15 × 25 × 17 mm3. The
transmitter can power the device up to 7 cm away and can trans-
mit data back to a base-station computer>2 m away. This makes
it ideal for running studies with multiple animals in individual
home cages receiving power through multiple transmission
sources and sending the information back to a central computer.
Although this device has not been tested in vivo, it demonstrates
promise that future iterations can be developed that are smaller
and robust.
Smaller components and devices are being progressively
implemented in more recent portable optogenetic devices.
Rossi et al.83 fitted their LED onto an optrode that can be
inserted into the brain. This allows experiments by this device
to be performed in deep brain regions without relying on optical
fibers. Although these LEDs are considered relatively large
compared to smaller μLEDs, this device represents a marked
improvement in portable devices compared to those previously
discussed. As can be seen in Table 3, this newer device is
smaller, lighter, and has a greater transmission range than other
devices. It does, however, require a battery to recharge the
device every 2 h, and other limitations exist, such as a lack
of recording features. One important advantage of this system
is that all of the components are commercially available and the
device can be constructed in any standard neuroscience lab. The
ability for most laboratories to construct their own device
becomes harder as the device dimensions are reduced, advanced
components and functions are utilized, and more fabrication
technologies are required.
3.3 Implantable Devices
Miniaturization of optogenetic devices is far from being com-
pletely realized, as newer classes of implantable optogenetic
systems are being introduced that are several orders of magni-
tude smaller in scale compared to early systems. Implantable
devices take advantage of μLEDs that are inserted into the
site of stimulation and are, therefore, less reliant on optical fibers
to deliver light. Optical fibers are typically able to illuminate
ventral structures from the fiber tip, whereas μLEDs have the
advantage of complete customizations, including the shape and
size of the photostimulation. μLEDs can come in a range of
sizes (625 to 10;000 μm2), can be fitted on a two-dimensional
array and spatially controlled for different illumination patterns,
and can output light in different directions using reflective
surfaces.73 Because of the low power demands of advanced
semiconductor μLEDs, power harvesting systems through radio-
frequency scavenging make it possible for an optogenetic
system to be at least partially implantable at the site of
Table 3 Transmission and device parameters of portable devices. Blank fields indicate no information given.
Parameter Ref. 74 Ref. 43 Ref. 78 Ref. 83 Refs. 73 and 84
LED wavelength 590∕630 nm 470 nm Various 465.5 nm Various
LED size Varies 1 × 1 mm Varies 240 × 320 × 140 μm 50 × 50 × 6.45 μm
Stimulation site Tissue surface Cortical surface Anywhere via optical fiber Anywhere via implant Anywhere via implant
Device dimensions 9 mm2 <1 cm3 15 × 25 × 17 mm 14 × 17 × 5 mm ∼1 cm3
Weight 2 g 7.4 g 2.9 g ∼2 g
Receiver frequency 1.6 GHz 2.4 to 2.485 GHz 868 MHz 2.4 to 2.5 GHz 910 MHz
Transmission range 15 cm Several cm <7 cm 4 m 1 to 2 m
Data rate 1 Mbit∕s 320 Kbit∕s 250 Kbit∕s
Power source EM midfield RF scavenging Inductive power Rechargeable battery RF scavenging
Neurophotonics 031206-8 Jul–Sep 2015 • Vol. 2(3)
Kale et al.: Evolution of optogenetic microdevices
Downloaded From: http://neurophotonics.spiedigitallibrary.org/ on 09/28/2016 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
292
stimulation. In partially implantable systems, only the power
harvesting components are exposed outside of the skull to effi-
ciently harness energy and ensure animal safety. An example of
implantable devices that use wireless energy harvesting is the
device developed by Kim et al.84 Through advanced microfab-
rication techniques as described in their protocol,73 their device
demonstrates how multiple components can be integrated onto
a miniature system. The system layers functional components
onto an injectable microneedle to conveniently implant the
optrode. The multitude of functions performed by this single
optrode include electrophysiological measurements (Pt-contact
pad, microelectrode), optical measurement (silicon μ-IPD), opti-
cal stimulation (μLED array), and temperature sensing (serpen-
tine Pt resistor). When dealing with functional components in
close proximity to internal tissue, thermal management is imper-
ative for the animal’s safety and it is important to measure the
temperature during device validation. Their device’s μLEDs
produced <0.10°C change in temperature, which is much
lower than the ∼2°C temperature change produced by deep
brain stimulation.85 At a distance of 1 m and a radio-frequency
scavenger output of 4.08 mW, the group was able to produce a
7 mW∕mm2 optical power output. The RF power that reaches
the animal at this distance is between 0.15 and 0.77 mW∕cm2,
much lower than the maximum permissible exposure limits for
humans. These cellular-scale μLEDs are only 6.45 μm thick and
50 × 50 μm2 in area, which are more than a thousand times
smaller than conventional LEDs. A collection of four μLEDs on
the single optrode was able to increase self-stimulated lever
presses by mice associated with dopamine release in the ventral
tegmental area.
Integration of μLEDs onto an array is a useful tool to pre-
cisely stimulate brain regions with complex shapes or topo-
graphic neuronal cell types. In such cases, having the ability
to target the region of interest without photostimulating other
regions allows researchers to control neuromodulation experi-
ments at the cellular scale. Grossman et al.33 implemented
4096 μLEDs, each only 20 μm in diameter, to create a
4 × 4 mm2 optogenetic array. Each 3 × 3 mm2 light spot created
by these μLEDs produces up to 3 mW∕mm2 optical power. With
lenses, this light spot can be demagnified by 10∶1 to produce
a 0.3 × 0.3 mm2 light spot with 300 mW∕mm2. Each one of
these μLEDs can be individually switched on or off and contain
different wavelength emitters for a broader range of opsin
activation. This capability also allows μLED arrays to activate
certain clusters of neural populations within regions, maximizing
activation precision. Research in sensory prosthetics and other
studies involving topographic regions of interest can benefit
from the cellular-scale precision offered by this device.
4 Conclusion
Advances in medical technology and fabrication techniques
have enabled brain research and increased the scope of potential
studies. New devices are constantly being developed and distrib-
uted for use by researchers. Tables 2 and 3 illustrate only a small
portion of important considerations in developing optogenetics
devices. Understanding the trends and advances is important for
designing improved systems for up-to-date research methods. A
device is within reach that would contain a modifiable LED
source, recording electrodes, and a microfluidics viral delivery
system all on a single optrode. The chip would be small enough
to sit on top of the skull yet be implanted under the skin and
incorporate a tiny rectenna that wirelessly powers the device,
transmits information, and alters the parameters in real time.
This way, animal behavior studies can be performed in large
scale and in parallel. This will enable researchers to better
understand the core neurobiology of diverse neurological and
psychiatric disorders, and facilitate the rational development of
treatments for wide-ranging neural syndromes, such as depres-
sion, epilepsy, Alzheimer’s disease, and more.
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Abstract   Deep brain stimulation (DBS) is a widely used, efficacious neu-
rosurgical treatment for neurological movement disorders. For example, 
electrical stimulation in the ventral intermediate thalamic nucleus drastically 
reduces tremor in patients with essential tremor. Likewise, stimulation in the 
subthalamic nucleus or the internal globus pallidus significantly attenuates 
tremor, rigidity, bradykinesia and gait complications of Parkinson’s disease. 
Its application is now rapidly expanding to a wide variety of conditions in-
cluding epilepsy, neuropsychiatric disorders, Tourette syndrome, Alz-
heimer’s disease, and intractable pain. However, the exact underlying ther-
apeutic mechanisms of action of DBS remain unclear. Despite this lack of 
understanding, clinical utility of DBS cannot be underappreciated, and there 
is a great need for studies that can elucidate patient-specific optimization of 
DBS parameters and targets. This chapter explores recent approaches for 
studying the underlying mechanisms of action of DBS. Additionally, it dis-
cusses the limitations of current open loop approaches to DBS and accentu-
ates the importance of developing a smart closed-loop DBS system that can 
optimize therapeutic parameters in real time to individual patients and symp-
toms. 
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Introduction 
As recently as thirty years ago, surgical techniques for treating many 
neurologic disorders involved ablative procedures potentially resulting in 
significant and sometimes generalized damage to the brain (Faria 2013; 
Walter and Vitek 2004). The advent of thermal and cryogenic lesioning 
brought forth greater spatial selectivity during surgery; however these pro-
cedures are irreversible and cannot be modulated if the treatment needs 
change (Bergman et al. 1990; Aziz et al. 1991; Benazzouz et al. 1993). In 
the early 1990’s, deep brain stimulation (DBS) became a reversible alterna-
tive to lesioning procedures for the treatment of movement disorders such 
as Parkinson disease and essential tremor (Benabid et al. 1991; Benabid et 
al. 1996; Perlmutter and Mink 2006). Since then, the use of DBS has become 
more widespread for the effective treatment of other neurologic disorders 
such as dystonia (Kumar et al. 1999; Lozano et al. 1997; Perlmutter and 
Mink 2006; Sellal et al. 1993), Tourette syndrome (Diederich et al. 2005; 
Houeto et al. 2005; Perlmutter and Mink 2006; Temel and Visser-
Vandewalle 2004; Visser-Vandewalle et al. 2003), epilepsy (Fisher et al. 
2010; Kocabicak et al. 2015; Tekriwal and Baltuch 2015), depression 
(Dougherty et al. 2015; Grubert et al. 2011; Mayberg et al. 2005; Merkl et 
al. 2013), neuropathic pain (Franzini et al. 2003; Katayama et al. 2001; 
Lozano et al. 1997; Perlmutter and Mink 2006) and obsessive-compulsive 
disorder (OCD) (Abelson et al. 2005; Gabriels et al. 2003). Additionally, 
DBS offers promising outcomes for the treatment of other neurological con-
ditions ranging from bipolar disorder (Holtzheimer et al. 2012) and Alz-
heimer’s disease (Laxton and Lozano 2013) to addiction (Luigjes et al. 
2012), cerebral palsy (Vidailhet et al. 2009; Marks et al. 2011), and hyper-
phagic obesity (Tekriwal and Baltuch 2015) (Table 1). However, the under-
lying therapeutic mechanisms of DBS remain unknown despite years of re-
search and successful clinical application.  
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The predominant hypothesis suggests that DBS modulates patho-
logical activity via excitation of axonal fibers of passage and inhibition of 
local cell bodies (Florence et al. 2015; McIntyre and Thakor 2002). How-
ever, the integration of spatially and temporally distant signals suggest that 
the neural mechanisms underlying DBS efficacy may be far more complex 
(Hess et al. 2013). Therefore, further advancement of DBS technology will 
require a greater understanding of the response to DBS on the molecular, 
biochemical, cellular, and circuitry levels. For example, the brain is a highly 
complex organ, with innumerable neural signals transmitted via distinct 
neurotransmitters capable of modulating neural activity across both local 
and global neural circuitry (Hamani and Temel 2012). Thus, DBS may in-
duce complex changes in synaptic plasticity that reorganize neural circuits 
and rectify neuropathological changes associated with neurological disor-
ders. These changes could help explain the different timescales in therapeu-
tic efficacy observed across different disorders. For example, DBS patients 
with Parkinson’s disease who experience immediate symptomatic relief, and 
patients with major depression who require longer intervals before sympto-
matic improvement can be observed (Herrington et al. 2016).  
Monitoring of Neural Activity 
 Numerous techniques are being utilized in clinical and preclinical 
studies to unravel the mechanisms of action of DBS and assist in target se-
lection as well as optimization of stimulation parameters (Herrington et al. 
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2016; Grahn et al. 2014). These techniques allow examination of the neural 
responses to DBS at local and network-levels with high spatio-temporal res-
olutions. The most commonly utilized techniques include electrophysiolog-
ical measurement of compound neural activity, electrochemical measure-
ment of neurotransmitter signaling, and functional imaging techniques. 
Electrophysiological monitoring 
 Electrophysiological analysis has played an instrumental role in un-
raveling the function of the central nervous system (CNS) since the early 
1950’s, when Hodgkin and Huxley demonstrated the electrical nature of the 
action potential (Hodgkin and Huxley 1952). Since then, electrophysiologi-
cal analysis techniques have evolved to enable the analysis of a broad range 
of neurological activity, from patch-clamp techniques that allowed the study 
of single ion channels, to single-unit recordings and global field potentials 
via multi-unit recording arrays (Neher et al. 1978). This technological di-
versity permits comprehensive evaluation of neurological activity from the 
subcellular to circuitry levels (Grahn et al., 2014). For example, electrophys-
iological techniques have been utilized to investigate the physiological 
mechanisms underlying DBS efficacy in the treatment of Tourette syndrome 
(Israelashvili et al. 2015). In this study, local field potential (LFP) recording 
electrodes were implanted into the thalamus, globus pallidus pars interna 
(GPi), or nucleus accumbens to analyze neural activity before, during, and 
after stimulation.  Results from this study suggest that the pathophysiology 
of Tourette syndrome is related to dysfunctional synaptic transmission 
within deep brain nuclei, producing oscillations of inappropriate frequency 
and amplitude, and preventing the effective inhibition of stereotypical be-
haviors and tics such as blinking, head jerking, sniffing, throat clearing, and 
other vocalizations (Albin and Mink 2006). Similarly, excitatory postsynap-
tic potentials (EPSPs) evoked by high and low frequency stimulation of neu-
rons within the subthalamic nucleus (STN) of 6-hydroxydopamine (6-
OHDA)-lesioned rats revealed that high frequency stimulation produced 
significant EPSP depression in dopamine-depleted rats (Yamawaki et al. 
2012). Similarly, low frequency stimulation resulted in EPSP augmentation 
in dopamine-intact rats (Yamawaki et al. 2012). 
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Neurochemical monitoring 
 Pre-clinical studies have demonstrated that neurotransmitter release 
is evoked by high frequency stimulation, and thus may be associated with 
the effects of DBS (Lee et al. 2004). Fixed potential amperometry is a tech-
nique for measuring neurotransmitters and other analytes such as Glutamate, 
and involves the application of a constant voltage through a carbon fiber 
microelectrode implanted within the target of interest (Gale et al., 2013; Tye 
et al., 2013). Carbon fiber microelectrodes are coated with specific enzymes 
that react with non-electroactive analytes of interest, resulting in electroac-
tive products that can be electrically measured (Koehne et al., 2011). The 
signals detected are caused by oxidative reactions between the applied volt-
age and the molecules of analyte within the extracellular space (Van Gompel 
et al., 2010). Unfortunately, the continuous enzyme delivery required to de-
tect the neurotransmitter of interest makes this technique impractical for 
chronic in vivo detection of neurochemicals (Jacobs et al., 2010). Fast scan 
cyclic voltammetry (FSCV) is an alternative electroanalytical technique ca-
pable of real-time detection of electroactive neurotransmitters, hormones, 
and other metabolites (Glanowska et al. 2012; Kita and Wightman 2008).  
Previous studies have demonstrated that FSCV can effectively detect sero-
tonin, norepinephrine, epinephrine, dopamine, and adenosine, as well as 
changes in oxygen and pH (Perry et al. 2009; Heien et al. 2004; Venton et 
al. 2003).  FSCV relies on the delivery of rapid voltage oscillations to allow 
oxidation and reduction of electrically active compounds of interest, result-
ing in the generation of unique electrical voltage versus current signatures 
specific for each analyte (Perry et al. 2009; Robinson et al. 2003). By taking 
advantage of FSCV and a Wireless Instantaneous Neurotransmitter Concen-
tration Sensing (WINCS) system designed to wirelessly measure neuro-
chemical responses during DBS, Chang and colleagues showed that the im-
mediate symptomatic relief induced by implantation of the DBS lead, also 
known as the microthalamotomy effect (Tasker 1998) was accompanied by 
a neurochemical signature resembling that of adenosine release (Chang et 
al. 2009; Chang et al. 2012) (Fig. 1). Previous preclinical animal studies 
have demonstrated that administration of adenosine A1 agonists alleviates 
tremor symptoms in mice models of harmaline-induced essential tremor 
(Bekar et al. 2008). Therefore, it is possible that enhancement of adenosine 
signaling induced by the microthalamotomy effect, or by the administration 
of adenosine agonists, inhibits the maladaptive excitatory signaling produc-
ing uncontrolled movement in patients with essential tremor.  However, the 
CNS contains multiple receptors for adenosine that operate through a variety 
304
of G-proteins, including Gs, Gq, and Gi. Variable effects in synaptic trans-
mission are observed based on their localization on presynaptic, postsynap-
tic, or astrocytic membranes and the subsequent downstream signaling from 
the G-protein coupled receptor (Olah and Stiles 1995).  
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Functional imaging  
 Functional magnetic resonance imaging (fMRI) is an MRI tech-
nique that measures changes in blood flow (Logothetis 2002).  The utility of 
this technique for characterizing the effects of DBS is based upon the prin-
ciple that the magnitude of cerebral blood flow and oxygen consumption is 
proportional to the relative activity of individual brain regions due to differ-
ential energy requirements during periods of neural activity (Uludag et al. 
2004).  Specifically, the blood-oxygen-level dependent (BOLD) signal 
measures changes in the magnetization of hemoglobin following deoxygen-
ation of blood within the CNS (Ogawa et al. 1993). This enables the gener-
ation of a oxyhemoglobin/deoxyhemoglobin heat map based upon changes 
in oxygen consumption resulting from modulation of neural activity (Rosen 
et al. 1998).     
To this end, fMRI has been recently used to characterize the effects 
of high (130 Hz) and low (10 Hz) frequency stimulation on neural activity 
in a swine model of DBS (Paek et al. 2015). In this study, modulation of 
activity in the sensorimotor cortex, basal ganglia, and cerebellum was ob-
served as a function of the stimulus voltage applied to the ventrolateral (VL) 
thalamus. Specifically, Paek and colleagues showed that high frequency 
stimulation produced a negative BOLD response in the motor cortex, while 
low frequency stimulation produced a positive BOLD response. Addition-
ally, they showed that by increasing the amplitude of the applied voltage, 
both the change in BOLD signal as well as the size of the affected brain 
region increased, correlating with an increase of neural activity (Fig. 2). This 
suggests that differences in BOLD response can be used to analyze brain 
responses to electrical stimulation and characterize these responses as a 
function of stimulation parameters.  
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In addition to characterization of the neural response to DBS, func-
tional imaging may be also effectively utilized to facilitate identification of 
optimal DBS targets (Perlmutter and Mink 2006). In this context, fMRI and 
positron emission tomography (PET) have already demonstrated clinical 
utility in the treatment of treatment-resistant depression. For example, an 
overactive subgenual cingulate cortex (Brodmann area 25) observed with 
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PET has been shown in patients with acute sadness (Mayberg et al. 1999). 
This overactivity has subsequently decreased in clinical responders follow-
ing antidepressant treatments (Mayberg et al. 1999; Mayberg et al. 2000; 
Dougherty et al. 2015). In 2005, Mayberg and colleagues used PET to show 
that chronic stimulation of the cingulate cortex in patients with treatment 
resistant depression normalized metabolic hyperactivity and produced clin-
ical benefits (Mayberg et al. 2005).  In that study, remission was accom-
plished in four out of six patients, with decreases in cerebral blood flow to 
subgenual cingulate, orbital frontal cortex, hypothalamus, anterior insula, 
and medial frontal cortex. At the same time, their results showed increases 
in cerebral blood flow within the dorsolateral prefrontal, dorsal anterior, 
posterior cingulate, premotor, and parietal regions.  
 
Novel stimulation paradigms 
While DBS has been used effectively to treat multiple disorders 
such as essential tremor and Parkinson disease, DBS technology must be 
further developed in order to improve patient care. For example, the existing 
DBS paradigm requires patients to return to the clinic for periodic adjust-
ment of their stimulation parameters as their disease progresses (Grahn et 
al. 2014; Mayberg et al. 2005; Deuschl et al. 2006). Switching the existing 
DBS paradigm from an open-loop strategy where stimulation parameters are 
fixed, to an adaptive paradigm that relies on biological feedback to adjust 
stimulation parameters will be crucial for developing the next generation of 
DBS systems. Thus, closed-loop DBS systems equipped with electrophysi-
ological, biochemical, and inertial sensors that monitor the molecular, cel-
lular, and behavioral responses to DBS may allow for automated titration of 
stimulation parameters for sustained therapeutic benefits in the face of a 
changing environment. Developing a greater understanding of the cellular 
and molecular mechanisms of DBS by leveraging functional imaging in con-
junction with neurochemical and electrophysiological techniques may also 
assist in optimizing DBS targets and stimulation parameters for specific dis-
orders and individual patients (Grahn et al., 2014). Ultimately, adaptive, 
closed-loop DBS systems will extend battery life, reduce required hospital 
visits and associated healthcare costs (Fraix et al. 2006). 
Several key factors need to be investigated before automated adjust-
ment of stimulation parameters can be clinically implemented. First, the 
complex relationships between clinical behavior and neural activity need to 
be elucidated. The advancement of electrochemical, electrophysiological, 
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and functional imaging techniques from preclinical to clinical settings will 
be essential for the development of next-generation smart DBS systems.  For 
example, optimal locations for recording of neural activity should be iden-
tified for specific disorders and specific patients. Furthermore, neurotrans-
mitters critical for pathological activity and therapeutic response will need 
to be identified (Fitzgerald, 2014). Additionally, specific neurotransmitter 
concentrations and their role in therapeutic efficacy will need to be eluci-
dated. Second, the type of sensors that will be used to monitor the environ-
ment in order to effectively adjust stimulation parameters must be identified.  
The material of these sensors must be MRI safe and biocompatible for 
chronic implantation. For example, efforts are underway to develop electro-
chemical-sensing techniques capable of extending electrode longevity by 
renewing the electrochemically active surface following adsorption of 
chemical species (Takmakov et al. 2010). This is paramount, as the carbon 
fiber microelectrodes typically used for FSCV are subject to electrode foul-
ing due to the charge imbalance of the waveforms required for FSCV and 
are thus not suitable for chronic measurements (Bennet et al. 2016). Recent 
efforts to overcome this limitation have been focused on the use of boron-
doped diamond microelectrodes that can be used over longer periods of time 
(Roham et al. 2007; Park et al. 2005; Park et al. 2008; Halpern et al. 2006; 
Xie et al. 2006; Bitziou et al. 2008; Singh et al. 2010; Zhao et al. 2010; 
Suzuki et al. 2007; Chan et al. 2009; Yoshimi et al. 2011; Marcelli and Patel 
2010). Third, correlation of multi-modal electrophysiological and neuro-
chemical activity may provide new insight into the cellular and molecular 
mechanisms of therapeutic neuromodulation. Therefore, efforts should be 
directed toward developing smart DBS controllers that rely on the relation-
ships between neural activity and the clinical effects of DBS to replace the 
trial-and-error process currently used for clinical DBS programming (Grahn 
et al., 2014; Pulliam et al., 2015; Swann et al., 2016). The versatility and 
adaptability of such controllers will allow optimization of DBS therapies to 
individual patients and symptoms. In turn, this will likely improve clinical 
outcomes, reduce the time and frequency of patient visits, and decrease 
overall health care costs. 
 
Conclusion 
 Despite its clinical efficacy, limitations in existing DBS technology 
make optimization of therapeutic benefits a difficult and expensive en-
deavor. However, combination of multi-modal electrophysiological and 
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neurochemical sensing with functional imaging techniques may provide 
new insight into the cellular and molecular mechanisms of therapeutic DBS. 
By focusing on these techniques that further the efforts in understanding the 
underlying therapeutic mechanisms of DBS, we may be able to tailor appli-
cation of DBS to individual patients and symptoms. Furthermore, the devel-
opment of closed-loop DBS strategies will likely lead to the improvement 
of therapeutic outcomes.  
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Abstract   Optogenetics has recently emerged to become one of the most 
significant tools for in vivo causal analysis of neural networks. Developed 
through decades of pioneering work, the optogenetic toolbox has ex-
panded utility to allow virtually total control over cellular actions. This ar-
ticle explores the emerging technologies that have been incorporated 
into making optogenetics a versatile technique in neuroscience research. 
Genetically engineered opsins continually evolve to directly activate or in-
hibit neuronal transmission with greater precision and functionality. A va-
riety of light sources and fiber coupling methods employ unique photoac-
tivation patterns and shapes. This article further explores the novel 
devices and systems that have been developed for the research setting 
and the technologies each system incorporates. These tethered systems, 
portable devices, and implantable microdevices have inherent benefits 
and detriments that are also discussed. Finally, emerging translational 
properties of optogenetics, particularly that for retinal pigmentosa, 
demonstrate how optogenetics may one day precipitate out of the re-
search setting and into our healthcare practice. 
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Introduction 
 The implementation of targeted light stimulation has enabled 
neuroscientists to perform brain circuitry dissection with an unprece-
dented level of selectivity and specificity in spatial and temporal domains. 
This tool, known as optogenetics, utilizes light to control neurons that are 
genetically sensitized to specific types of light. To define optogenetics, Mi-
chael Häusser, a leading researcher in neural computation, states:  
There's a broad definition and a narrow definition. The broad definition is rooted in 
etymology: any approach that combines optical interrogation with genetic targeting 
qualifies as 'optogenetic', and that includes the use of genetically encoded activity 
sensors. However, most people generally use the term optogenetics to mean the use of 
probes to manipulate activity, and (as is usual in English) usage normally wins 
(Adamantidis et al. 2015). 
Optogenetics exploits the function of genetically engineered light-sensi-
tive membrane proteins that gate the ionic flux between internal and ex-
ternal space of the cell in a high temporal resolution. Ionic influx and ef-
flux causes neuronal depolarization (activation) or hyperpolarization 
(inhibition), modulating the neuron’s membraine potential. Furthermore, 
cell-types can specifically be targeted to respond to light stimulation, as 
opposed to whole regions being vulnerable to the stimulation. The result 
is full control of neuronal firing patterns of preselected photosensitive 
neurons. Photosensitivity of neurons is possible through their induced ex-
pression of specialized proteins that are responsive to light. These pro-
teins act as gated ion channels that open as wavelength-specific photons 
are absorbed. Activation of these channels floods the cell with either posi-
tive or negative ions as shown in Figure 1. The type of ion and its charge is 
dependent on the type of light-sensitive protein used. Investigators utilize 
this technique to control neurons both in vivo and in vitro for a diverse 
range of experiments including neuronal connectivity mapping, functional 
connectivity, behavioral experiments, and induction of disease. These ex-
periments can be carried out in cell cultures or in animal models, and one 
day may translate to clinical therapies for human patients. 
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Fig. 1. Representation of channelrhodopsin and halorhodopsin in their closed conformational 
state. When activated by a light source, channelrhodopsin (at 460 nm wavelength) and halorho-
dopsin (at 590 nm wavelength) allow passage into the cellular membrane for cations (cellular 
depolarization) and anions (cellular hyperpolarization) respectively. 
Currently, optogenetic experiments are exclusive to preclinical settings. 
The first step in performing optogenetic studies is acquiring a genetically 
photosensitive cell group or animal. For example, murine optogenetic ex-
perimentation utilizes transgenic knock-in rodents. Knock-in rodent mod-
els incorporate a specific photosensitive protein into the animal’s cellular 
DNA, and subsequently express this protein to become optogenetically vi-
able. Transgenic animal lines are available almost exclusively within 
mouse models, but transgenic rats are becoming more available. The al-
ternative to this is implementing viral vectors to specifically target neu-
ronal cells of interest within the brain. Viral vectors offer more feasible 
transfection than transgenic cell lines in terms of resources, and can be 
performed in multiple types of animal models instead of genetically trac-
table rodents (Witten et al. 2011). 
Photoactivation of cells was originally pioneered by Richard Fork in 1971 
by stimulating native abdominal ganglia cells of marine mollusks at Bell 
Laboratories (Fork 1971). Decades later in 2005, Karl Deisseroth’s lab first 
transfected mammalian cells with photosensitive proteins and performed 
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millisecond-timescale activity control on these cells (Boyden et al. 2005). 
He would later coin the term ‘optogenetics’ and this technique would be 
hailed as Nature’s method of the year in 2010 (NatureMethods 2011). A 
growing number of laboratories and research groups are continually 
make advances in optogenetics and the future of this technique seems 
endless in possibilities. We describe some of these advances in terms of 
photosensitive proteins, light sources, optical fibers and coupling, optoge-
netic microdevices and systems, and translational properties. 
Opsins 
Achieving optical neuronal control through optogenetics is often depend-
ent on the photosensitive protein (known as an opsin) that is genetically 
encoded into the cell. Once expressed, opsins travel to the neuronal sur-
face and are bound to the membrane. Naturally, opsins mediate photo-
synthetic functions by storing light energy into conjugated molecular 
bonds. Photon absorption results in conformational changes of the opsin 
into an open state to allow passage of ions across cell membranes. These 
opsins allow neuronal manipulation of the electrical potential in a high 
temporal precision (millisecond-scale) with light. Mediating light-driven 
depolarizations and hyperpolarizations of neurons with the opsins has 
proven to be facile (Boyden 2011). 
The light-sensitive proteins channelrhodopsin-2 (ChR-2) from the alga 
Chlamydomonas reinhardtii and halorhodopsin (NpHR) from the archaeon 
Natronomonas pharaonis are two of the most commonly employed op-
sins in optogenetics (Zhang et al. 2007). Due to their robust temporarily 
precise control of neural activity in vitro (Boyden et al. 2005) and in vivo 
(Nagel et al. 2005; Schroll et al. 2006; Petreanu et al. 2007; Arenkiel et al. 
2007; Aravanis et al. 2007), the use of these opsins, originally identified in 
microbes, has exploded in the neuroscience field. When illuminated by 
~470 nm blue light (Nagel et al. 2003), ChR-2 functions as a cation channel 
that evokes the influx of positive voltage change through ions such as so-
dium ions and protons but also potassium and calcium ions. Such influx 
results in depolarization of the basal membrane potential in specific pop-
ulation of neurons that are expressing ChR-2. Reversely, once illuminated 
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by ~580 nm yellow light, NpHR functions as a chloride ion pump that in-
hibits cell firing of neurons that are expressing it (Duschl et al. 1990). ChR-
2 and NpHR can be utilized simultaneously, allowing concurrent bidirec-
tional control of neuronal activity. Archaerhodopsin-3 (Arch) is yet an-
other opsin that has been identified to produce strong inhibitory photo-
currents at yellow light wavelengths (566 nm) (Chow et al. 2010). These 
photocurrents can be as high as 900 pA, dwarfing those of NpHR photo-
currents of 38.9 pA (Gradinaru et al. 2008). These three opsins have origi-
nally allowed researchers to modulate cellular activity with some variety 
of optical parameters, however their effective power densities (EPD50) 
are relatively quite low compared to today’s bioengineered opsins. EPD50 
is a measure of the light intensity required for 50% of the opsin popula-
tion to become activated. The EPD50 of ChR-2 for example is 
1.3mW/mm2 while the EPD50 of Arch is about 7.5mW/mm2 (Mattis et al. 
2012). 
Opsins have been artificially advanced through genetic engineering 
throughout the years. These newer opsin versions expand the optogenet-
ics toolbox, allowing researchers to stimulate or inhibit cells at optical 
wavelengths and intensities much different than from their native forms. 
For example, ChETA was derived from ChR-2 to produce sustained spike 
trains greater than 200 Hz, compared to only 40 Hz of ChR-2 (Gunaydin et 
al. 2010). ChETA was among the first class of bioengineered opsins that 
was produced through singe-amino-acid-substitutions of ChR-2. A second 
class of opsins was produced through combining segments of ChR-1 and 
ChR-2. ChIEF is one of these opsins and was developed to produce more 
reliable photoactivation during persistent light stimulation (Lin et al. 
2009). At higher frequencies, ChIEF experiences only 33% inactivation 
compared to ChR-2’s 77% inactivation. This allows ChIEF to produce ac-
tion potentials that more closely resemble normal neuronal spiking pat-
terns. Currently there exists a variety of stimulating opsins that is availa-
ble with an assortment of unique properties. ReaCHR for example is a 
ChR-2 variant that has been red-shifted to respond to orange or red light, 
which is completely on the other side of the optical spectrum compared 
to ChR-2’s blue light optimal excitation (Lin et al. 2013). ReaCHR opens up 
the possibility of manipulating retinal cells with wavelengths that do not 
cause damage to the eye, and allows the possibility of clinical optogenetic 
332
6  
treatment for ocular conditions such as retinal pigmentosa (discussed at 
the end of this chapter). Interestingly, the amount of light that is ab-
sorbed by the tissue is dependent on the wavelength (Aravanis et al. 
2007), (Yaroslavsky et al. 2002). Shorter wavelengths will tend to have 
higher absorption in the tissue and therefor have a lower volume of pene-
trance through the brain. Therefore, the wavelength at which the opsin 
responds can dictate the overall volume of illumination penetrance within 
the brain. ChR-2 has also been modified into forms that gate inhibitory 
chloride ions in order to hyperpolarize the cell, such as iCIC2 and slow 
chloride-conducting channelrhodopsin (SloChloC) (Berndt et al. 2014), 
(Wietek et al. 2014). Halorhodopsins have similarly observed evolutions 
with the implementation of eNpHR2.0 (Gradinaru et al. 2008). This origi-
nal adaptation solved the issue of NpHR’s poor expression in cells by pro-
moting membrane localization and ER export. Photocurrents of this 
adapted NpHR therefore increased to 68.1 pA. This was followed by the 
production of eNpHR3.0, which had substantially increased light sensitiv-
ity and could respond to illuminations as weak as 3.5mW/mm2 (Gradinaru 
et al. 2010). Other inhibitory proton pumps, including ArchT (Han et al. 
2011) and Mac (Chow et al. 2010) have observed similar modifications as 
NpHR (Mattis et al. 2012). Table 1 offers a summary of opsins and their 
parameters that are typically used in optogenetics. Finally, an interesting 
class of opsins have also been bioengineered that act on second messen-
ger systems instead of gating ion channels. These opsins are referred to 
as OptoXR’s and can be used to modulated cellular signaling molecules 
and cascades. At 473 nm light, Opto-α1-AR has the ability to activate IP3 or 
DAG recruiter GPCR while Opto-β2-AR activates cAMP recruiter GPCR 
(Chow et al. 2010). These second messenger manipulations provide an 
even greater control of intricate molecular pathways of the cell to allow 
more refined modulations that mimic the actions of pharmaceutical drugs 
or specific diseased states. 
Table 1 Examples of opsins used in optogenetics and their characteristics. 
Opsin Subfamily Gating Type Activation  λ 
(nm) 
EPD50 
(mW∕mm2)  
Photocur-
rent 
Channelrhodopsin ChR-2 Cation Channel 460 1.3 1-1.5 nA 
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Channelrhodopsin ChETAA Cation Channel 470 3.1 <0.5 nA 
Channelrhodopsin ChIEF Cation Channel 470 ~1.5 390 pA 
Halorhodopsin NpHR Chloride Pump 589 5.4 38.9 pA 
Halorhodopsin eNpHR3.0 Chloride Pump 566 5.5 450 pA 
Archaerhodopsin Arch Proton Pump 566 ∼7.5 900 pA 
Archaerhodopsin ArchT1.0 Proton Pump 566 ~6.5 ~0.2 nA 
Archaerhodopsin eArch3.0 Proton Pump 566 ~7.5 ~1.2 nA 
Leptosphaeria rho-
dopsins 
eMac3.0 Proton Pump 540 ~2.0 ~0.3 nA 
  
Recently, a new method has come into the spotlight for its ability to edit, 
knockdown, or activate specific genes in localized or global cell popula-
tions. This genetic control can occur either at the germline level or in ma-
ture animal models. Known as CRISPR (clustered regularly interspaced 
short palindromic repeats), this method would allow researchers to take 
full control of genetic manipulations. Of the many fascinating possibilities 
CRISPR can unearth, one of particular interest is its ability to genetically 
produce neurological disease models in animal research. However the 
spatiotemporal precision of CRSIPR lacks feasibility, especially considering 
the amount of toxic effects many of the chemicals used for CRISPR control 
can induce onto the cell and surrounding tissue during experimentation. 
This problem was alleviated with the production of photoactivatable-Cas9 
(paCas9) (Nihongaki et al. 2015). Cas-9 is a vital control point in the 
CRISPR method as it produces DNA breakages to allow targeted genome 
editing. Thus, paCas9 allows researchers to turn this system on or off with 
precision by stimulating with blue light. This blue light activates a photoin-
ducible dimerization system called Magnets to bring the two components 
of paCas-9 together using ionic coupling. The functional paCas-9 can then 
produce targeted DNA breakage as shown in Figure 2. Once the light is 
turned off, the Magnets decouple and the CRISPR system shuts down, re-
versing the original effects. The potential of this system is far-reaching in 
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biomedical sciences, with abundance in both exciting opportunities for re-
search and ethical concerns for the human population (Caplan et al. 
2015). 
 
Fig. 2. Left: In the absence of blue light, nonfunctional paCas-9 is separated into two components 
that are each attached to Magnets. Nonfunctional paCas-9 does not interact with DNA (green 
bar). Right: with the induction of blue light, the Magnets come together and form ionic bonds, 
allowing paCas-9 to dimerize into its functional form. The functional form is then able to produce 
DNA linkage breaks for targeted gene editing.  
Light Sources 
 Cellular performance of optogenetic stimulation relies on ade-
quate delivery of photons from a light source. This light delivery has to oc-
cur at certain set parameters. These parameters include the specific 
wavelength of the photons needed for opsin activation, as well as the fre-
quency and pulse width of the stimulation that govern the cell’s response. 
As shown in Figure 3, the needed wavelength of the produced light is de-
pendent on the type of opsin and can range from near-infrared to near-
ultraviolet light. Deviating from the optimal opsin-specific wavelength re-
sults in lower total activation. The frequency and pulse duration, how-
ever, can change based on the brain region and neuron type, as well as 
the behavior that is being sought.  
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Fig. 3.  Simplified activation profiles for ChR-2, Arch, and NpHR over the visible light spectrum. 
The greater the deviation from optimal wavelength, the less relative activity is expected from 
the opsins expressed by the cells. 
A variety of different light sources have been utilized to modulate neu-
ronal activity in optogenetics experiments. These include lasers, liquid 
crystal displays (LCDs), arc lamps, halogen lights, light emitting diodes 
(LEDs) and organic LEDs (OLEDs). Previously, a majority of optogenetic 
systems have incorporated a laser-based system as the light source. How-
ever more recently, LEDs have become a primary source of photostimula-
tion due to their benefits over laser-based systems in price, beam stabil-
ity, instrumentation size, and high-frequency temporal precision 
(Clements et al. 2013). In order to deliver a sufficient amount of light for 
ChR-2 activation, a relatively modest illumination irradiance is necessary. 
At 470 nm, these opsins necessitate between 0.1 – 1 mW/mm2 (Degenaar 
et al. 2009). Falling below this range results in less than 10% activation of 
ChR-2 (Grossman et al. 2011). Experiments have shown that LEDs 
(Gradinaru et al. 2007; Huber et al. 2008) can adequately supply this irra-
diance. Other experiments that use high intensity light sources, including 
lasers (Aravanis et al. 2007; Gradinaru et al. 2009; Han et al. 2009) and arc 
lamps (Boyden et al. 2005; Zhang et al. 2006) have been performed. How-
ever, these powerful light sources promote the risk of damaging or killing 
the neural tissue by heating up the cell. Furthermore, these light sources 
produce only a single-point illumination, whereas OLEDs and LCDs can 
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produce diverse patterns of 2-dimensional arrays of illumination. How-
ever their irradiance potential is around 1 × 10-4 mW/mm2, which is 3 or-
ders of magnitude too low for ChR-2 activation (Grossman et al. 2010). 
Neuromodulation experiments that utilize photostimulation, as opposed 
to electrical stimulation, beneficially produce very low intensity stimula-
tion artifacts. Having low artifacts facilitates better detection during sim-
ultaneous recording by increasing the signal to noise ratio. Various neural 
recording platforms have been incorporated into optogenetics experi-
ments, including local-field potential (Filali et al. 2004), evoked-potential 
(Maegaki et al. 2000; Dinner et al. 2002), electroencephalogram (Swann 
et al. 2011), and single neuron recording (Filali et al. 2004). Each study 
would have to consider all possible artifacts that could hinder their re-
cording signal strength. Generally, there are three sources of artifacts oc-
curring at the recording electrode level that are actively suppressed 
through signal filtering: capacitive coupling, common-mode conversion, 
and voltage gradients (McGill et al. 1982; Kent and Grill 2012). The inten-
sity of this noise generated by recording instruments (at the millivolt 
range) is orders of magnitude larger than the artifacts produced by opto-
genetics system (at the microvolts range) (Clements et al. 2013). There-
fore, the noise produced by optogenetic instruments can be relatively 
negligible and easy to minimize. These low-frequency artifacts are typi-
cally the product of the photoelectric effect, which is brought on by illu-
mination induced temperature kinetics directly changing the electrode 
conductance and releasing electrons picked up by the recorder (Cardin et 
al. 2010). Low frequency artifacts produced by optogenetics can be reme-
died through high-pass filtering (Han et al. 2009). 
Fiber Coupling  
 The interface between light that is being produced and the neural 
region being modulated needs to retain efficiency in optogenetics experi-
ments. Often this can be a limiting factor in the necessary power con-
sumed by the system as well as the intensity of neural damage from opti-
cal fiber insertion into the brain. Optical fibers are typically inserted into 
the brain to transmit light into deep neural regions. Optical fibers are rel-
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atively inert and thin materials, which helps minimize the immune and in-
flammatory response of foreign body insertion as well as promote bio-
compatibility. Generally, a thinner optical fiber produces a smaller “kill-
zone” in neural tissue (Stensaas and Stensaas 1975). Thinner optical fibers 
are, however, less efficient at transmitting light because of the smaller 
cross-sectional area for photons to enter the fiber. Optogenetics studies 
on larger animal models can tolerate thicker materials when inserted into 
the brain. Mice are able to tolerate optical fibers up to 300 µm whereas 
rats can tolerate up to 400 µm (Carter and de Lecea 2011). 
Maximizing efficiency of optical fiber transmission is imperative, as it en-
sures sufficient photoactivation while simultaneous minimizing power 
consumption. Efficiency is influenced by the uniformity in direction that 
the photons travel once they exit the light source. Lasers inherently pro-
duce unidirectional light, but other light sources produce photons that are 
more scattered. The light source’s viewing angle greatly affects the sys-
tem’s overall efficiency, as wider-angled light sources result in a smaller 
percentage of photons that are able to enter the core of the optical fiber. 
Multimodal optical fiber cores, which have a greater core diameter com-
pared to single-mode fibers, are preferred as the proportion of their 
cross-sectional core area is greater. A visual representation of viewing an-
gle and fiber types is seen in Figure 4. This directly relates to the numeri-
cal aperture (NA) of the fiber, which can be measured as 
𝑁𝐴 =  √𝑛𝑐𝑜𝑟𝑒
2 − 𝑛𝑐𝑙𝑎𝑑𝑑𝑖𝑛𝑔
2 , 
where ηcore represents the fiber core’s refractive index and ηckadding repre-
sents the fiber cladding’s refractive index. Cladding is the material that 
lines the core and helps prevent the light from refracting out of the core 
as it reflects down the fiber. The NA is an important measure when com-
paring the relative light gathering capabilities of different fibers. Addition-
ally, lenses can be used to focus light into the optical fiber’s core, as long 
as the numerical aperture of the fiber is greater than the numerical aper-
ture of the lens. Typically, the lens’ refractive index should be greater 
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than 1.9 or else the maximum coupling efficiency is equivalent to simply 
butt-coupling the light source to the fiber (Wetzel 1993). 
 
Fig. 4. Left: Different viewing angles created by two LEDs. Although they produce the same 
amount of energy, Θ2 viewing angle will have better efficiency when coupling to a fiber because 
the energy is more directed towards the fiber’s core. Right: Single-modal (top) and multi-modal 
(bottom) optical fibers with the outer cladding stripped back to demonstrate light transmission. 
Multi-modal fibers have larger core diameters, allowing for more light to enter the fiber and be 
delivered to the photoactivation region, thereby increasing efficiency. 
More recently, there have been successful modifications to optical fibers 
for enhanced functionality during stimulation. For example, tapering the 
fiber produces a thinner fiber tip for focused activation while also mini-
mizing neural damage at the proximal location to the site of stimulation. 
This helps the likelihood of maintaining the neural connections that may 
otherwise be damaged with a wider fiber penetrating the area of interest. 
Tapering can be accomplished chemically (Royer et al. 2010; Hanks et al. 
2015) or thermo-mechanically (Sileo et al. 2015). Tapered fibers can also 
be coated with a thin metallic film, such as gold, to offer electrophysiolog-
ical recording capabilities along the optical fiber (Ozden et al. 2013). In 
this case, the metallic film is inserted into a polyamide tube covered by a 
stainless steel tube. The multiple layers results in a larger diameter but is 
necessary for electrical insulation during electrophysiology recording and 
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mechanical rigidity. Optical fibers have also been modified through fo-
cused ion beams to create optical windows on the fiber (Pisanello et al. 
2014; Pisanello et al. 2015). These are essential small holes that allow 
photons to escape at specific points along the fiber. Fabricating multiple 
windows and modifying the input angle can direct the light to exit 
through specific windows only. Therefore, researchers are able to target 
different neural sites using a single optical fiber that are easily changea-
ble. These windows also allow the optical fiber to act as optical array by 
allowing the light to escape through multiple windows at once. This is 
demonstrated by Figure 5. The implementation of optical windows on fi-
bers further enhances the spatiotemporal resolution that optogenetics of-
fers, and can be utilized with any optogenetic device that uses fibers. 
 
Fig. 5. A tapered optical fiber with optical windows. Depending on the angle of the incoming 
light source, the windows will project light out at different intensities. In this way, specific re-
gions along the fiber can be targeted. 
Devices 
 The number of novel optogenetic systems that are being intro-
duced into the research setting is vastly growing every year. Either for 
specific investigations or for commercial sales, these systems are becom-
ing increasingly diverse in their functionality, size, cost, throughput and 
more. The types of optogenetic systems that are being developed can be 
classified into 3 main categories: tethered systems, portable devices, and 
implantable microdevices (Kale et al. 2015b). Each of these has their own 
unique advantages and disadvantages, which will be discussed. Therefore, 
it is in the researcher’s best interest to carefully determine which type of 
system suits their needs and would be optimal for their investigation.  
Tethered Systems 
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Neuromodulation experiments typically require a power source to 
deliver stimulations to the intended neurons. In tethered systems, an op-
tical fiber cord directly connects the animal to an external light source 
that is outside the animal’s habitat. This light source is then connected to 
a wall power outlet, which delivers essentially an infinite supply of power 
to the system. Therefore tethered systems can harness a very high cur-
rent to power their light source, and deliver optical power with as much 
illuminance as needed. This process comes with limitations, particularly 
due to the animal being tethered to the light source. This setting potenti-
ates the risk of the animal becoming tangled by its optical fiber cord. It 
would be difficult and dangerous to freely stimulate multiple animals dur-
ing social behavior studies while preventing them from damaging each 
other’s cords and implants. Additionally, behavioral tests in mood disor-
der models would be negatively affected by the cord as they deviate from 
the animal’s naturalistic setting. The animal can become tangled by its 
own cord unless open-top homecage and behavioral apparatuses are 
used (Land et al. 2014). This issue may be alleviated with a rotary joint, 
however, these components inflict stressful rotational torques on the ani-
mal. Mice can typically withstand rotational pulling of up to 150 μN·m 
whereas rats can withstand upwards of 300 μN·m (Klorig and Godwin 
2014). Thus, selecting the ideal pulling strength is imperative – too soft 
and the cord could become tangled around the animal, too hard and the 
force would cause stress and injury. Tethered optogenetic systems may 
be ideal for experiments that compare stimulation of motor pathways 
and the resulting muscle movements the animal performs. Recent studies 
have gained insights into how motor control is affected by optogenetic 
modulation of cells (Heiney et al. 2014; Seeger-Armbruster et al. 2015).  
A majority of tethered studies incorporate laser-based light sources be-
cause of their ability to harness high power demands. However as previ-
ously discussed, LEDs can be advantageous to optogenetic studies 
(Clements et al. 2013). With the incorporation of LEDs, one possibility is 
to eliminate the optical fiber entirely and simultaneously add a deep brain 
electrophysiological component onto a single optrode (Cao et al. 2013). 
This is accomplished by incorporating the LED onto the tip of the optrode, 
so that the light source sits proximal to the site of photostimulation. 
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Other tethered systems have used hybrid multielectrode recording and fi-
ber optic arrays for both neuromodulations and measurements of cortical 
cells (Kwon et al. 2013; Wang et al. 2012). Multifunctional systems can be 
adapted to a single platform and are not limited to electrophysiological 
recordings only. A novel device has combined a microfluidic channel to 
the recording and stimulating optrode (Rubehn et al. 2013). This technol-
ogy offers a combination of optogenetics, recording, and drug delivery, 
with the potential viral redelivery function to maintain opsin expression 
for long-term longitudinal studies. 
 Portable Devices 
 Most devices and technologies have a tendency to miniaturize 
over time. This concept is no exception in optogenetics. The detriments of 
tethering can pose a challenge to experimenters. Having the device 
mountable or wearable by the animal has exceptional value to the study, 
particularly in behavioral experiments. Tethered systems are capable of 
restricting behavioral experiments involved in complex paradigms such as 
wheel running, pain, and social interactions with other animals (McCall et 
al. 2013). These restrictions can be minimized or eliminated with smaller 
portable devices when implemented in animal research. However, limita-
tions inherently exist with portable devices too. The most obvious limita-
tion is the lack of a power source capable of producing unlimited continu-
ous power, which is not an issue with tethered systems. As a result, 
power consumption of the device needs to be minimized. This can come 
at the expense of limited functionality, lower optical power output, and 
potentially a higher cost of consumables.  
Typically, portable devices can harness power from either a battery or 
through wireless energy harvesting. Batteries offer a reliable and cost-ef-
fective approach compared to wireless energy harvesters. For example, 
the amount of sophisticated components and circuitry is modest com-
pared to wireless energy harvesters. However, batteries tend to be quite 
heavy, and this poses a problem for small animal research. Furthermore, 
inherent issues with thermodynamic chemical reactions that take place in 
batteries include slow recharging, limited charge and discharge cycles, 
and issues of being a biohazard if the internal chemicals are leaked (Brodd 
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et al. 2004), (Armand and Tarascon 2008). Also considering that the ani-
mal may also destroy the battery and ingest the hazardous toxins, the 
risks of using batteries is often greater to animals in weakly constructed 
devices. At the same time, the battery would likely need to be easily ac-
cessible and replaced during the experiment. Therefore, there is a 
tradeoff between accessibility of the battery for the researcher and risks 
posed to the animal. Despite these risks, battery-powered microdevices 
can be relatively cost-effective compared to tethered systems and wire-
less energy harvesters. Teams that produce portable optogenetic devices 
claim to have a low-cost product that is easily manufactured using com-
mercially available components (Gagnon-Turcotte et al. 2015; Iwai et al. 
2011). Alternative components have been utilized in bioelectronics to cir-
cumvent battery usage, such as piezoelectric, thermoelectric, biopotential 
harvesting, and glucose harvesting (Ma and Poon). However, these com-
ponents tend to produce energy densities much too low for portable de-
vices. 
A more sophisticated method for powering portable optogenetic devices 
is through wireless energy harvesting. This can be accomplished through 
radio-frequency (RF) transmission. Although this technology is relatively 
new, portable optogenetic devices have successfully utilized wireless en-
ergy harvesting (Kale et al. 2015a). They incorporate an antenna and rec-
tifying circuitry to form a rectenna (Hosain et al. 2014). This rectenna sup-
plies the circuit with DC power supplied from an RF transmitter some 
distance away. This harnessed current is subsequently used to power the 
light source. The light source, however, does not require constant power, 
but instead typically pulses at set frequencies and pulse widths that de-
pend on the experimental parameters. Therefore, the energy must be 
stored within the circuit and pulsed in bursts to the light source. Two tra-
ditional components can accomplish this to some degree – batteries and 
capacitors. As described, there are inherent flaws with batteries such as 
size limitations and charge/discharge capacities. There is also little pur-
pose utilizing RF transmission to power a bulky battery, as the benefits of 
size reduction are diminished. Furthermore, power densities of batteries 
are relatively low while energy densities are sufficiently high. On the 
other hand, capacitors usually have sufficient power densities but provide 
too low energy densities (Meng et al. 2013). A fundamental middle-
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ground is needed between batteries and capacitors. Fortunately there ex-
ists a component that satisfies the sufficient energy and power densities 
to power an LED for optogenetics – supercapacitors. An electric double-
layer capacitor, known as a supercapacitor, can be produced that 
measures only 1 mm3 and can produce a high enough area of capacitance 
at 1.3 mF/mm2 (Meng et al. 2013). 
Supercapacitors have a tendency to be damaged by high current loads. 
This can be rectified through the use of a boost converter, which limits 
the current intensity on the circuit by increasing the voltage. An RF har-
nessing headstage was developed by Wentz et al. (2011) that makes use 
of this boost converter in mice, with the headstage weight totaling about 
2 grams (Wentz et al. 2011). This team has since formed a company (Ken-
dall Research Systems) that produce wireless optogenetics headstages 
that concurrently transfer wireless neural data for closed-loop stimula-
tion. Closed-loop systems can modify the stimulation parameters in real-
time to only stimulate when certain brain activity patterns are detected. 
Incorporating a recording electrode into the device has key benefits for 
closed-loop systems. With this, Ameli et al. (2013) produced a headstage 
that can wirelessly transfer the neural readouts to a basestation over 2 
meters away. A centralized basestation offers control of multiple animals 
in parallel for high-throughput studies. Other devices have been devel-
oped that eliminate the optical fiber entirely by fitting the LED onto an 
optrode for direct stimulation deep into the brain (Rossi et al. 2015). A 
lower illumination intensity can be used when the LED is implanted into 
the site of stimulation because efficiency loss from fiber-coupling is elimi-
nated. This results in a lower power consumption of the overall head-
stage. 
 Implantable Microdevices 
 Newer technologies are allowing researchers to implement 
smaller components into their optogenetic systems, and in many cases 
these systems can become fully implantable. µLEDs, which can range in 
sizes from 625 to 10,000 µm2, greatly reduce the overall dimensions of 
the implanted light source compared to traditional LEDs. Once implanted, 
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they are able to direct the light to specific sites on the tissue with minia-
ture lenses (McCall et al. 2013). µLEDs can also be produced in an array 
format to deliver light distribution in complex shapes and designs, provid-
ing enhanced spatial resolution at the cellular scale (Grossman et al. 
2010). Partially implanted microdevices have been produced that incor-
portate a rectenna system that is exposed outside the skull, while the ma-
jority of the components are implanted within the animal (Kim et al. 
2013) (McCall et al. 2013). This device has the ability to optically stimulate 
while concurrently take electrophysiological recordings using a Pt-contact 
pad, optical measurements using a µ-IPD and a senses temperature using 
a serpentine platinum resistor. Optical measurement provides assurance 
that light is being produced by the device since light can be difficult to see 
when implanted. The temperature sensor ensures animal safety as heat 
can be produced by any electrical and optical components within the im-
plant. 
Research groups more recently have been successful at producing micro-
devices that are small and safe enough to be fully implanted into the ani-
mal. Dr. Deisseroth’s team at Stanford University have accomplished this 
by creating a chamber that uses resonance cavities to produce RF signals 
(Montgomery et al. 2015). These signals target the optogenetics device 
that is implanted into the mouse and provide the energy to activate it. 
The mouse can move freely inside of an enclosure that is above the cham-
ber. These devices are miniscule in size and weight, with the smallest ver-
sion of the system being 10 mm3 and weighing 20 mg. This same group 
had previously developed implanted microdevices that use direct induc-
tive coupling between two coils to power their device (Yeh et al. 2013). 
However, electromagnetic fields produce stronger localization for energy 
in the low gigahertz frequencies, allowing for smaller coils to be utilized in 
RF systems compared to inductive coupling. RF-powered wireless technol-
ogies appear to be fruitful in the preclinical setting because they can 
more easily compensate for the different orientations that the animal can 
take, and can utilize sophisticated resonance chambers for the animal to 
reside in. On the other hand, midfield technologies may offer a unique 
method of coupling internal devices for humans to external power 
sources that are easily replaceable (Ho et al. 2013). One important differ-
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ence between human and animal implants is that the human device ori-
entation is unlikely to move in relation to the power transmission coil. 
Midfield technologies may one day facilitate the translational properties 
of optogenetics to be incorporated into the clinical setting. 
Translational Properties 
Performing clinical optogenetic therapy to treat neurological dis-
eases may be decades from becoming a reality, however, concerns exist 
such as the invasiveness of this technique. Viral stability may also be an is-
sue, and antibiotic-driven promoters may offer a solution for the future, 
as they provide precisely tuned gene expression and even complete 
shutoff at undesirable instances (Chow and Boyden 2013). However, this 
task is hindered by regulatory agencies requiring full toxicology investiga-
tions before becoming clinically viable. Despite these setbacks, current 
therapeutic advances are being researched in the preclinical realm, mak-
ing the translational properties of optogenetics a possible reality. One ex-
ample worth noting is a type of blindness, and optogenetics may offer a 
remedy to many that are affected. 
Retinal Pigmentosa 
Retinal pigmentosa (RP) is a retinal degenerative disorder that 
currently affects roughly 100,000 patients in the US (Chow and Boyden 
2013). Investigations are occurring into activating ON bipolar or retinal 
ganglion cells of the eye using ChR-2. The light delivered to the eye from a 
light source transduces the photons into signals that can be processed by 
the visual system to enable sight (Busskamp and Roska 2011). Simultane-
ous inhibition of dysfunctional cells may resensitize retinal photorecep-
tors through inhibitory opsins. The eye, through intravitreal injections can 
express these opsins. This is a relatively noninvasive procedure when 
compared to viral injections into the brain. The alternative to intravitreal 
viral injections would be nanoparticles or gene-gun approaches; however, 
viral vectors offer rapid delivery, high infectivity, and cell-specificity 
(Henriksen et al. 2014). This offers a unique translational property of 
optogenetics to patient therapy before full-blown neural interfacing oc-
curs. Currently, preclinical intravitreal transfection in primates remains 
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difficult due to the poor transport of the virus through the inner limiting 
membrane (Dalkara et al. 2009). Scaling viral delivery to primate eyes also 
proves to be difficult as a massive amount of particle numbers is neces-
sary for whole eye coverage compared to regional coverage of the brain. 
The noninvasiveness nature of optogenetic RP therapy demonstrates the 
important benefits of promoting translational research. However, many 
device and computational issues would need to be addressed. Ambient 
light would not sufficiently produce illumination intensities strong enough 
to activate opsins in the eye. Outerwear goggles can transmit the light at 
strong enough intensities with precise temporal and spatial locations onto 
the eye. The goggles would reproduce visual images from the external vis-
ual field, amplify this signal, and output the transformed visual images 
onto the retina through wavelengths that the ocular opsins can respond 
to (Goetz et al. 2013). Sophisticated components would be necessary to 
accomplish optogenetic RP therapy. One that stands out is the need for 
inward eye-tracking capabilities. Normally, eyes receive visual input from 
images that are produced from both a static retina and a moving retina. 
Exclusively static retinal images could produce visual stimulation different 
than what healthy individuals see, and therefore the goggles would need 
to compensate through altered arrays of projected intensities. Otherwise 
constant static images would result in adaptations to the eye, ultimately 
depressing visual response (Roska and Agboh). Additionally, computa-
tional compensation for ocular vergence would need to be performed for 
binocular vision of objects at different fixation points. Healthy-sighted in-
dividuals automatically adjust both eyes positions simultaneously to 
maintain the site on an approaching object. This allows photons coming 
from the object to fall directly onto the focal point of the retina as it ap-
proaches or retracts away. Eye-tracking functionality could mediate this 
by actively adjusting the image’s projected location so the retina can cor-
rect itself by radial stretch in the fovea, among other methods (Asher et 
al. 2007). 
RP therapy has one of the highest translatable properties of any disease 
for optogenetics. However, many other disease states are being investi-
gated by researchers. Animal models of disease coupled with optogenet-
ics are providing these researchers with tools to further understand the 
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underlying basis of disease genesis and progression, as well as novel 
methods to treat them. These diseases include but are not limited to anxi-
ety, depression, schizophrenia, addiction, social dysfunction, Parkinson’s 
disease, and epilepsy (Tye and Deisseroth 2012). As scientists gain more 
knowledge of these diseases, better targeting drugs and personalized 
treatment options may be available as better treatment options for pa-
tients. 
Conclusion 
 Advancing technologies in the optogenetic technique are emerg-
ing in this exciting and revolutionary field. The current trends towards 
technological sophistication and diverse functionality give this relatively 
new technique an exciting prospect to its future potentials both in pre-
clinical and translational sciences. Clinical optogenetics may see a place in 
the future for patient healthcare once all of its caveats have been solved. 
For now optogenetics continues to inspire new research in complimen-
tary areas, such as genetic engineering and neurostimulation. Novel 
methods are being investigated because of the excitement, such as fo-
cused ultrasound that offers noninvasive brain stimulation in deep re-
gions of the brain (Yoo et al. 2011). Albeit the possibility exists that newer 
neurostimulation techniques may be adapted that are more translatable 
compared to optogenetics. But the high degree of causal information 
gained, coupled with the incredible spatiotemporal properties of this 
technique will make optogenetics a viable option for uncovering the deep 
mysteries of the brain for years to come. 
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